In search of the â€~missing selfâ€. MHC molecules and

Trends in Immunology 11, 237-244

DOI: 10.1016/0167-5699(90)90097-s

Citation Report

#	Article	IF	CITATIONS
1	Peptide Presentation by Major Histocompatibility Class I Molecules. Chemical Immunology and Allergy, 1993, 57, 1-17.	1.7	0
2	Empty MHC class I molecules come out in the cold. Nature, 1990, 346, 476-480.	13.7	905
3	Role of major histocompatibility complex class-I molecules in tumor rejection. Immunologic Research, 1990, 9, 298-313.	1.3	12
4	Resistance to NK Cell-Mediated Cytotoxicity (in K-562 Cells) does not Correlate with Class I MHC Antigen Levels. Immunobiology, 1991, 183, 23-39.	0.8	12
5	CD3 ⁻ Leukocytes Present in the Human Uterus During Early Placentation: Phenotypic and Morphologic Characterization of the CD56 ⁺⁺ Population. Autoimmunity, 1991, 1, 169-190.	0.6	262
6	Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2 Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 5989-5992.	3.3	120
7	Recognition of beta 2-microglobulin-negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 10332-10336.	3.3	239
8	On the nature and function of human uterine granular lymphocytes. Trends in Immunology, 1991, 12, 432-435.	7.5	290
9	Mouse hepa-1 tumor is rejected by H-2db-restricted CTL despite decreased MHC class I antigen expression. Cellular Immunology, 1991, 136, 414-424.	1.4	1
10	To thine own self be true …. Current Biology, 1991, 1, 239-241.	1.8	10
11	Sera from patients with colon, breast and lung cancer induce resistance to lysis mediated by NK cytotoxic factors (NKCF). British Journal of Cancer, 1991, 63, 893-896.	2.9	6
12	Human MHC Class I Antigens are Associated with a 90-kDa Cell Surface Protein. Scandinavian Journal of Immunology, 1991, 34, 221-227.	1.3	9
13	Tumors developing in nude mice express unusually large amounts of MHC class I antigens. Apmis, 1991, 99, 1111-1119.	0.9	5
14	Allospecific recognition of hemic cellsin vitro by natural killer cells from athymic rats: Evidence that allodeterminants coded for by single major histocompatibility complex haplotypes are recognized. European Journal of Immunology, 1991, 21, 2167-2175.	1.6	47
15	Rejection of bone marrow cell allografts by natural killer cell subsets: 5E6+ cell specificity for Hh-1 determinant 2 shared by H-2d and H-2f. European Journal of Immunology, 1991, 21, 2821-2828.	1.6	35
16	Enhancement of natural-killer-cell susceptibility of human breast-cancer cells by estradiol and v-Ha-ras Oncogene. International Journal of Cancer, 1991, 47, 445-449.	2.3	18
16	Enhancement of natural-killer-cell susceptibility of human breast-cancer cells by estradiol and v-Ha-ras Oncogene. International Journal of Cancer, 1991, 47, 445-449. The RMA-S lymphoma mutant; consequences of a peptide loading defect on immunological recognition and graft rejection. International Journal of Cancer, 1991, 47, 38-44.	2.3	18

#	Article	IF	CITATIONS
19	Molecular abnormalities in the expression of HLA class-I antigens by melanoma cells. International Journal of Cancer, 1991, 47, 101-105.	2.3	6
20	Frequency of abnormal expression of HLA-A,B,C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence. International Journal of Cancer, 1991, 47, 155-162.	2.3	35
21	Immunological and non-immunological influence of H-2Kb gene transfection on the metastatic ability of B16 melanoma cells. International Journal of Cancer, 1991, 48, 270-276.	2.3	27
22	Differential mRNA levels of c-myc, c-fos and MHC class I in several clones of a murine fibrosarcoma. International Journal of Cancer, 1991, 49, 906-910.	2.3	14
23	Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes. Cancer Immunology, Immunotherapy, 1991, 34, 128-132.	2.0	14
24	Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunology, Immunotherapy, 1991, 33, 45-49.	2.0	12
25	MHC antigen expression in human oral squamous carcinoma cell lines. Journal of Pathology, 1991, 165, 129-136.	2.1	13
26	Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target Journal of Experimental Medicine, 1991, 174, 327-334.	4.2	60
27	Tumor Eradication by Adoptive Transfer of Cytototic T Lymphocytes. Advances in Cancer Research, 1992, 58, 143-175.	1.9	242
28	Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells Journal of Experimental Medicine, 1992, 175, 843-846.	4.2	64
29	Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2) Journal of Experimental Medicine, 1992, 176, 963-971.	4.2	216
30	Skin graft rejection by beta 2-microglobulin-deficient mice Journal of Experimental Medicine, 1992, 175, 885-893.	4.2	146
31	Correlation between lymphocyte-induced donor-specific tolerance and donor cell recirculation Journal of Experimental Medicine, 1992, 176, 407-413.	4.2	54
32	Interferon- \hat{I}^3 Potentiates the Antitumor Effect of Cyclosporine-Induced Autoimmunity. Stem Cells and Development, 1992, 1, 75-84.	1.0	29
33	Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans Journal of Experimental Medicine, 1992, 175, 709-718.	4.2	192
34	Relationship Between myc Oncogene Activation and MHC Class I Expression. Advances in Cancer Research, 1992, 60, 181-246.	1.9	42
35	Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 7983-7985.	3.3	152
36	Role for major histocompatibility complex class I in regulating natural killer cell-mediated killing of virus-infected cells Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 8337-8341.	3.3	49

#	ARTICLE	IF	Citations
37	Target recognition by bovine mononuclear, MHC-unrestricted cytotoxic cells. Veterinary Microbiology, 1992, 33, 383-392.	0.8	13
38	10 Immunological aspects of pre-eclampsia. Bailliere's Clinical Obstetrics and Gynaecology, 1992, 6, 601-615.	0.6	62
39	Existence of a natural killer (NK) cell repertoire for (allo)antigen recognition: Definition of five distinct NK-determined allospecificities in humans. Pharmacological Research, 1992, 26, 98-99.	3.1	0
40	Cross-species transplantation: NK cell number and function are normal in fully xenogeneic chimeras (rat → mouse). Journal of Pediatric Surgery, 1992, 27, 307-311.	0.8	0
41	CD5+ B lymphocytes correspond to generalist lymphocytes predicted by a computational model of affinity maturation. Journal of Theoretical Biology, 1992, 154, 399-401.	0.8	0
42	MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature, 1992, 358, 66-70.	13.7	737
43	High Sensitivity to Peripheral Blood Lymphocytes and Low HLA-class I Antigen Expression of Small Cell Lung Cancer Cell Lines with Diverse Chemo-radiosensitivity. Japanese Journal of Cancer Research, 1992, 83, 736-745.	1.7	7
44	Studies on the susceptibility to NK-mediated lysis and the simultaneous expression of various surface molecules in anthracyclin-treated K562 cells and in four K562 cell clones. Immunology Letters, 1992, 34, 45-55.	1.1	5
45	Natural killer cells. Current Opinion in Immunology, 1992, 4, 38-42.	2.4	44
46	NK cells and T cells: mirror images?. Trends in Immunology, 1992, 13, 244-247.	7.5	28
47	Allorecognition by NK cells: nonself or no self?. Trends in Immunology, 1992, 13, 300-306.	7.5	192
48	Effects of \hat{I}^2 -2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/neu oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis. Cellular Immunology, 1992, 141, 219-232.	1.4	11
49	A function-associated molecule on rat natural killer cells identified by anti-idiotypic monoclonal antibodies. Cellular Immunology, 1992, 141, 293-305.	1.4	4
50	Mechanisms involved in NK resistance induced by interferon-Î ³ . Cellular Immunology, 1992, 140, 248-256.	1.4	12
51	An inducer of NKCF (NK cytotoxic factor) release: Localization on target-cell membrane and initial characterization. Cellular Immunology, 1992, 142, 370-384.	1.4	7
52	Histocompatibility antigens and natural killer susceptibility. Immunologic Research, 1992, 11, 133-140.	1.3	2
53	An unexpected petition for pardon. Current Biology, 1992, 2, 613-615.	1.8	28
54	Isolation of mononuclear cytotoxic cells from cattle vaccinated against foot-and-mouth disease. Archives of Virology, 1992, 122, 293-306.	0.9	22

#	Article	IF	CITATIONS
55	Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer-and lymphokine-activated-killer-mediated cytotoxicity. Cancer Immunology, Immunotherapy, 1992, 34, 272-278.	2.0	8
56	c-myc-induced natural killer cell sensitivity of human melanoma cells is reversed by HLA-B27 transfection. European Journal of Immunology, 1992, 22, 2737-2740.	1.6	17
57	Relationship between sensitivity to natural killer cells and MHC class-I antigen expression in colon carcinoma cell lines. International Journal of Cancer, 1992, 50, 659-664.	2.3	7
58	Involvement of histo-blood-group antigens in the susceptibility of colon carcinoma cells to natural killer-mediated cytotoxicity. International Journal of Cancer, 1992, 52, 609-618.	2.3	29
59	Analysis of factors associated with the tumorigenic potential of 12 tumor clones derived from a single rat colon adenocarcinoma. International Journal of Cancer, 1992, 52, 934-940.	2.3	18
60	Enhanced chondrocyte destruction by lymphokine-activated killer cells. possible role in rheumatoid arthritis. Arthritis and Rheumatism, 1993, 36, 500-513.	6.7	12
61	Reduced expression of major histocompatibility complex class I free heavy chains and enhanced sensitivity to natural killer cells after incubation of human lymphoid lines with \hat{I}^2 2-microglobulin. European Journal of Immunology, 1993, 23, 1752-1756.	1.6	32
62	TNFα protects SW742 human colon carcinoma cells against non-MHC-restricted cytolysis. Immunology Letters, 1993, 38, 215-222.	1.1	2
63	Rejuvenated expression of H-2Kb in RMA-S cells does not affect alloreactive T cell- and natural killer cell-mediated lysis. Immunology Letters, 1993, 38, 77-83.	1.1	3
64	Antigen-presenting cell types. Current Opinion in Immunology, 1993, 5, 374-382.	2.4	157
65	Association between ICAM-1 expression and metastatic capacity of murine B-cell hybridomas. Clinical and Experimental Metastasis, 1993, 11, 213-226.	1.7	23
66	Natural killer-cell function in hemodialysis patients: Effect of the dialysis membrane. Kidney International, 1993, 43, 1298-1305.	2.6	37
67	Decreased adhesion to endothelial cells and matrix proteins of H-2Kb gene transfected tumour cells. British Journal of Cancer, 1993, 68, 862-867.	2.9	10
68	The self and the nonself: Immunorecognition and immunologic functions. Immunologic Research, 1993, 12, 168-182.	1.3	7
69	MHC class I up-regulation protects some but not all targets against LAK-mediated lysis: possible implications for the existence of LAK cell subpopulations using different recognition strategies. Immunology Letters, 1993, 38, 59-62.	1.1	6
70	Human Natural Killer Cells: Origin, Clonality, Specificity, and Receptors. Advances in Immunology, 1993, 55, 341-380.	1.1	197
71	Interferonâ€"A Major Regulator of Natural Killer Cell-Mediated Cytotoxicity. Journal of Interferon Research, 1993, 13, 247-257.	1.2	89
72	MHC Class I-Deficient Mice. Advances in Immunology, 1993, 55, 381-421.	1.1	105

#	ARTICLE	IF	Citations
73	In situ hybridization and northern blot demonstration of HLA-G mRNA in human trophoblast populations by locus-specific oligonucleotide. Human Immunology, 1993, 37, 17-22.	1.2	71
74	Effect of IFN- \hat{I}^3 and IFN- \hat{I}^\pm on killing of human trophoblast by decidual LAK cells. Journal of Reproductive Immunology, 1993, 23, 51-62.	0.8	32
75	Regulation of hematopoiesis in vitro by alloreactive natural killer cell clones Journal of Experimental Medicine, 1993, 177, 1117-1125.	4.2	53
76	Downregulation of HLA Class I expression by c-myc in human melanoma is independent of enhancer A. Nucleic Acids Research, 1993, 21, 1179-1185.	6.5	25
77	Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science, 1993, 260, 1121-1124.	6.0	223
78	Abnormalities in HLA Class I Antigen Expression by Melanoma Cells: Structural Characterization and Functional Implications Journal of Investigative Dermatology, 1993, 100, 226S-230S.	0.3	0
79	P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities Journal of Experimental Medicine, 1993, 178, 597-604.	4.2	513
80	Specificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type Journal of Experimental Medicine, 1993, 178, 1321-1336.	4.2	169
81	Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes Journal of Experimental Medicine, 1993, 178, 1397-1406.	4.2	210
82	Effects of Class I MHC Gene Products on the Immunobiological Properties of BL6 Melanoma Cells. Advances in Molecular and Cell Biology, 1993, 7, 177-204.	0.1	0
83	Genetic Conflicts in Human Pregnancy. Quarterly Review of Biology, 1993, 68, 495-532.	0.0	1,059
84	Molecular Mechanisms Used by Tumors to Escape Immune Recognition. Journal of Immunotherapy, 1993, 14, 182-190.	1.2	115
85	Allele-specific peptide ligand motifs of HLA-C molecules Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 12005-12009.	3.3	122
86	HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 12000-12004.	3.3	419
87	Natural Killer Cell Activity of Lymphocytes Exposed to Ovine, Type I, Trophoblast Interferon. American Journal of Reproductive Immunology, 1993, 29, 26-34.	1.2	40
88	A novel type of class I gene organization in vertebrates: a large family of non-MHC-linked class I genes is expressed at the RNA level in the amphibian Xenopus EMBO Journal, 1993, 12, 4385-4396.	3.5	128
89	Abnormalities in HLA Class I Antigen Expression by Melanoma Cells: Structural Characterization and Functional Implications. Journal of Investigative Dermatology, 1993, 100, S226-S230.	0.3	1
90	ras Oncogene Activation Does Not Induce Sensitivity to Natural Killer Cell—Mediated Lysis in Human Melanoma. Journal of Investigative Dermatology, 1994, 103, S117-S121.	0.3	4

#	Article	IF	CITATIONS
91	NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80 Journal of Experimental Medicine, 1994, 180, 1235-1242.	4.2	317
92	Expression of different members of the Ly-49 gene family defines distinct natural killer cell subsets and cell adhesion properties Journal of Experimental Medicine, 1994, 180, 2287-2295.	4.2	164
93	ANTI-CD3 AND ANTI-CD16 MONOCLONAL-ANTIBODY IN-VITRO ENHANCEMENT OF NK ACTIVITY IN PBL FROM GASTROINTESTINAL-TRACT CANCER-PATIENTS. International Journal of Oncology, 1994, 5, 683-8.	1.4	0
94	A natural killer cell receptor specific for a major histocompatibility complex class I molecule Journal of Experimental Medicine, 1994, 180, 687-692.	4.2	154
95	Ly-49 mediates EL4 lymphoma adhesion to isolated class I major histocompatibility complex molecules Journal of Experimental Medicine, 1994, 179, 1011-1015.	4.2	155
96	Lysis of Porcine Trophoblast Cells by Endometrial Natural Killer-Like Effector Cells in Vitro does not Require Interleukin-21. Biology of Reproduction, 1994, 51, 1279-1284.	1.2	27
97	Human natural killer cell receptors for HLA-class I molecules. Evidence that the Kp43 (CD94) molecule functions as receptor for HLA-B alleles Journal of Experimental Medicine, 1994, 180, 545-555.	4.2	204
98	Control of rat natural killer cell-mediated allorecognition by a major histocompatibility complex region encoding nonclassical class I antigens Journal of Experimental Medicine, 1994, 180, 641-651.	4.2	82
99	ras Oncogene Activation Does Not Induce Sensitivity to Natural Killer Cell-Mediated Lysis in Human Melanoma Journal of Investigative Dermatology, 1994, 103, 117S-121S.	0.3	5
100	Prolactin induces rapid p95/p70 tyrosine phosphorylation, and protein binding to GAS-like sites in the anx lcp35 and c-fos genes Endocrinology, 1994, 134, 1979-1985.	1.4	22
101	In vivo activation of NK cells induces inhibition of lung colonization of H-2 positive and H-2 negative fibrosarcoma tumor clones. Clinical and Experimental Metastasis, 1994, 12, 31-36.	1.7	6
102	Double fluorescence analysis of human cytomegalovirus (HCMV) infected human fibroblast cultures by flow cytometry: increase of class I MHC expression on uninfected cells and decrease on infected cells. Archives of Virology, 1994, 135, 75-87.	0.9	19
103	Lysis of endothelial cells by autologous lymphokine-activated killer cells. Cancer Immunology, Immunotherapy, 1994, 38, 317-322.	2.0	12
104	MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens. Cancer Immunology, Immunotherapy, 1994, 38, 185-193.	2.0	10
105	Origin and functions of human natural killer cells. International Journal of Clinical and Laboratory Research, 1994, 24, 181-186.	1.0	17
106	Psychoneuroimmunology and the course of breast cancer: An overview the impact of psychosocial factors on progression of breast cancer through immune and endocrine mechanisms. Psycho-Oncology, 1994, 3, 271-288.	1.0	34
107	In vivo phenotypic characteristics of AKR T-cell lymphomas with different leukemic potential: Possible role of $\hat{l}\pm4\hat{l}^27$ integrin in the progression towards the leukemic phenotype. International Journal of Cancer, 1994, 56, 560-567.	2.3	7
108	Rat interleukin-2-activated natural killer (A-NK) cell-mediated lysis is determined by the presence of CD18 on A-NK cells and the absence of major histocompatibility complex class I on target cells. European Journal of Immunology, 1994, 24, 171-175.	1.6	19

#	Article	IF	CITATIONS
109	The ability of H-2Dd molecule to affect natural resistance to hemopoietic allografts is an intrinsic property shared by Ddm1 but not Ld. European Journal of Immunology, 1994, 24, 336-342.	1.6	5
110	Self class I molecules protect normal cells from lysis mediated by autologous natural killer cells. European Journal of Immunology, 1994, 24, 1003-1006.	1.6	91
111	Multiple natural killer cell-activating signals are inhibited by major histocompatibility complex class I expression in target cells. European Journal of Immunology, 1994, 24, 1323-1331.	1.6	80
112	Ly-49-independent inhibition of natural killer cell-mediated cytotoxicity by a soluble major histocompatibility complex class I molecule. European Journal of Immunology, 1994, 24, 2110-2114.	1.6	9
113	The human natural killer cell receptor for major histocompatibility complex class I molecules. Surface modulation of p58 molecules and their linkage to CD3 ζ chain, FcεRI γ chain and the p56lck kinase. European Journal of Immunology, 1994, 24, 2527-2534.	1.6	55
114	Invertebrate immune recognition, natural immunity and the evolution of positive selection. Trends in Immunology, 1994, 15, 316-320.	7.5	70
115	Ontogeny, specific functions and receptors of human natural killer cells. Immunology Letters, 1994, 40, 83-88.	1.1	20
116	Human trophoblast cell surface molecules: HLA-G and reproduction. Placenta, 1994, 15, 331-337.	0.7	0
117	Expression of MHC class I antigen in Morris rat hepatoma and normal liver. Cancer Letters, 1994, 84, 51-57.	3.2	1
118	Ly-49A, a receptor for H-2Dd, has a functional carbohydrate recognition domain. Immunity, 1994, 1, 785-792.	6.6	114
119	In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression Journal of Experimental Medicine, 1994, 179, 1215-1224.	4.2	184
120	Immune Response against Tumors. Advances in Immunology, 1994, 57, 281-351.	1.1	71
121	Tumour necrosis factor- \hat{l}_{\pm} induces an increase in susceptibility of human glioblastoma U87-MG cells to natural killer cell-mediated lysis. British Journal of Cancer, 1994, 69, 627-632.	2.9	19
122	Altered natural killer cell repertoire in Tap-1 mutant mice Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 6520-6524.	3.3	87
123	Natural killer cell receptors specific for major histocompatibility complex class I molecules Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3081-3085.	3.3	80
124	Antigen Presentation By Class I Major Histocompatibility Complex Molecules: A Context for Thinking About HLAâ€G. American Journal of Reproductive Immunology, 1995, 34, 10-19.	1.2	37
125	Inhibition of selective signaling events in natural killer cells recognizing major histocompatibility complex class I Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 6484-6488.	3.3	75
126	Natural killer cells: Right-side-up and up-side-down NK-cell receptors. Current Biology, 1995, 5, 982-985.	1.8	26

#	Article	IF	CITATIONS
127	Characterization of a Distinct Subpopulation of Bovine $\hat{l}^3\hat{l}$ T cells. Zoonoses and Public Health, 1995, 42, 162-174.	1.4	3
128	Alloreactive natural killer cells in the rat: complex genetics of major histocompabitility complex control. European Journal of Immunology, 1995, 25, 1249-1256.	1.6	62
129	Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules. European Journal of Immunology, 1995, 25, 1286-1291.	1.6	32
130	Susceptibility of colorectal-carcinoma cells to natural-killer-mediated lysis: Relationship to CEA expression and degree of differentiation. International Journal of Cancer, 1995, 61, 854-860.	2.3	33
131	Engagement of MHC Class I Proteins on Natural Killer Cells Inhibits their Killing Capacity. Scandinavian Journal of Immunology, 1995, 42, 34-38.	1.3	9
132	Tumor Heterogeneity and Immunotherapy of Cancer. Immunological Reviews, 1995, 145, 91-122.	2.8	51
133	The enigma of the natural killer cell. Nature, 1995, 378, 245-248.	13.7	237
134	Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. British Journal of Cancer, 1995, 72, 405-411.	2.9	148
135	Hanging in the balance: natural killer cell recognition of target cells. Chemistry and Biology, 1995, 2, 429-435.	6.2	20
136	Natural killer cell receptors. Current Opinion in Immunology, 1995, 7, 110-120.	2.4	167
137	The role of natural killer cells in transplantation. Current Opinion in Immunology, 1995, 7, 626-631.	2.4	30
138	Changes in LAK susceptibility of tumor cells as their MHC class I antigen expression levels regenerate after treatment at pH 3.0. Immunology Letters, 1995, 44, 7-11.	1.1	6
139	Enhanced MHC I antigen expression on tumour target cells is inversely correlated to lysis by allogenic but not by xenogenic NK cells. Journal of Biosciences, 1995, 20, 515-523.	0.5	0
140	Upregulation of B7 molecules by the Epsteinâ€"Barr virus enhances susceptibility to lysis by a human NK-like cell line. Cellular Immunology, 1995, 160, 104-114.	1.4	28
141	Materno-fetal immunobiology in normal pregnancy and its possible failure in recurrent spontaneous abortion?. Human Reproduction, 1995, 10, 107-113.	0.4	28
142	Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells Journal of Experimental Medicine, 1995, 182, 875-884.	4.2	439
143	Altered phenotype and function of natural killer cells expressing the major histocompatibility complex receptor Ly-49 in mice transgenic for its ligand Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 1649-1653.	3.3	121
144	Carbohydrate Recognition by a Natural Killer Cell Receptor, Ly-49C. Journal of Biological Chemistry, 1995, 270, 9691-9694.	1.6	67

#	Article	IF	CITATIONS
145	A reassessment of the role of B7-1 expression in tumor rejection Journal of Experimental Medicine, 1995, 182, 1415-1421.	4.2	181
146	Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science, 1995, 267, 1016-1018.	6.0	300
147	Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science, 1995, 268, 405-408.	6.0	714
148	Coexpression of two functionally independent p58 inhibitory receptors in human natural killer cell clones results in the inability to kill all normal allogeneic target cells Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3536-3540.	3.3	64
149	Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity, 1995, 2, 439-449.	6.6	561
150	Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity, 1995, 3, 801-809.	6.6	319
151	The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity, 1995, 3, 583-590.	6.6	138
152	MHC-recognizing receptors: They're not just for T cells anymore. Immunity, 1995, 3, 5-8.	6.6	64
153	An evolutionary conserved target cell antigen along with MHC class I molecules influences susceptibility to murine NK cell lysis. Developmental and Comparative Immunology, 1995, 19, 347-355.	1.0	0
154	Altered MHC class I presented peptide repertoire is not sufficient to induce NK cell mediated F1-hybrid resistance. Molecular Immunology, 1995, 32, 789-794.	1.0	5
155	Dd is the only gene that controls NK cell resistance of heterozygous H-2bd cells. Molecular Immunology, 1995, 32, 773-776.	1.0	0
156	Cancer: A biological problem without any natural immunological solution? A unified theory, with implications for grafts, pregnancy and tumour immunoprophylaxis. Medical Hypotheses, 1995, 45, 317-324.	0.8	4
157	Natural killer cell receptors: The offs and ons of NK cell recognition. Cell, 1995, 82, 697-700.	13.5	169
158	A family of murine NK cell receptors specific for target cell MHC class I molecules. Seminars in Immunology, 1995, 7, 89-101.	2.7	53
159	Inhibitory effects of class I molecules on murine NK cells: speculations on function, specificity and self-tolerance. Seminars in Immunology, 1995, 7, 103-107.	2.7	25
160	Hla Class I Antigens in Human Tumors. Advances in Cancer Research, 1995, 67, 155-195.	1.9	121
161	Express yourself or die: peptides, MHC molecules, and NK cells. Science, 1995, 267, 978-979.	6.0	164
162	Binding of diverse peptides to MHC class I molecules inhibits target cell lysis by activated natural killer cells. Immunity, 1995, 2, 61-71.	6.6	165

#	Article	IF	CITATIONS
163	Lymphocyte infiltration following allo-and xenomyoblast transplantation in mdx mice. Muscle and Nerve, 1995, 18, 39-51.	1.0	71
164	Decidua in human implantation. Human Reproduction, 1995, 10, 14-21.	0.4	146
165	Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferonî³ (IFN-î³) are recognised by T cells while resisting destruction by natural killer (NK) cells. European Journal of Cancer, 1996, 32, 1408-1412.	1.3	8
166	Anti-viral cytotoxic cells in the channel catfish (Ictalurus punctatus). Developmental and Comparative Immunology, 1996, 20, 115-127.	1.0	72
167	HLA-All-mediated protection from NK cell-mediated lysis. Human Immunology, 1996, 49, 1-12.	1.2	13
168	The Role of MHC Class I Expression in Rat NK Cell-Mediated Lysis of Syngeneic Tumor Cells and Virus-Infected Cells. Immunobiology, 1996, 195, 286-299.	0.8	12
169	Origin of blood-group antigens: A self-declaration mechanism in somatic cell society. Medical Hypotheses, 1996, 46, 290-294.	0.8	3
170	Triggering of Natural Killer Cells by the Costimulatory Molecule CD80 (B7-1). Immunity, 1996, 5, 311-317.	6.6	220
171	The Role of Ly49A and 5E6(Ly49C) Molecules in Hybrid Resistance Mediated by Murine Natural Killer Cells Against Normal T Cell Blasts. Immunity, 1996, 4, 67-76.	6.6	213
172	Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors. Advances in Neuroimmunology, 1996, 6, 233-247.	1.8	24
173	Independent Modes of Natural Killing Distinguished in Mice Lacking Lag3. Science, 1996, 272, 405-408.	6.0	158
174	Protection from Natural Killer Cell-Mediated Lysis by HLA-G Expression on Target Cells. Science, 1996, 274, 792-795.	6.0	477
175	HLA-Class I-Specific Inhibitory Receptors of NK Type on a Subset of Human T Cells. Chemical Immunology and Allergy, 1996, 64, 135-145.	1.7	0
176	Natural Killer Cells in MHC Class I Deficient Mice. Chemical Immunology and Allergy, 1996, 64, 44-58.	1.7	2
177	Inhibitory and Activatory Receptors for HLA Class I Molecules in Human Natural Killer Cells. Chemical Immunology and Allergy, 1996, 64, 77-87.	1.7	7
178	Functional Resemblance between the Ig-Related NK Cell Receptors Specific for HLA Class I Molecules and the CD94 C-Type Lectin. Chemical Immunology and Allergy, 1996, 64, 116-134.	1.7	0
179	Molecular Structures of HLA-Specific Human NK Cell Receptors. Chemical Immunology and Allergy, 1996, 64, 88-103.	1.7	2
180	NKB1: A Killer Cell Inhibitory Receptor for Class I HLA-B Allotypes. Chemical Immunology and Allergy, 1996, 64, 104-115.	1.7	O

#	Article	IF	CITATIONS
181	Role of the Major Histocompatibility Complex Class I Regions in Rat Natural Killer Cell Allograft Responses in vivo and in vitro. Chemical Immunology and Allergy, 1996, 64, 59-76.	1.7	2
182	The role of granzyme B in murine models of acute graft-versus-host disease and graft rejection. Blood, 1996, 87, 1232-1237.	0.6	126
183	The natural killer cell receptor Ly-49A recognizes a peptide-induced conformational determinant on its major histocompatibility complex class I ligand Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11792-11797.	3.3	78
184	Immunology of human implantation: an evolutionary perspective. Human Reproduction, 1996, 11, 283-286.	0.4	45
185	Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 12433-12438.	3.3	224
186	Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1453-1457.	3.3	103
187	RECEPTORS FOR HLA CLASS-I MOLECULES IN HUMAN NATURAL KILLER CELLS. Annual Review of Immunology, 1996, 14, 619-648.	9.5	833
188	HLA expression and tumor-infiltrating immune cells in uveal melanoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 1996, 234, 34-42.	1.0	77
189	The molecular basis of Natural Killer (NK) cell recognition and function. Journal of Clinical Immunology, 1996, 16, 243-253.	2.0	35
190	Correlation between Graft-Versus-Host Induced Immunosuppression and Host Natural Killer Cell Activity in Small Bowel Transplantation. World Journal of Surgery, 1996, 20, 1041-1051.	0.8	5
191	Alternatively splicedLy-49D andH transcripts are found in IL-2-activated NK cells. Immunogenetics, 1996, 44, 478-482.	1.2	18
192	NK cell receptor gene of the KIR family with two IG domains but highest homology to KIR receptors with three IG domains. Tissue Antigens, 1996, 48, 285-295.	1.0	105
193	Functions of Human Decidual NK Cells. American Journal of Reproductive Immunology, 1996, 35, 258-260.	1.2	86
194	Methylcholanthreneâ€induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. Apmis, 1996, 104, 629-639.	0.9	35
195	Nonclassical HLA-G molecules are classical peptide presenters. Current Biology, 1996, 6, 305-314.	1.8	194
196	Immunology: Keeping mother at bay. Current Biology, 1996, 6, 638-641.	1.8	36
197	Major histocompatibility complex genes determine natural killer cell tolerance. European Journal of Immunology, 1996, 26, 151-155.	1.6	62
198	Natural killer clones recognize specific soluble HLA class I molecules. European Journal of Immunology, 1996, 26, 683-689.	1.6	42

#	Article	IF	CITATIONS
199	Semi-allogeneic (F1) versus fully allogeneic blood transfusions: differences in their ability to induce specific immunological unresponsiveness. European Journal of Immunology, 1996, 26, 1468-1474.	1.6	14
200	A novel surface molecule homologous to the p58/p50 family of receptors is selectively expressed on a subset of human natural killer cells and induces both triggering of cell functions and proliferation. European Journal of Immunology, 1996, 26, 1816-1824.	1.6	126
201	Threonine 80 on HLA-B27 confers protection against lysis by a group of natural killer clones. European Journal of Immunology, 1996, 26, 1974-1977.	1.6	56
202	Influence of glycosylphosphatidylinositol-linked H-2Dd molecules on target cell protection and natural killer cell specificity in transgenic mice. European Journal of Immunology, 1996, 26, 2127-2132.	1.6	8
203	CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies. European Journal of Immunology, 1996, 26, 2487-2492.	1.6	130
204	Negative regulation of rat natural killer cell activity by major histocompatibility complex class I recognition. European Journal of Immunology, 1996, 26, 2582-2586.	1.6	39
205	Major histocompatibility complex class I-dependent cell binding to isolated Ly-49A: evidence for high-avidity interaction. European Journal of Immunology, 1996, 26, 3219-3223.	1.6	14
206	Cis-diamminedichloroplatinum(II) augments expression of tumor-associated antigens on human gastric cancer cell line KATO-3 and increases susceptibility and binding of tumor cells to various cytotoxic effector cells., 1996, 62, 162-170.		2
207	Natural resistance against tumors grafted into the brain in association with histocompatibility-class-l-antigen expression., 1996, 67, 365-371.		10
208	Opposing functions of activatory T-cell receptors and inhibitory NK-cell receptors on cytotoxic T cells. Trends in Immunology, 1996, 17, 450-453.	7.5	23
209	Natural killer cell receptors specific for MHC class I molecules. Current Opinion in Immunology, 1996, 8, 101-107.	2.4	73
210	Recognition events that inhibit and activate natural killer cells. Current Opinion in Immunology, 1996, 8, 372-377.	2.4	52
212	Interaction of natural killer cells with MHC class II: reversal of HLAâ€DR1â€mediated protection of K562 transfectant from natural killer cellâ€mediated cytolysis by brefeldinâ€A. Immunology, 1996, 87, 481-486.	2.0	32
213	An autosomal dominant locus, Nka, mapping to the Ly-49 region of a rat natural killer (NK) gene complex, controls NK cell lysis of allogeneic lymphocytes Journal of Experimental Medicine, 1996, 183, 2197-2207.	4.2	117
214	Genes in two MHC class I regions control recognition of a single rat NK cell allodeterminant. International Immunology, 1996, 8, 1779-1785.	1.8	29
215	The Ly-49D Receptor Activates Murine Natural Killer Cells. Journal of Experimental Medicine, 1996, 184, 2119-2128.	4.2	198
216	Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo. Journal of General Virology, 1996, 77, 217-225.	1.3	57
217	Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules Journal of Experimental Medicine, 1996, 184, 913-922.	4.2	317

#	Article	IF	CITATIONS
218	Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection Journal of Experimental Medicine, 1996, 184, 2037-2041.	4.2	106
219	Heterogeneous phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of different human histocompatibility leukocyte antigens types appear genetically regulated, but not linked to major histocompatibility complex haplotype Journal of Experimental Medicine. 1996. 183. 1817-1827.	4.2	150
220	Genetic Analysis of a Sarcoma Accidentally Transplanted from a Patient to a Surgeon. New England Journal of Medicine, 1996, 335, 1494-1497.	13.9	69
221	A fresh look at the causes and treatments of recurrent miscarriage, especially its immunological aspects. Human Reproduction Update, 1996, 2, 271-293.	5.2	111
222	A Common Inhibitory Receptor for Major Histocompatibility Complex Class I Molecules on Human Lymphoid and Myelomonocytic Cells. Journal of Experimental Medicine, 1997, 186, 1809-1818.	4.2	847
223	A New Mechanism of NK Cell Cytotoxicity Activation: The CD40–CD40 Ligand Interaction. Journal of Experimental Medicine, 1997, 185, 2053-2060.	4.2	213
224	Human Histocompatibility Leukocyte Antigen (HLA)-G Molecules Inhibit NKAT3 Expressing Natural Killer Cells. Journal of Experimental Medicine, 1997, 185, 385-392.	4.2	141
225	Selective Activation of cAMP-dependent Protein Kinase Type I Inhibits Rat Natural Killer Cell Cytotoxicity. Journal of Biological Chemistry, 1997, 272, 5495-5500.	1.6	68
226	Natural Killer Cell Tolerance in Mice with Mosaic Expression of Major Histocompatibility Complex Class I Transgene. Journal of Experimental Medicine, 1997, 186, 353-364.	4.2	123
227	Multiple receptors for HLA-G on human natural killer cells. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 14666-14670.	3.3	83
228	The Ly-49 family: regulation of cytokine production in murine NK cells. Journal of Leukocyte Biology, 1997, 62, 381-388.	1.5	23
229	HLA AND CANCER: IMPLICATIONS FOR CANCER IMMUNOTHERAPY AND VACCINATION. International Journal of Immunogenetics, 1997, 24, 293-312.	1.2	21
230	Pulmonary perspective: immunology in diagnosis and treatment of lung cancer. European Respiratory Journal, 1997, 10, 1703-1719.	3.1	16
231	Two Distinct Populations of Primary Cytotoxic Cells Infiltrating into Allografted Tumor Rejection Sites: Infiltration of Macrophages Cytotoxic against Allografted Tumor Precedes That of Multiple Sets of Cytotoxic T Lymphocytes with Distinct Specificity to Alloantigens. Microbiology and Immunology, 1997, 41, 149-159.	0.7	26
232	The Binding Site of NK Receptors on HLA-C Molecules. Immunity, 1997, 6, 341-350.	6.6	94
233	Functionally and Structurally Distinct NK Cell Receptor Repertoires in the Peripheral Blood of Two Human Donors. Immunity, 1997, 7, 739-751.	6.6	689
234	Human Diversity in Killer Cell Inhibitory Receptor Genes. Immunity, 1997, 7, 753-763.	6.6	1,010
235	Signal Transduction during Natural Killer Cell Activation: Inside the Mind of a Killer. Immunity, 1997, 6, 655-661.	6.6	245

#	Article	IF	Citations
236	A Novel Immunoglobulin Superfamily Receptor for Cellular and Viral MHC Class I Molecules. Immunity, 1997, 7, 273-282.	6.6	627
237	The CD94/NKG2C-type lectin receptor complex in recognition of HLA class I molecules. Research in Immunology, 1997, 148, 155-159.	0.9	5
238	Inhibitory and activatory receptors for MHC class I molecules. Research in Immunology, 1997, 148, 172-179.	0.9	2
240	Establishment and characterization of porcine cytolytic cell lines and clones. Veterinary Immunology and Immunopathology, 1997, 59, 337-347.	0.5	28
241	Characterization of three new membrane structures on rat NK cells which are involved in activation of the lytic machinery. Immunobiology, 1997, 197, 429-443.	0.8	12
242	MHC-I antigen expression determines sensitivity of hematopoetic progenitor cells as targets for NK cells. Immunobiology, 1997, 197, 494-504.	0.8	6
243	Natural killer cells in immune regulation. Clinical Immunology Newsletter, 1997, 17, 151-154.	0.1	0
244	Killer cell inhibitory receptor interactions with HLA class I molecules. Human Immunology, 1997, 52, 1-11.	1.2	15
245	Japanese population does not manifest significant association between low NK activity and HLA-B(C) locus homozygosity. Human Immunology, 1997, 53, 17-22.	1.2	0
246	The mother-child union: The case of missing-self and protection of the fetus. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 5998-6000.	3.3	30
247	Self and viral peptides can initiate lysis by autologous natural killer cells. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 4604-4609.	3.3	69
248	Involvement of Thyroid Hormones in the Expression of MHC class I Antigens During Ontogeny in <i>Xenopus</i> . Autoimmunity, 1997, 5, 133-144.	0.6	36
249	The killer cell inhibitory receptor genomic region on human chromosome 19q13.4. Tissue Antigens, 1997, 49, 557-563.	1.0	52
250	Acute cellular xenograft rejection. Xenotransplantation, 1997, 4, 11-19.	1.6	52
251	Natural killer cells in xenotransplantation. Xenotransplantation, 1997, 4, 201-211.	1.6	58
252	How to recongnize a foreign submarine. Immunological Reviews, 1997, 155, 5-9.	2.8	117
253	Host MHC class I gene control of NK-cell specificity in the mouse. Immunological Reviews, 1997, 155, 11-28.	2.8	145
254	Allorecognition by murine natural killer cells: lysis of T-lymphoblasts and rejection of bone-marrow grafts. Immunological Reviews, 1997, 155, 29-40.	2.8	59

#	Article	IF	Citations
255	Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Immunological Reviews, 1997, 155, 41-52.	2.8	212
256	The Ly-49 family: genes, proteins and recognition of class I MHC. Immunological Reviews, 1997, 155, 67-77.	2.8	169
257	Positive and negative MHC class I recognition by rat NK cells. Immunological Reviews, 1997, 155, 91-104.	2.8	51
258	Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunological Reviews, 1997, 155, 105-117.	2.8	333
259	Human NK cells: their ligands, receptors and functions. Immunological Reviews, 1997, 155, 119-125.	2.8	75
260	Killer cell receptors: keeping pace with MHC class I evolution. Immunological Reviews, 1997, 155, 155-164.	2.8	109
261	Domain organization and sequence relationship of killer cell inhibitory receptors. Immunological Reviews, 1997, 155, 175-182.	2.8	12
262	Signal transduction by human NK cell MHC-recognizing receptors. Immunological Reviews, 1997, 155, 197-203.	2.8	40
263	A vision of cell death: insights into immune privilege. Immunological Reviews, 1997, 156, 167-184.	2.8	167
264	From stem cells to lymphocytes; biology and transplantation. Immunological Reviews, 1997, 157, 13-40.	2.8	64
265	Antiviral immune responses modulate the nature of central nervous system (CNS) disease in a murine model of multiple sclerosis. Immunological Reviews, 1997, 159, 177-193.	2.8	57
266	Regulation of Abortion by $\hat{I}^{3}\hat{I}$ » T Cells. American Journal of Reproductive Immunology, 1997, 37, 87-93.	1.2	49
267	Effects of Serum from Pregnant Versus Nonpregnant Women on Natural Killer Cell Activity. American Journal of Reproductive Immunology, 1997, 37, 365-367.	1.2	7
268	HLA-class I-specific inhibitory receptors in human cytolytic T lymphocytes. Molecular characterization, distribution in lymphoid tissues and coexpression by individual T cells. Immunology Letters, 1997, 56, 12.	1.1	0
269	Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors. Immunological Reviews, 1997, 155, 127-133.	2.8	114
270	Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. Immunological Reviews, 1997, 155, 165-174.	2.8	130
275	Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors. Nature, 1997, 389, 96-100.	13.7	154
277	The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature, 1997, 386, 514-517.	13.7	302

#	Article	IF	CITATIONS
278	A new human gene complex encoding the killer cell inhibitory receptors and related monocyte/macrophage receptors. Current Biology, 1997, 7, 615-618.	1.8	179
279	Regulation through inhibitory receptors: Lessons from natural killer cells. Trends in Cell Biology, 1997, 7, 473-479.	3.6	71
280	Trophoblast interaction with decidual NK cells in human implantation. Placenta, 1997, 18, 173-180.	0.7	0
281	The CD94/NKG2 C-type lectin receptor complex. Immunologic Research, 1997, 16, 175-185.	1.3	14
282	HLA-C revisited. Immunologic Research, 1997, 16, 203-214.	1.3	34
283	Inhibitory receptors for HLA class I molecules on cytolytic T lymphocytes. International Journal of Clinical and Laboratory Research, 1997, 27, 87-94.	1.0	5
284	Missing self by heterogeneous natural killer cells. Journal of Biosciences, 1997, 22, 3-12.	0.5	3
285	Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. Journal of Molecular Medicine, 1997, 75, 400-413.	1.7	40
286	HLA class I specific inhibitory receptors. Current Opinion in Immunology, 1997, 9, 694-701.	2.4	98
287	Role of murine NK cells and their receptors in hybrid resistance. Current Opinion in Immunology, 1997, 9, 52-56.	2.4	52
288	Mechanism of interaction of pH 3.0 treated tumor cells expressing lower levels of class I MHC antigens, with IL-2 activated NK cells. Immunology Letters, 1997, 55, 167-171.	1.1	0
289	Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Trends in Immunology, 1997, 18, 89-95.	7.5	708
290	Ontogeny of inhibitory receptors for MHC molecules on NK cells. Trends in Immunology, 1997, 18, 146.	7.5	6
291	The Susceptibility to Cytotoxic T Lymphocyte Mediated Lysis of Chemically Induced Sarcomas from Immunodeficient and Normal Mice. Scandinavian Journal of Immunology, 1997, 45, 28-35.	1.3	8
292	Restoration of MHC Class I Surface Expression and Endogenous Antigen Presentation by a Molecular Chaperone. Scandinavian Journal of Immunology, 1997, 45, 605-612.	1.3	32
293	Infection with rat cytomegalovirus (CMV) in the immunocompromised host is associated with the appearance of a T cell population with reduced CD8 and T cell receptor (TCR) expression. Clinical and Experimental Immunology, 1997, 110, 349-357.	1.1	10
294	Autologous killing by a population of intermediate Tâ€cell receptor cells and its NK1.1 + and NK1.1 â^' subsets, using Fas ligand/Fas molecules. Immunology, 1997, 91, 219-226.	2.0	49
295	Lack of F1 anti-parental resistance in H-2b/d F1 hybrids devoid of \hat{l}^2 2-microglobulin. European Journal of Immunology, 1997, 27, 342-345.	1.6	4

#	Article	IF	CITATIONS
296	The CD94 and NKG2-A C-type lectins covalently assemble to form a natural killer cell inhibitory receptor for HLA class I molecules. European Journal of Immunology, 1997, 27, 563-567.	1.6	257
297	Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor. European Journal of Immunology, 1997, 27, 1374-1380.	1.6	151
298	Differential association of phosphatases with hematopoietic co-receptors bearing immunoreceptor tyrosine-based inhibition motifs. European Journal of Immunology, 1997, 27, 1994-2000.	1.6	133
299	Location-specific regulation of transgenic Ly49A receptors by major histocompatibility complex class I molecules. European Journal of Immunology, 1997, 27, 2057-2065.	1.6	28
300	Control of self-reactive cytotoxic T lymphocytes expressing $\hat{I}^{3}\hat{I}$ T cell receptors by natural killer inhibitory receptors. European Journal of Immunology, 1997, 27, 2812-2821.	1.6	150
301	Fetal and neonatal NK1.1+ Ly-49â^² cells can distinguish between major histocompatibility complex class Ihi and class Ilo target cells: Evidence for a Ly-49-independent negative signaling receptor. European Journal of Immunology, 1997, 27, 3100-3104.	1.6	30
302	Sendai Viruses with Altered P, V, and W Protein Expression. Virology, 1998, 242, 327-337.	1.1	53
303	Unmasking the killer's accomplice. Nature, 1998, 391, 642-643.	13.7	21
304	Craters of doom. Nature, 1998, 391, 643-643.	13.7	0
305	Human NK cell and ADCC reactivity against xenogeneic porcine target cells including fetal porcine islet cells. Xenotransplantation, 1998, 5, 132-145.	1.6	36
306	Review: Analogies Between Trophoblastic and Malignant Cells. American Journal of Reproductive Immunology, 1998, 39, 41-49.	1.2	31
307	Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment. Nature Medicine, 1998, 4, 173-180.	15.2	78
308	Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems. Immunological Reviews, 1998, 165, 47-61.	2.8	116
309	Suppression of Natural Killer Cell Activity and Interleukinâ€2 Concentration of Serum Obtained from ⟨i>In Vitro⟨ i> Fertilizationâ€Embryo Transfer Patients. American Journal of Reproductive Immunology, 1998, 40, 9-12.	1.2	2
310	Unique Biochemical Properties of Human Leukocyte Antigenâ€E Allow for a Highly Specific Function in Immune Recognition. American Journal of Reproductive Immunology, 1998, 40, 177-182.	1.2	7
311	Etiology and pathogenesis of preeclampsia: Current concepts. American Journal of Obstetrics and Gynecology, 1998, 179, 1359-1375.	0.7	672
	Gynecology, 1776, 177, 1337-1373.		
312	Genetic Therapies for Xenotransplantation. Journal of the American College of Surgeons, 1998, 186, 388-396.	0.2	18

#	Article	IF	CITATIONS
314	Kinetics of in vitro natural killer activity against K562 cells as detected by flow cytometry., 1998, 32, 280-285.		29
315	$\hat{l}^22\hat{a}$ €‰-Microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains. European Journal of Immunology, 1998, 28, 370-378.	1.6	49
316	MHC class I expression protects target cells from lysis by Ly49-deficient fetal NK cells. European Journal of Immunology, 1998, 28, 47-56.	1.6	45
317	Signaling through human killer cell activating receptors triggers tyrosine phosphorylation of an associated protein complex. European Journal of Immunology, 1998, 28, 599-609.	1.6	93
318	Fine tuning of natural killer cell specificity and maintenance of self tolerance in MHC class I-deficient mice. European Journal of Immunology, 1998, 28, 1315-1321.	1.6	51
319	The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles. European Journal of Immunology, 1998, 28, 2384-2394.	1.6	57
320	Impaired MHC class I (H-2Dd)-mediated protection against Ly-49A+ NK cells after amino acid substitutions in the antigen binding cleft. European Journal of Immunology, 1998, 28, 2872-2881.	1.6	18
321	Isotypic variation of novel immunoglobulin-like transcript/killer cell inhibitory receptor loci in the leukocyte receptor complex. European Journal of Immunology, 1998, 28, 3959-3967.	1.6	101
322	α1 / α2 domains of H-2Dd, but not H-2Ld, induce "missing self―reactivityin vivo – No effect of H protection against NK cells expressing the inhibitory receptor Ly49G2. European Journal of Immunology, 1998, 28, 4198-4206.	-2Ld on 1.6	26
323	The Qa-1b molecule binds to a large subpopulation of murine NK cells. European Journal of Immunology, 1998, 28, 4356-4361.	1.6	67
324	2F1 antigen, the mouse homolog of the rat "mast cell function-associated antigenâ€; is a lectin-like type II transmembrane receptor expressed by natural killer cells. European Journal of Immunology, 1998, 28, 4409-4417.	1.6	71
325	HLA-E is the ligand for the natural killer cell CD94/NKG2 receptors. Journal of Biomedical Science, 1998, 5, 321-331.	2.6	25
326	Natural Killer Cells and Recognition of MHC Class I Molecules: New Perspectives and Challenges in Immunology. Scandinavian Journal of Immunology, 1998, 47, 412-425.	1.3	30
327	Natural killer cell proliferation induced by anti-NK1.1 and IL-2. Immunology and Cell Biology, 1998, 76, 143-152.	1.0	23
328	Do Primary Cutaneous Non-T Non-B CD4+CD56+ Lymphomas Belong to the Myelo-Monocytic Lineage?. Journal of Investigative Dermatology, 1998, 111, 1242-1244.	0.3	26
329	Lack of association between childhood common acute lymphoblastic leukaemia and an HLA-C locus dimorphism influencing the specificity of natural killer cells. British Journal of Haematology, 1998, 102, 1279-1283.	1.2	2
330	Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Trends in Immunology, 1998, 19, 153-157.	7.5	230
331	Effect of mild acute stress on immune cell distribution and natural killer cell activity in breast cancer patients. Biological Psychology, 1998, 48, 21-35.	1.1	14

#	ARTICLE Why certain antibodies cross-react with HLA- A and HLA-G: Epitope mapping of two common MHC class I	IF	CITATIONS
332	reagentsfn2fn2This work was supported by a grant from the National Institutes of Health (R01Al38577-01) and by a Reproductive Scientist Development Award, the Society for Gynecologic Investigation, and National Institutes of Health Grant K12HD00849 (to D.J.S.). Molecular Immunology,	1.0	125
333	1998, 35, 177-188. Natural killer cell reactivity: activation and cytolysis mechanism models, involving heat shock protein, haemopoietic histocompatibility, major histocompatibility complex and complement molecules. Medical Hypotheses, 1998, 51, 5-9.	0.8	5
334	The Lectin-Like NK Cell Receptor Ly-49A Recognizes a Carbohydrate-Independent Epitope on Its MHC Class I Ligand. Immunity, 1998, 8, 245-254.	6.6	70
335	The Crystal Structure of H-2Dd MHC Class I Complexed with the HIV-1-Derived Peptide P18-I10 at 2.4 Å Resolution. Immunity, 1998, 9, 199-208.	6.6	69
336	Cytotoxic Lymphocyte Recognition of HLA-E. Immunity, 1998, 9, 289-294.	6.6	42
337	Kinetics of Interaction of HLA-C Ligands with Natural Killer Cell Inhibitory Receptors. Immunity, 1998, 9, 337-344.	6.6	112
338	The Pathway for Processing Leader-Derived Peptides that Regulate the Maturation and Expression of Qa-1b. Immunity, 1998, 9, 413-421.	6.6	31
339	Follow the Leader: NK Cell Receptors for Classical and Nonclassical MHC Class I. Cell, 1998, 92, 705-707.	13.5	147
340	Mouse CD94/NKG2A Is a Natural Killer Cell Receptor for the Nonclassical Major Histocompatibility Complex (MHC) Class I Molecule Qa-1b. Journal of Experimental Medicine, 1998, 188, 1841-1848.	4.2	447
341	INNOVATIVE THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA. Hematology/Oncology Clinics of North America, 1998, 12, 173-206.	0.9	8
342	NK CELL RECEPTORS. Annual Review of Immunology, 1998, 16, 359-393.	9.5	1,553
343	Developmentally Regulated Extinction of Ly-49 Receptor Expression Permits Maturation and Selection of NK1.1+ T Cells. Journal of Experimental Medicine, 1998, 187, 2109-2114.	4.2	61
344	Altered expression of Ly-49 receptors on NK cells developing in mixed allogeneic bone marrow chimeras International Immunology, 1998, 10, 1943-1955.	1.8	38
345	Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence–derived Peptides by CD94/NKG2 Confers Protection from Natural Killer Cell–mediated Lysis. Journal of Experimental Medicine, 1998, 187, 813-818.	4.2	639
346	Acquisition of Ly49 Receptor Expression by Developing Natural Killer Cells. Journal of Experimental Medicine, 1998, 187, 609-618.	4.2	151
347	Apoptosis induced by NK cells is modulated by the NK-active cytokines IL-2 and IL-12. International Immunology, 1998, 10, 719-725.	1.8	17
348	Major histocompatibility complex (MHC) class I KbDb -/- deficient mice possess functional CD8+ T cells and natural killer cells. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 12492-12497.	3.3	114
349	Possible protective and pathogenic roles of gamma delta T lymphocytes in HIV-infections (Review) International Journal of Molecular Medicine, 1998, 1, 409-13.	1.8	11

#	Article	IF	CITATIONS
350	Immunology of human implantation: from the invertebrates' point of view. Human Reproduction, 1998, 13, 455-459.	0.4	24
351	The effects of surgical stress and psychological stress on the immune function of operative cancer patients. Psychology and Health, 1998, 13, 1015-1026.	1.2	14
352	The Labyrinthine Ways of Cancer Immunotherapy–T Cell, Tumor Cell Encounter: "How Do I Lose Thee? Let Me Count the Ways― Advances in Cancer Research, 1998, 75, 203-249.	1.9	23
353	Blocking of MHC Class I Antigens on Leukemic B-Cells Enhances their Conjugate Formation with Cytotoxic Lymphocytes and their Susceptibility to Lysis. Leukemia and Lymphoma, 1998, 28, 573-581.	0.6	4
354	Molecular Typing Shows a High Level of HLA Class I Incompatibility in Serologically Well Matched Donor/Patient Pairs: Implications for Unrelated Bone Marrow Donor Selection. Blood, 1998, 92, 4864-4871.	0.6	79
355	Interleukin-12–Activated Natural Killer Cells Recognize B7 Costimulatory Molecules on Tumor Cells and Autologous Dendritic Cells. Blood, 1998, 91, 196-206.	0.6	75
356	Modulation of Ly49A receptors on mature cells to changes in major histocompatibility complex class I molecules. Immunology, 1998, 95, 126-131.	2.0	11
357	Genetic Control Of Natural Killing and In Vivo Tumor Elimination by the Chok Locus. Journal of Experimental Medicine, 1998, 188, 2243-2256.	4.2	48
358	In Vivo Expression of Natural Killer Cell Inhibitory Receptors by Human Melanoma–Specific Cytolytic T Lymphocytes. Journal of Experimental Medicine, 1999, 190, 775-782.	4.2	179
359	Immunobiology of the Cornea. , 1999, 30, 110-128.		1
360	Identification and Molecular Characterization of Nkp30, a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells. Journal of Experimental Medicine, 1999, 190, 1505-1516.	4.2	664
361	Hospitals, Heal Yourselves. New England Journal of Medicine, 1999, 340, 309-310.	13.9	40
362	Anticytokine Therapy â€" A New Era in the Treatment of Rheumatoid Arthritis?. New England Journal of Medicine, 1999, 340, 310-312.	13.9	112
363	Respiratory Viruses in Acute Otitis Media. New England Journal of Medicine, 1999, 340, 312-314.	13.9	17
364	Does a Low Level of Expression of HLA Molecules Engender Autoimmunity?. New England Journal of Medicine, 1999, 340, 314-315.	13.9	7
365	Mouse Ly-49D Recognizes H-2Dd and Activates Natural Killer Cell Cytotoxicity. Journal of Experimental Medicine, 1999, 189, 493-500.	4.2	129
366	The Murine Nonclassical Class I Major Histocompatibility Complex–like CD1.1 Molecule Protects Target Cells from Lymphokine-activated Killer Cell Cytolysis. Journal of Experimental Medicine, 1999, 189, 483-491.	4.2	45
367	Killer-Cell Inhibitory Receptors, CD158a/b, are Upregulated by Interleukin-2, but not Interferon- \hat{l}^3 or Interleukin-4. Mediators of Inflammation, 1999, 8, 313-318.	1.4	12

#	Article	IF	CITATIONS
368	Mini symposium. The major histocompatibility complex in pregnancy: Part II. Placental HLA-G protein expression in vivo: where and what for?. Human Reproduction Update, 1999, 5, 223-233.	5.2	95
369	Natural killing of MHC class l– lymphoblasts by NK cells from long-term bone marrow culture requires effector cell expression of Ly49 receptors. International Immunology, 1999, 11, 1239-1246.	1.8	12
370	Leukocyte function-associated antigen-1 expression on decidual natural killer cells in patients with early pregnancy loss. Molecular Human Reproduction, 1999, 5, 1083-1088.	1.3	20
371	Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3864-3869.	3.3	101
372	Natural killer cell activity in the peripheral blood of patients with Cushing's syndrome. European Journal of Endocrinology, 1999, 140, 299-306.	1.9	22
373	Immunological aspects of implantation and implantation failure. Human Reproduction, 1999, 14, 26-36.	0.4	49
374	Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5640-5644.	3.3	238
375	The natural killer gene complex genetic locus Chok encodes Ly-49D, a target recognition receptor that activates natural killing. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 6330-6335.	3.3	84
376	Killer Cell Immunoglobulin Receptors and T Cell Receptors Bind Peptide-Major Histocompatibility Complex Class I with Distinct Thermodynamic and Kinetic Properties. Journal of Biological Chemistry, 1999, 274, 28329-28334.	1.6	110
377	Recognition of the Class Ib Molecule Qa-1b by Putative Activating Receptors Cd94/Nkg2c and Cd94/Nkg2e on Mouse Natural Killer Cells. Journal of Experimental Medicine, 1999, 190, 1801-1812.	4.2	203
378	Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3870-3875.	3.3	101
379	The Transmembrane Sequence of Human Histocompatibility Leukocyte Antigen (HLA)-C as a Determinant in Inhibition of a Subset of Natural Killer Cells. Journal of Experimental Medicine, 1999, 189, 1265-1274.	4.2	28
380	Development and tolerance of natural killer cells. Current Opinion in Immunology, 1999, 11, 129-134.	2.4	74
381	Role of $\hat{I}^3\hat{I}$ T cells in tumor immunity and their control by NK receptors. Microbes and Infection, 1999, 1, 227-234.	1.0	19
382	Immunoreceptor tyrosine-based inhibition motif-bearing receptors regulate the immunoreceptor tyrosine-based activation motif-induced activation of immune competent cells. Immunology Letters, 1999, 68, 3-15.	1.1	63
383	Murine class I major histocompatibility complex H–2Dd: expression, refolding and crystallization. Acta Crystallographica Section D: Biological Crystallography, 1999, 55, 260-262.	2.5	29
384	Characterization of Subpopulations of T-Cell Receptor Intermediate (TCRint) T Cells. Scandinavian Journal of Immunology, 1999, 49, 611-619.	1.3	8
385	Direct Binding of Purified HLA Class I Antigens by Soluble NKG2/CD94 C-Type Lectins from Natural Killer Cells. Scandinavian Journal of Immunology, 1999, 49, 459-465.	1.3	8

#	Article	IF	CITATIONS
386	H-2Dd engagement of Ly49A leads directly to Ly49A phosphorylation and recruitment of SHP1. Immunology, 1999, 97, 656-664.	2.0	17
387	Control of γδT cells by NK receptors. Microbes and Infection, 1999, 1, 263-267.	1.0	13
388	Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers. Immunological Reviews, 1999, 168, 177-185.	2.8	62
389	Signal transduction by the major histocompatibility complex class I molecule:. Apmis, 1999, 107, 887-895.	0.9	26
390	Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand. Nature, 1999, 402, 623-631.	13.7	247
391	c-Myc and E1A induced cellular sensitivity to activated NK cells involves cytotoxic granules as death effectors. Oncogene, 1999, 18, 2181-2188.	2.6	11
392	Survival of Fetuses and Viruses: Universal Mechanisms of Coâ€Existence with an Immunological Potent Host. American Journal of Reproductive Immunology, 1999, 41, 353-355.	1.2	1
393	Proliferation and Differentiation of Alloselective NK Cells after Alloimmunization—Evidence for an Adaptive NK Response. Cellular Immunology, 1999, 197, 10-18.	1.4	7
394	HLA-G and HLA-C at the feto–maternal interface: lessons learned from pathogenic viruses. Seminars in Cancer Biology, 1999, 9, 37-46.	4.3	30
395	How do NK cells sense the expression of HLA-G class Ib molecules?. Seminars in Cancer Biology, 1999, 9, 19-26.	4.3	39
396	Expression analysis of new Ly49 genes: most transcripts of Ly49j lack the transmembrane domain. Immunogenetics, 1999, 49, 685-691.	1.2	29
397	Molecular cloning of mouse NKG2A and C. Immunogenetics, 1999, 49, 727-730.	1.2	14
398	Sensitization of resting T cells to autologous natural-killer-cell-mediated lysis by phytohemagglutinin. Cancer Immunology, Immunotherapy, 1999, 48, 507-516.	2.0	0
399	The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors— lessons from normal and immunodeficient mice. Medical Oncology and Tumor Pharmacotherapy, 1999, 16, 223-238.	1.0	28
400	Immune therapy of recurrent abortion. Reproduktionsmedizin, 1999, 15, 200-211.	0.1	2
401	Viral immunoevasive strategies and trophoblast class I major histocompatibility complex antigens. Journal of Reproductive Immunology, 1999, 43, 243-251.	0.8	7
402	Human leucocyte antigen-G and its recognition by natural killer cells. Journal of Reproductive Immunology, 1999, 43, 127-137.	0.8	23
403	NK cell mediated recognition of HLA class Ib molecules: role of CD94/NKG2 receptors. Journal of Reproductive Immunology, 1999, 43, 167-173.	0.8	8

#	Article	IF	CITATIONS
404	Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. Experimental Hematology, 1999, 27, 1627-1636.	0.2	211
405	HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Trends in Molecular Medicine, 1999, 5, 178-186.	2.6	321
406	NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. European Journal of Immunology, 1999, 29, 1656-1666.	1.6	392
407	Selection of phenotypically distinct NK1.1+ T cells upon antigen expression in the thymus or in the liver. European Journal of Immunology, 1999, 29, 2330-2343.	1.6	26
408	Dual role of TNF-α in NK / LAK cell-mediated lysis of chronically HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-mediated lysis. European Journal of Immunology, 1999, 29, 3654-3662.	1.6	14
409	Activation and selection of NK cells via recognition of an allogeneic, non-classical MHC class I molecule, RT1-E. European Journal of Immunology, 1999, 29, 3663-3673.	1.6	16
410	MHC class Ia molecules alone control NK-mediated bone marrow graft rejection. European Journal of Immunology, 1999, 29, 3683-3690.	1.6	28
411	The human natural killer cell immune synapse. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 15062-15067.	3.3	372
412	HLA and HIV-1: Heterozygote Advantage and B*35-Cw*04 Disadvantage. Science, 1999, 283, 1748-1752.	6.0	1,151
413	Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. European Journal of Cancer, 1999, 35, 721-726.	1.3	30
415	Structure of CD94 Reveals a Novel C-Type Lectin Fold. Immunity, 1999, 10, 75-82.	6.6	129
416	Direct Assessment of MHC Class I Binding by Seven Ly49 Inhibitory NK Cell Receptors. Immunity, 1999, 11, 67-77.	6.6	278
417	Clonal Acquisition of the Ly49A NK Cell Receptor Is Dependent on the trans-Acting Factor TCF-1. Immunity, 1999, 11, 433-442.	6.6	81
418	Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare) Tj ETQq1 1	0.784314 rgl	3T/Overlock
420	The development of a bi-specific anti-CD161A×anti-tumor antibody for rat NK cell targeting. Immunobiology, 1999, 200, 31-48.	0.8	5
421	From the Decidual Cell Internet: Trophoblast-Recognizing T Cells. Biology of Reproduction, 1999, 60, 227-233.	1.2	51
422	Purification of antigenic peptide from murine hepatoma cells recognized by Class-I major histocompatibility complex molecule-restricted cytotoxic T-lymphocytes induced with B7-1-gene-transfected hepatoma cells. Journal of Hepatology, 1999, 30, 1119-1129.	1.8	21
423	Structure of a human natural killer cell inhibitory receptor. Transplantation Proceedings, 1999, 31, 1871-1872.	0.3	2

#	Article	IF	CITATIONS
424	Mono-allelic Ly49 NK cell receptor expression. Seminars in Immunology, 1999, 11, 349-355.	2.7	16
425	Murine fetal natural killer cells are functionally and structurally distinct from adult natural killer cells. Journal of Leukocyte Biology, 1999, 66, 625-633.	1.5	17
426	Ly-49 receptor expression and functional analysis in multiple mouse strains. Journal of Leukocyte Biology, 1999, 66, 512-520.	1.5	46
427	A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Journal of Leukocyte Biology, 1999, 66, 375-381.	1.5	154
428	The leukocyte immunoglobulin-like receptors (LIRs): a new family of immune regulators. Journal of Leukocyte Biology, 1999, 66, 231-236.	1.5	23
429	Processing and presentation of phagocytosed antigens to the immune system. Advances in Cellular and Molecular Biology of Membranes and Organelles, 1999, 5, 379-406.	0.3	4
430	Depletion of NK cell activity results in growth of hepatic micrometastases in a murine ocular melanoma model. Current Eye Research, 1999, 19, 426-431.	0.7	27
431	Natural immunity and HIV disease progression. Aids, 1999, 13, 557-563.	1.0	50
432	Leukocyte Integrinâ€Dependent and Antibodyâ€Independent Cytotoxicity of Macrophage against Allografts. Microbiology and Immunology, 2000, 44, 57-67.	0.7	18
433	Ly49I NK Cell Receptor Transgene Inhibition of Rejection of H2b Mouse Bone Marrow Transplants. Journal of Immunology, 2000, 164, 1793-1799.	0.4	42
434	Murine Natural Killer Cells and Hybrid Resistance to Hemopoietic Cells In Vivo., 2000, 121, 61-71.		4
435	Role of Qa-1b-binding receptors in the specificity of developing NK cells. European Journal of Immunology, 2000, 30, 1094-1101.	1.6	28
436	CD56 DIRECTLY INTERACTS IN THE PROCESS OF NCAM-POSITIVE TARGET CELL-KILLING BY NK CELLS. Cell Biology International, 2000, 24, 101-108.	1.4	22
437	Memory CD8 T lymphocytes express inhibitory MHC-specific Ly49 receptors. European Journal of Immunology, 2000, 30, 236-244.	1.6	121
438	Visualization of inhibitory Ly49 receptor specificity with soluble major histocompatibility complex class I tetramers. European Journal of Immunology, 2000, 30, 300-307.	1.6	72
439	Differential effects on T cell and NK cell development by tissue-specific expression of H-2Dd transgene. European Journal of Immunology, 2000, 30, 525-533.	1.6	3
440	2B4 functions as a co-receptor in human NK cell activation. European Journal of Immunology, 2000, 30, 787-793.	1.6	202
441	Expression of Ly49A on T cells alters the threshold for T cell responses. European Journal of Immunology, 2000, 30, 2849-2856.	1.6	26

#	Article	IF	CITATIONS
442	Differential expression of CD28 and CD94 / NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node. European Journal of Immunology, 2000, 30, 3699-3706.	1.6	27
443	Functional Inhibitory Receptors Expressed by a Cutaneous T Cell Lymphoma-Specific Cytolytic Clonal T Cell Population. Journal of Investigative Dermatology, 2000, 115, 994-999.	0.3	9
444	Expression of CD94/NKG2 Subtypes on Tumor-Infiltrating Lymphocytes in Primary and Metastatic Melanoma. Journal of Investigative Dermatology, 2000, 114, 941-947.	0.3	31
445	The human hair follicle immune system: cellular composition and immune privilege. British Journal of Dermatology, 2000, 142, 862-873.	1.4	305
446	Expression of HLA-C-specific natural killer cell receptors (CD158a and CD158b) on peripheral blood mononuclear cells after allogeneic bone marrow transplantation. British Journal of Haematology, 2000, 108, 778-783.	1.2	26
447	TAP deficiency syndrome. Clinical and Experimental Immunology, 2000, 121, 173-178.	1.1	173
448	HLA class I antigen downregulation by interleukin (IL)-10 is predominantly governed by NF-kappaB in the short term and by TAP1+2 in the long term. Tissue Antigens, 2000, 55, 326-332.	1.0	14
449	Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunological Reviews, 2000, 174, 77-89.	2.8	80
450	In vivo acute depletion of CD8+ T cells before murine cytomegalovirus infection upregulated innate antiviral activity of natural killer cells. International Journal of Immunopharmacology, 2000, 22, 707-718.	1.1	44
451	Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Trends in Immunology, 2000, 21, 228-234.	7.5	326
452	Human NK-cell receptors. Trends in Immunology, 2000, 21, 420-422.	7.5	156
453	Inhibitory MHC class I receptors on $\hat{I}^3\hat{I}^\prime$ T cells in tumour immunity and autoimmunity. Trends in Immunology, 2000, 21, 187-191.	7.5	53
454	Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nature Immunology, 2000, $1,119-126$.	7.0	773
455	Exposing tumor cells to killer cell attack. Nature Medicine, 2000, 6, 867-868.	15.2	17
456	Proliferative and Cytotoxic capabilities of CD16 i ; $\frac{1}{2}$ CD56?and CD16 i ; $\frac{1}{2}$ CD56+ natural killer cells. Apmis, 2000, 108, 831-837.	0.9	19
457	Immunology of implantation. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2000, 14, 827-837.	1.4	60
458	Structural basis of cell–cell interactions in the immune system. Current Opinion in Structural Biology, 2000, 10, 656-661.	2.6	33
459	Recognition of Trophoblast HLA Class I Molecules by Decidual NK Cell Receptors—A Review. Placenta, 2000, 21, S81-S85.	0.7	139

#	Article	IF	CITATIONS
460	Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. Journal of Neuroimmunology, 2000, 107, 220-225.	1.1	103
461	Extensive gene duplications and a large inversion characterize the human leukocyte receptor cluster. Immunogenetics, 2000, 51, 703-713.	1.2	64
462	Molecular cloning, gene structure, and expression pattern of pig immunoreceptor DAP12. Immunogenetics, 2000, 51, 436-442.	1.2	14
463	Differential recognition of MHC class I molecules of xeno-/allo-endothelial cells by human NK cells. Science in China Series C: Life Sciences, 2000, 43, 176-182.	1.3	2
464	Synergistic effects of in vivo depletion of Ly-49A and Ly-49G2 natural killer cell subsets in the rejection of H2b bone marrow cell allografts. Blood, 2000, 95, 3840-3844.	0.6	14
465	CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis. Blood, 2000, 96, 224-233.	0.6	14
466	Human Natural Killer Cells in Asymptomatic Human Immunodeficiency Virus-1 Infection. Intervirology, 2000, 43, 294-301.	1.2	4
467	Fractalkine-Mediated Endothelial Cell Injury by NK Cells. Journal of Immunology, 2000, 164, 4055-4062.	0.4	180
468	Vigorous Allograft Rejection in the Absence of Danger. Journal of Immunology, 2000, 164, 3065-3071.	0.4	73
469	Cutting Edge Commentary: A Copernican Revolution? Doubts About the Danger Theory. Journal of Immunology, 2000, 165, 1725-1728.	0.4	50
470	Functional Defects of NK Cells Treated with Chloroquine Mimic the Lytic Defects Observed in Perforin-Deficient Mice. Journal of Immunology, 2000, 165, 5048-5053.	0.4	34
471	Stress Renders T Cell Blasts Sensitive to Killing by Activated Syngeneic NK Cells. Journal of Immunology, 2000, 165, 2390-2397.	0.4	32
472	Generation of Short-Term Murine Natural Killer Cell Clones to Analyze Ly49 Gene Expression. , 2000, 121, 5-12.		3
473	Ly-49P Activates NK-Mediated Lysis by Recognizing H-2Dd 1. Journal of Immunology, 2000, 165, 1771-1781.	0.4	36
474	Self-MHC class Ia (RT1-An) protects cells co-expressing the activatory allogeneic MHC class Ib molecule (RT1-Eu) from NK lysis. International Immunology, 2000, 12, 843-850.	1.8	9
475	Emergence of CD8+T Cells Expressing NK Cell Receptors in Influenza A Virus-Infected Mice. Journal of Immunology, 2000, 165, 4964-4969.	0.4	102
476	The Mouse Tumor Cell Lines EL4 and RMA Display Mosaic Expression of NK-Related and Certain Other Surface Molecules and Appear to Have a Common Origin. Journal of Immunology, 2000, 164, 5094-5102.	0.4	29
477	Human Cytomegalovirus Strain-Dependent Changes in NK Cell Recognition of Infected Fibroblasts. Journal of Immunology, 2000, 164, 4775-4782.	0.4	69

#	Article	IF	CITATIONS
478	Ly49A expression on T cells alters T cell selection. International Immunology, 2000, 12, 215-222.	1.8	30
479	Posttranscriptional Inhibition of Class I Major Histocompatibility Complex Presentation on Hepatocytes and Lymphoid Cells in Chronic Woodchuck Hepatitis Virus Infection. Journal of Virology, 2000, 74, 4483-4494.	1.5	59
480	Recruitment and Activation of Natural Killer (Nk) Cells in Vivo Determined by the Target Cell Phenotype. Journal of Experimental Medicine, 2000, 191, 129-138.	4.2	143
481	A Sequence-Ready Physical Map of the Region Containing the Human Natural Killer Gene Complex on Chromosome 12p12.3–p13.2. Genomics, 2000, 65, 129-136.	1.3	38
482	HLA class I recognition by killer cell Ig-like receptors. Seminars in Immunology, 2000, 12, 101-108.	2.7	84
483	A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Seminars in Immunology, 2000, 12, 121-127.	2.7	121
484	NK Cells Modulate MHC Class I Expression on Tumor Cells and their Susceptibility to Lysis. Immunobiology, 2000, 202, 326-338.	0.8	9
485	Bone marrow cells inhibit the generation of autologous EBV-specific CTL. Human Immunology, 2000, 61, 538-547.	1.2	13
486	Expression of the CD80 and CD86 molecules enhances cytotoxicity by human natural killer cells. Human Immunology, 2000, 61, 721-728.	1.2	34
487	Functional alteration of granulocytes, NK cells, and natural killer T cells in centenarians. Human Immunology, 2000, 61, 908-916.	1.2	102
488	N-linked carbohydrate on human leukocyte antigen-C and recognition by natural killer cell inhibitory receptors. Human Immunology, 2000, 61, 1202-1218.	1.2	17
489	Can viruses help us to understand and classify the MHC class I molecules at the maternal–fetal interface?. Human Immunology, 2000, 61, 1169-1176.	1.2	24
490	Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Human Immunology, 2000, 61, 44-50.	1.2	54
491	Molecular analyses of the interactions between human NK receptors and their HLA ligands. Human Immunology, 2000, 61, 28-38.	1.2	47
492	NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Human Immunology, 2000, 61, 18-27.	1.2	121
493	HLA-class I-specific inhibitory receptors in HIV-1 infection. Human Immunology, 2000, 61, 74-81.	1.2	36
494	Clonal Acquisition of Inhibitory Ly49 Receptors on Developing NK Cells Is Successively Restricted and Regulated by Stromal Class I MHC. Immunity, 2000, 13, 143-153.	6.6	114
495	Rapid Evolution of NK Cell Receptor Systems Demonstrated by Comparison of Chimpanzees and Humans. Immunity, 2000, 12, 687-698.	6.6	271

#	Article	IF	CITATIONS
496	Cytotoxically impaired transplant recipients can efficiently resist major histocompatibility complex-matched bone marrow allografts. Biology of Blood and Marrow Transplantation, 2000, 6, 456-464.	2.0	20
497	NK cells expressing killer cell inhibitory receptors after allogeneic bone marrow transplantation. Transplantation Proceedings, 2000, 32, 2447.	0.3	1
498	Immunology. Cell, 2000, 100, 129-138.	13.5	101
500	Viral Subversion of the Immune System. Annual Review of Immunology, 2000, 18, 861-926.	9.5	764
501	THEIMMUNOLOGICALSYNAPSE. Annual Review of Immunology, 2001, 19, 375-396.	9.5	821
502	The Biology of Natural Killer Cells and Implications for Therapy of Human Disease. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 451-463.	1.8	34
503	Differential Expression of Cytotoxic Molecules and Killer Cell Inhibitory Receptors in CD8+ and CD56+ Cutaneous Lymphomas. American Journal of Pathology, 2001, 158, 1593-1598.	1.9	32
504	ACTIVATINGRECEPTORS ANDCORECEPTORSINVOLVED INHUMANNATURALKILLERCELL-MEDIATEDCYTOLYSIS. Annual Review of Immunology, 2001, 19, 197-223.	9.5	1,609
505	Activation of c-Jun N-terminal kinase in the absence of NFκB function prior to induction of NK cell death triggered by a combination of Anti-Class I and Anti-CD16 antibodies. Human Immunology, 2001, 62, 320-331.	1.2	10
506	HLA-G Expression by Tumors. American Journal of Reproductive Immunology, 2001, 45, 103-107.	1.2	40
507	Mechanisms of molluscan host resistance and of parasite strategies for survival. Parasitology, 2001, 123, 159-167.	0.7	115
508	Human natural killer cell function and receptors. Current Opinion in Pharmacology, 2001, 1, 387-391.	1.7	79
509	Divergent and convergent evolution of NK-cell receptors. Trends in Immunology, 2001, 22, 52-57.	2.9	146
510	Autoimmunity mediated by innate immune effector cells. Trends in Immunology, 2001, 22, 301.	2.9	0
511	Natural killer cells and nitric oxide. International Immunopharmacology, 2001, 1, 1513-1524.	1.7	49
512	ULBPs, Novel MHC Class I–Related Molecules, Bind to CMV Glycoprotein UL16 and Stimulate NK Cytotoxicity through the NKG2D Receptor. Immunity, 2001, 14, 123-133.	6.6	1,118
513	Innate Immune Responses to Transplants. Immunity, 2001, 14, 369-376.	6.6	95
514	Molecular Competition for NKG2D. Immunity, 2001, 15, 201-211.	6.6	118

#	Article	IF	CITATIONS
515	Conformational Plasticity Revealed by the Cocrystal Structure of NKG2D and Its Class I MHC-like Ligand ULBP3. Immunity, 2001, 15, 1039-1049.	6.6	139
516	Natural Killer Cells and the Syndrome of Chronic Natural Killer Cell Lymphocytosis. Leukemia and Lymphoma, 2001, 41, 277-284.	0.6	26
517	Human Natural Killer Cell Receptors and Signal Transduction. International Reviews of Immunology, 2001, 20, 333-370.	1.5	51
518	Interactions between natural killer and dendritic cells during bacterial infections. , 2007, , 119-138.		0
519	Human Natural Killer Receptors and Their Ligands. Current Protocols in Immunology, 2001, 46, Unit 14.10.	3.6	20
520	Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood, 2001, 97, 2625-2632.	0.6	112
521	Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood, 2001, 98, 705-713.	0.6	212
523	MHC Class I Recognition by NK Receptors in the Ly49 Family Is Strongly Influenced by the \hat{l}^2 2-Microglobulin Subunit. Journal of Immunology, 2001, 166, 7327-7334.	0.4	34
524	Adhesive Interactions between Human NK Cells and Porcine Endothelial Cells. Scandinavian Journal of Immunology, 2001, 54, 70-75.	1.3	32
525	The UL16-binding proteins, a novel family of MHC class I-related ligands for NKG2D, activate natural killer cell functions. Immunological Reviews, 2001, 181, 185-192.	2.8	128
526	Biology of T memory type 1 cells. Immunological Reviews, 2001, 181, 269-278.	2.8	65
527	Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunological Reviews, 2001, 181, 279-289.	2.8	64
528	Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model. Immunological Reviews, 2001, 184, 236-243.	2.8	19
529	Quantity of cytomegalovirus DNA in different leukocyte populations during active infection in vivo and the presence of gB and UL18 transcripts. Journal of Medical Virology, 2001, 64, 283-289.	2.5	38
530	Parameters for monitoring treatment effects in CIDP with anti-MAC/SGPG IgM antibody. Muscle and Nerve, 2001, 24, 701-704.	1.0	6
531	Active immunization against cancer with dendritic cells: The near future. International Journal of Cancer, 2001, 94, 459-473.	2.3	285
532	Identification of NKp80, a novel triggering molecule expressed by human NK cells. European Journal of Immunology, 2001, 31, 233-242.	1.6	185
533	Synergistic effect of IFN- \hat{l}^3 and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. European Journal of Immunology, 2001, 31, 2926-2935.	1.6	66

#	Article	IF	CITATIONS
534	Purified MHC class I molecules inhibit activated NK cells in a cell-free systemin vitro. European Journal of Immunology, 2001, 31, 869-875.	1.6	20
535	Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. European Journal of Immunology, 2001, 31, 1076-1086.	1.6	299
536	Recognition of viral hemagglutinins by NKp44 but not by NKp30. European Journal of Immunology, 2001, 31, 2680-2689.	1.6	357
537	Critical role of NK but not NKT cells in acute rejection of parental bone marrow cells in F1 hybrid mice. European Journal of Immunology, 2001, 31, 3147-3152.	1.6	33
538	MHC-dependent shaping of the inhibitory Ly49 receptor repertoire on NK cells: evidence for a regulated sequential model. European Journal of Immunology, 2001, 31, 3370-3379.	1.6	40
539	Annotated References by Year., 2001,, 651-770.		0
540	Therapeutic Strategies for Xenograft Rejection. Journal of Cardiac Surgery, 2001, 16, 374-382.	0.3	2
541	Blueprints for life or death. Nature Immunology, 2001, 2, 379-380.	7.0	3
542	Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28 \hat{a} '/ \hat{a} ' mice. Nature Medicine, 2001, 7, 557-562.	15.2	195
543	Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature, 2001, 409, 1055-1060.	13.7	844
544	Quantitative competitive NASBA for measuring mRNA expression levels of the immediate early 1, late pp67, and immune evasion genes US3, US6 and US11 in cells infected with human cytomegalovirus. Journal of Virological Methods, 2001, 96, 133-147.	1.0	12
545	The biology of natural killer cells in cancer, infection, and pregnancy. Experimental Hematology, 2001, 29, 1157-1168.	0.2	117
546	NK and T cells constitute two major, functionally distinct intestinal epithelial lymphocyte subsets in the chicken. International Immunology, 2001, 13, 757-762.	1.8	132
547	HLA class I molecules in implantation. Fetal and Maternal Medicine Review, 2001, 12, 299-314.	0.3	1
548	H-2D Ligand Expression by Ly49A+ Natural Killer (NK) Cells Precludes Ligand Uptake from Environmental Cells. Journal of Experimental Medicine, 2001, 194, 1531-1539.	4.2	79
549	MHC Class I-Ly49 Interactions Shape the Ly49 Repertoire on Murine NK Cells. Journal of Immunology, 2001, 166, 6585-6592.	0.4	37
550	Recognition of HLA-Cw4 but Not HLA-Cw6 by the NK Cell Receptor Killer Cell Ig-Like Receptor Two-Domain Short Tail Number 4. Journal of Immunology, 2001, 166, 7260-7267.	0.4	102
551	Functional Analysis of the Molecular Factors Controlling Qa1-Mediated Protection of Target Cells from NK Lysis. Journal of Immunology, 2001, 166, 1601-1610.	0.4	20

#	Article	IF	CITATIONS
552	The Repertoire of Killer Cell Ig-Like Receptor and CD94:NKG2A Receptors in T Cells: Clones Sharing Identical $\hat{l}\pm\hat{l}^2$ TCR Rearrangement Express Highly Diverse Killer Cell Ig-Like Receptor Patterns. Journal of Immunology, 2001, 166, 3923-3932.	0.4	119
553	Expression of Ly49E and CD94/NKG2 on Fetal and Adult NK Cells. Journal of Immunology, 2001, 166, 4302-4311.	0.4	58
554	Spatial Organization of Signal Transduction Molecules in the NK Cell Immune Synapses During MHC Class I-Regulated Noncytolytic and Cytolytic Interactions. Journal of Immunology, 2001, 167, 4358-4367.	0.4	161
555	Inoculation of Human Interleukin-17 Gene-Transfected Meth-A Fibrosarcoma Cells Induces T Cell-Dependent Tumor-Specific Immunity in Mice. Oncology, 2001, 61, 79-89.	0.9	111
556	Deficiency in \hat{I}^2 2-Microglobulin, But Not CD1, Accelerates Spontaneous Lupus Skin Disease While Inhibiting Nephritis in MRL-Fas <i>lpr</i> Mice: An Example of Disease Regulation at the Organ Level. Journal of Immunology, 2001, 167, 2985-2990.	0.4	76
557	A Central Role for Death Receptor-Mediated Apoptosis in the Rejection of Tumors by NK Cells. Journal of Immunology, 2001, 167, 2068-2073.	0.4	165
558	Mouse CD94 Participates in Qa-1-Mediated Self Recognition by NK Cells and Delivers Inhibitory Signals Independent of Ly-49. Journal of Immunology, 2001, 166, 3771-3779.	0.4	18
559	Inhibition of the Death Receptor Pathway by cFLIP Confers Partial Engraftment of MHC Class I-Deficient Stem Cells and Reduces Tumor Clearance in Perforin-Deficient Mice. Journal of Immunology, 2001, 167, 4230-4237.	0.4	15
560	Ly-49W, an Activating Receptor of Nonobese Diabetic Mice With Close Homology to the Inhibitory Receptor Ly-49G, Recognizes H-2Dk and H-2Dd. Journal of Immunology, 2001, 166, 2333-2341.	0.4	36
561	Signaling at the inhibitory natural killer cell immune synapse regulates lipid raft polarization but not class I MHC clustering. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 14547-14552.	3.3	101
562	MHC class I molecules on adenovirus E1A-expressing tumor cells inhibit NK cell killing but not NK cell-mediated tumor rejection. International Immunology, 2001, 13, 1301-1307.	1.8	8
563	Acquisition of External Major Histocompatibility Complex Class I Molecules by Natural Killer Cells Expressing Inhibitory Ly49 Receptors. Journal of Experimental Medicine, 2001, 194, 1519-1530.	4.2	94
564	Intercellular Transfer and Supramolecular Organization of Human Leukocyte Antigen C at Inhibitory Natural Killer Cell Immune Synapses✪. Journal of Experimental Medicine, 2001, 194, 1507-1517.	4.2	164
565	Intramembrane Proteolysis of Signal Peptides: An Essential Step in the Generation of HLA-E Epitopes. Journal of Immunology, 2001, 167, 6441-6446.	0.4	167
566	Expression Dynamics of Human Cytomegalovirus Immune Evasion GenesUS3, US6, and US11 in the Blood of Lung Transplant Recipients. Journal of Infectious Diseases, 2001, 184, 247-255.	1.9	18
567	Immunological Tolerance of the Human Fetus. American Journal of Perinatology, 2001, 18, 299-312.	0.6	94
568	Cell Types Involved in Allogeneic Contact Reactions of the Solitary Ascidian, Halocynthia roretzi. Zoological Science, 2001, 18, 195-205.	0.3	6
569	Biology of Natural Killer Cells in Cancer and Infection. Cancer Investigation, 2002, 20, 405-419.	0.6	60

#	Article	IF	CITATIONS
570	Oxygen as a regulator of cellular phenotypes in pregnancy and cancer. Canadian Journal of Physiology and Pharmacology, 2002, 80, 103-109.	0.7	22
571	NK Cell Inhibitory Receptor Ly-49C Residues Involved in MHC Class I Binding. Journal of Immunology, 2002, 168, 793-800.	0.4	13
572	The CD8+ Dendritic Cell Subset Selectively Endocytoses Dying Cells in Culture and In Vivo. Journal of Experimental Medicine, 2002, 195, 1289-1302.	4.2	581
573	Genetically Modified HLA Class I Molecules Able to Inhibit Human NK Cells Without Provoking Alloreactive CD8+ CTLs. Journal of Immunology, 2002, 168, 3266-3274.	0.4	26
574	Ly-49s3 Is a Promiscuous Activating Rat NK Cell Receptor for Nonclassical MHC Class I-Encoded Target Ligands. Journal of Immunology, 2002, 169, 22-30.	0.4	37
575	Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 868-873.	3.3	79
576	NK Cell Activity During Human Cytomegalovirus Infection Is Dominated by US2–11-Mediated HLA Class I Down-Regulation. Journal of Immunology, 2002, 169, 3257-3266.	0.4	89
577	NK Cell CD94/NKG2A Inhibitory Receptors Are Internalized and Recycle Independently of Inhibitory Signaling Processes. Journal of Immunology, 2002, 169, 6102-6111.	0.4	40
578	Characterization of a Novel Killer Cell Lectin-Like Receptor (KLRH1) Expressed by Alloreactive Rat NK Cells. Journal of Immunology, 2002, 168, 5147-5154.	0.4	27
579	Autocrine IL-15 Mediates Intestinal Epithelial Cell Death Via the Activation of Neighboring Intraepithelial NK Cells. Journal of Immunology, 2002, 169, 6187-6192.	0.4	37
580	Preventing NK Cell Activation by Donor Dendritic Cells Enhances Allospecific CD4 T Cell Priming and Promotes Th Type 2 Responses to Transplantation Antigens. Journal of Immunology, 2002, 169, 2979-2987.	0.4	49
581	UL16-Binding Proteins, Novel MHC Class I-Related Proteins, Bind to NKG2D and Activate Multiple Signaling Pathways in Primary NK Cells. Journal of Immunology, 2002, 168, 671-679.	0.4	229
582	CD66a Interactions Between Human Melanoma and NK Cells: A Novel Class I MHC-Independent Inhibitory Mechanism of Cytotoxicity. Journal of Immunology, 2002, 168, 2803-2810.	0.4	163
583	The Pmed1 Gene Promoter of Human Fcl³RIIIA Can Function as a NK/T Cell-Specific Restriction Element, Which Involves Binding of Sp1 Transcription Factor. Journal of Immunology, 2002, 168, 2857-2864.	0.4	2
584	Cutting Edge: Differential Segregation of the Src Homology 2-Containing Protein Tyrosine Phosphatase-1 Within the Early NK Cell Immune Synapse Distinguishes Noncytolytic from Cytolytic Interactions. Journal of Immunology, 2002, 168, 3150-3154.	0.4	76
585	Expression of Inhibitory Receptors Ly49E and CD94/NKG2 on Fetal Thymic and Adult Epidermal TCR VÎ ³ 3 Lymphocytes. Journal of Immunology, 2002, 168, 3295-3302.	0.4	54
586	Characterization of the expression of MHC proteins in human embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9864-9869.	3.3	628
587	Pivotal Role of KARAP/DAP12 Adaptor Molecule in the Natural Killer Cell–mediated Resistance to Murine Cytomegalovirus Infection. Journal of Experimental Medicine, 2002, 195, 825-834.	4.2	101

#	Article	IF	CITATIONS
588	Clinical scale isolation of T cell-depleted CD56+ donor lymphocytes in children. Bone Marrow Transplantation, 2002, 29, 497-502.	1.3	51
589	Activation of natural killer cells by heat shock protein 70. International Journal of Hyperthermia, 2002, 18, 576-585.	1.1	126
590	Comprehensive gene expression analysis of human NK cells and CD8+ T lymphocytes. International Immunology, 2002, 14, 1085-1098.	1.8	98
591	Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8826-8831.	3.3	673
592	A Ligand for the Murine NK Activation Receptor Ly-49D: Activation of Tolerized NK Cells from \hat{l}^2 2-Microglobulin- Deficient Mice. Journal of Immunology, 2002, 169, 126-136.	0.4	52
593	The Role of NK Cells in Innate Immunity. , 2000, 479, 137-145.		11
594	Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells. Journal of Experimental Medicine, 2002, 195, 343-351.	4.2	877
595	Rolling adhesion of human NK cells to porcine endothelial cells mainly relies on CD49d-CD106 interactions1. Transplantation, 2002, 73, 789-796.	0.5	31
596	Natural Killer Cells and Their Role in Disease. Laboratory Medicine, 2002, 33, 278-282.	0.8	7
597	Increased bone marrow allograft rejection by depletion of NK cells expressing inhibitory Ly49 NK receptors for donor class I antigens. Blood, 2002, 100, 3026-3033.	0.6	36
598	Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells. Blood, 2002, 99, 1723-1729.	0.6	68
599	Relationships between early B- and NK-lineage lymphocyte precursors in bone marrow. Blood, 2002, 100, 3672-3680.	0.6	45
600	STRUCTURE ANDFUNCTION OFNATURALKILLERCELLRECEPTORS: Multiple Molecular Solutions to Self, Nonself Discrimination. Annual Review of Immunology, 2002, 20, 853-885.	9.5	305
601	The Role of NK Cells in Autoimmune Disease. Autoimmunity, 2002, 35, 1-14.	1.2	91
602	Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood, 2002, 100, 1935-1947.	0.6	449
603	NK Cells and Asthma. Current Pharmaceutical Design, 2002, 8, 1871-1876.	0.9	27
605	NK inhibitory-receptor blockade for purging of leukemia: Effects on hematopoietic reconstitution. Biology of Blood and Marrow Transplantation, 2002, 8, 17-25.	2.0	21
606	Modulation of Ly49D Expression after Allogeneic Bone Marrow Transplantation and Functional Consequences. Immunobiology, 2002, 205, 267-281.	0.8	7

#	Article	IF	Citations
607	NK cells: a lesson from mismatched hematopoietic transplantation. Trends in Immunology, 2002, 23, 438-444.	2.9	191
608	NK cells and transplantation. Transplant Immunology, 2002, 9, 111-114.	0.6	37
609	Natural killer cells and their receptors. Transplant Immunology, 2002, 10, 147-164.	0.6	159
610	Channel catfish cytotoxic cells: a mini-review. Developmental and Comparative Immunology, 2002, 26, 141-149.	1.0	139
611	NK cells become Ki-67+ in MLC and expand depending on the lack of ligand for KIR on stimulator cells in IL-2 supplemented MLC. Human Immunology, 2002, 63, 638-646.	1.2	5
612	Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Molecular Immunology, 2002, 38, 637-660.	1.0	242
613	Killer Ig-Like Receptor Haplotype Analysis by Gene Content: Evidence for Genomic Diversity with a Minimum of Six Basic Framework Haplotypes, Each with Multiple Subsets. Journal of Immunology, 2002, 169, 5118-5129.	0.4	361
614	Antigenic Peptide Transporter. , 1999, 12, 289-312.		O
615	Expression of p58.2 or CD94/NKG2A inhibitory receptors in an NK-like cell line, YTINDY, leads to HLA Class I-mediated inhibition of cytotoxicity in the p58.2- but not the CD94/NKG2A-expressing transfectant. Cellular Immunology, 2002, 219, 57-70.	1.4	8
616	Human natural killer cells: their origin, receptors and function. European Journal of Immunology, 2002, 32, 1205.	1.6	217
617	Regulation of CD1d expression by murine tumor cells: Escape from immunosurveillance or alternate target molecules?. International Journal of Cancer, 2002, 98, 389-397.	2.3	25
618	Immunological reconstitution and immunoregulatory cells in hematopoietic stem cell transplantation. International Journal of Hematology, 2002, 76, 191-194.	0.7	8
619	Viral immune evasion: a masterpiece of evolution. Immunogenetics, 2002, 54, 527-542.	1.2	225
620	A rat cytomegalovirus strain with a disruption of the r144 MHC class I-like gene is attenuated in the acute phase of infection in neonatal rats. Archives of Virology, 2002, 147, 813-824.	0.9	14
621	Cell adhesion and polarity during immune interactions. Immunological Reviews, 2002, 186, 68-82.	2.8	90
622	The innate immune response to tumors and its role in the induction of T-cell immunity. Immunological Reviews, 2002, 188, 9-21.	2.8	194
623	Visualization of signaling pathways and cortical cytoskeleton in cytolytic and noncytolytic natural killer cell immune synapses. Immunological Reviews, 2002, 189, 161-178.	2.8	91
624	Imaging immune surveillance by T cells and NK cells. Immunological Reviews, 2002, 189, 179-192.	2.8	24

#	Article	IF	CITATIONS
625	The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunological Reviews, 2002, 190, 40-52.	2.8	406
626	Comparative genomic analysis of the MHC: the evolution of class I duplication blocks, diversity and complexity from shark to man. Immunological Reviews, 2002, 190, 95-122.	2.8	206
627	Heterogeneity in the effect of different ixodid tick species on human natural killer cell activity. Parasite Immunology, 2002, 24, 23-28.	0.7	34
628	NK cell receptors in antiviral immunity. Current Opinion in Immunology, 2002, 14, 509-516.	2.4	34
629	Natural killer T (NKT) cells and their role in antitumor immunity. Critical Reviews in Oncology/Hematology, 2002, 41, 287-298.	2.0	95
630	Natural killer cell activation receptors in innate immunity to infection. Microbes and Infection, 2002, 4, 1513-1521.	1.0	34
631	NK cell receptors: emerging roles in host defense against infectious agents. Microbes and Infection, 2002, 4, 1523-1530.	1.0	5
632	Human NK cells and their receptors. Microbes and Infection, 2002, 4, 1539-1544.	1.0	64
633	Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission. British Journal of Haematology, 2002, 116, 299-307.	1.2	23
634	Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma. British Journal of Haematology, 2002, 118, 778-785.	1.2	21
635	Human Cytomegalovirus (HCMV)-Infected Endothelial Cells and Macrophages are Less Susceptible to Natural Killer Lysis Independent of the Downregulation of Classical HLA Class I Molecules or Expression of the HCMV Class I Homologue, UL18. Scandinavian Journal of Immunology, 2002, 55, 149-161.	1.3	31
636	The Role of an Exposed Loop in the $\hat{l}\pm 2$ Domain in the Mouse MHC Class I H-2Dd Molecule for Recognition by the Monoclonal Antibody 34-5-8S and the NK-Cell Receptor Ly49A. Scandinavian Journal of Immunology, 2002, 55, 129-139.	1.3	5
637	NK Cells, MHC Class I Molecules and the Missing Self. Scandinavian Journal of Immunology, 2002, 55, 221-228.	1.3	260
638	Natural Killer Cells: A Mystery No More. Scandinavian Journal of Immunology, 2002, 55, 229-232.	1.3	42
639	The Natural Killer Cell - Friend or Foe in Autoimmune Disease?. Scandinavian Journal of Immunology, 2002, 55, 432-441.	1.3	74
640	What is a natural killer cell?. Nature Immunology, 2002, 3, 6-8.	7.0	312
641	Clever, cleverer, cleverest. Nature Immunology, 2002, 3, 505-506.	7.0	10
642	Tumor cell recognition by natural killer cells. Seminars in Cancer Biology, 2002, 12, 57-61.	4.3	73

#	Article	IF	Citations
643	HLA-Cw7 zygosity affects the size of a subset of CD158b+ natural killer cells. Journal of Clinical Immunology, 2002, 22, 28-36.	2.0	21
644	HLA-G inhibits xenogenetic cytotoxicity mediated by human NK cells and T lymphocytes against PECs. Science Bulletin, 2003, 48, 148.	1.7	1
645	Immunology and functional genomics of Behï $\it i$ ½et's disease. Cellular and Molecular Life Sciences, 2003, 60, 1903-1922.	2.4	117
646	Pathogenesis of Selective Expansion of PNH Clones. International Journal of Hematology, 2003, 77, 121-124.	0.7	13
647	Biology and clinical impact of human natural killer cells. International Journal of Hematology, 2003, 78, 7-17.	0.7	93
648	Immunoregulatory Cells for Transplantation Tolerance and Graft-versus-Leukemia Effect. International Journal of Hematology, 2003, 78, 188-194.	0.7	8
649	Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy. Cancer Immunology, Immunotherapy, 2003, 52, 53-58.	2.0	34
650	Surface receptors and functional interactions of human natural killer cells: from bench to the clinic. Cellular and Molecular Life Sciences, 2003, 60, 2139-2146.	2.4	13
651	HLA-G and IL-10 expression in human cancerâ€"different stories with the same message. Seminars in Cancer Biology, 2003, 13, 337-342.	4.3	91
652	Tumour immunology, vaccination and escape strategies. International Journal of Immunogenetics, 2003, 30, 177-183.	1.2	47
653	Expression of the UL16 glycoprotein of Human Cytomegalovirus protects the virus-infected cell from attack by natural killer cells. BMC Immunology, 2003, 4, 4.	0.9	62
654	Characterisation of RT1-E2, a multigenic family of highly conserved rat non-classical MHC class I molecules initially identified in cells from immunoprivileged sites. BMC Immunology, 2003, 4, 7.	0.9	12
655	Rapid and highly efficient gene transfer into natural killer cells by nucleofection. Journal of Immunological Methods, 2003, 274, 245-256.	0.6	69
656	Human Natural Killer cell receptors: insights into their molecular function and structure. Journal of Cellular and Molecular Medicine, 2003, 7, 376-387.	1.6	102
657	Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. International Journal of Cancer, 2003, 104, 354-361.	2.3	227
658	Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. International Journal of Cancer, 2003, 106, 905-912.	2.3	103
659	A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity. European Journal of Immunology, 2003, 33, 381-391.	1.6	147
660	Natural killer cell-mediated lysis of dorsal root ganglia neurons via RAE1/NKG2D interactions. European Journal of Immunology, 2003, 33, 92-100.	1.6	50

#	Article	IF	Citations
661	MHC class I antigens, immune surveillance, and tumor immune escape. Journal of Cellular Physiology, 2003, 195, 346-355.	2.0	422
662	Regulation of perforin-independent NK cell-mediated cytotoxicity. European Journal of Immunology, 2003, 33, 2727-2735.	1.6	83
663	Generation of the Natural Killer Cell Repertoire: The Sequential vs. the Two-step Selection Model. Bulletin of Mathematical Biology, 2003, 65, 199-218.	0.9	8
664	Cellular and molecular basis of natural killer and natural killer-like activity. Immunology Letters, 2003, 88, 89-93.	1.1	25
665	NK-cell activity in immunotoxicity drug evaluation. Toxicology, 2003, 185, 241-250.	2.0	37
666	Regulation of antiviral CD8+ T cells by inhibitory natural killer cell receptors. Microbes and Infection, 2003, 5, 169-177.	1.0	10
667	Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens, 2003, 62, 243-250.	1.0	72
668	Innate immune recognition by stimulatory immunoreceptors. Current Opinion in Immunology, 2003, 15, 37-44.	2.4	88
669	The NK cell receptor repertoire: formation, adaptation and exploitation. Current Opinion in Immunology, 2003, 15, 233-237.	2.4	28
670	Natural killer cells and viral infections. Current Opinion in Immunology, 2003, 15, 45-51.	2.4	243
671	MHC-dependent and -independent modulation of endogenous Ly49 receptors on NK1.1+ T lymphocytes directed by T-cell receptor type. Immunology, 2003, 110, 313-321.	2.0	18
672	Cell-mediated cytotoxicity in recovery from poxvirus infections. Reviews in Medical Virology, 2003, 13, 223-232.	3.9	33
673	Killer immunoglobulin-like receptor expression on single cells: a cautionary note. Immunology, 2003, 110, 421-426.	2.0	3
674	Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nature Immunology, 2003, 4, 801-807.	7.0	243
675	What does it take to make a natural killer?. Nature Reviews Immunology, 2003, 3, 413-425.	10.6	437
676	HLA-G in skin cancer: a wolf in sheep's clothing?. Human Immunology, 2003, 64, 1073-1080.	1.2	15
677	Special organization of the HLA-G protein on the cell surface. Human Immunology, 2003, 64, 1011-1016.	1.2	29
678	The immunobiology of natural killer cells and bone marrow allograft rejection. Biology of Blood and Marrow Transplantation, 2003, 9, 727-741.	2.0	53

#	Article	IF	CITATIONS
679	Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nature Reviews Immunology, 2003, 3, 108-122.	10.6	150
680	Assessment of killer cell immunoglobulinlike receptor expression and corresponding HLA class I phenotypes demonstrates heterogenous KIR expression independent of anticipated HLA class I ligands. Human Immunology, 2003, 64, 183-193.	1.2	34
681	Ultrastructural characterization of effector-target interactions for human neonatal and adult NK cells reveals reduced intercellular surface contacts of neonatal cells. Human Immunology, 2003, 64, 490-496.	1.2	3
682	Human natural killer cell function and their interactions with dendritic cells. Vaccine, 2003, 21, S38-S42.	1.7	41
683	Channel catfish NK-like cells are armed with IgM via a putative Fc \hat{l} /4R. Developmental and Comparative Immunology, 2003, 27, 699-714.	1.0	75
684	Induction of thymic tolerance as possibility in prevention of recurrent spontaneous abortion. Medical Hypotheses, 2003, 60, 520-524.	0.8	4
685	GATA-3 Promotes Maturation, IFN- \hat{I}^3 Production, and Liver-Specific Homing of NK Cells. Immunity, 2003, 19, 701-711.	6.6	218
686	NK cells: a lesson from mismatched hematopoietic transplantation. Trends in Immunology, 2003, 24, 8-9.	2.9	3
687	IFNα regulates NK cell cytotoxicity through STAT1 pathway. Cytokine, 2003, 23, 190-199.	1.4	64
688	The Size of the Synaptic Cleft and Distinct Distributions of Filamentous Actin, Ezrin, CD43, and CD45 at Activating and Inhibitory Human NK Cell Immune Synapses. Journal of Immunology, 2003, 170, 2862-2870.	0.4	106
689	Effects of Human Cytomegalovirus Infection on Ligands for the Activating NKG2D Receptor of NK Cells: Up-Regulation of UL16-Binding Protein (ULBP)1 and ULBP2 Is Counteracted by the Viral UL16 Protein. Journal of Immunology, 2003, 171, 902-908.	0.4	161
690	Activating and Inhibitory Ly49 Receptors Modulate NK Cell Chemotaxis to CXC Chemokine Ligand (CXCL) 10 and CXCL12. Journal of Immunology, 2003, 171, 2889-2895.	0.4	29
691	Complexes of HLA-G Protein on the Cell Surface Are Important for Leukocyte Ig-Like Receptor-1 Function. Journal of Immunology, 2003, 171, 1343-1351.	0.4	136
692	Are Major Histocompatibility Complex Molecules Involved in the Survival of Naive CD4+ T Cells?. Journal of Experimental Medicine, 2003, 198, 1089-1102.	4.2	73
693	Receptor Glycosylation Regulates Ly-49 Binding to MHC Class I. Journal of Immunology, 2003, 171, 4235-4242.	0.4	15
694	Differential Roles for IL-15R α-Chain in NK Cell Development and Ly-49 Induction. Journal of Immunology, 2003, 171, 5085-5090.	0.4	52
695	Analysis of HLA-E Peptide-Binding Specificity and Contact Residues in Bound Peptide Required for Recognition by CD94/NKG2. Journal of Immunology, 2003, 171, 1369-1375.	0.4	124
696	Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma. Journal of Immunology, 2003, 171, 6891-6899.	0.4	295

#	Article	IF	CITATIONS
697	Cutting Edge: Stimulation with the Cognate Self-Antigen Induces Expression of the Ly49A Receptor on Self-Reactive T Cells Which Modulates Their Responsiveness. Journal of Immunology, 2003, 171, 6334-6338.	0.4	7
698	New directions in natural killer cell-based immunotherapy of human cancer. Expert Opinion on Biological Therapy, 2003, 3, 237-250.	1.4	32
699	Immune Reconstitution and Tolerance after Allogeneic Hematopoietic Stem Cell Transplantation. Hematology, 2003, 8, 19-26.	0.7	48
700	Selective Activation of the c-Jun NH2-terminal Protein Kinase Signaling Pathway by Stimulatory KIR in the Absence of KARAP/DAP12 in CD4+ T Cells. Journal of Experimental Medicine, 2003, 197, 437-449.	4.2	71
701	Experimental appraisal of the lack of antitumor natural killer cellâ€"mediated immunosurveillance in response to lymphomas growing in the mouse brain. Journal of Neurosurgery, 2003, 98, 599-606.	0.9	7
702	Update on Natural Killer Cells. Cancer Journal (Sudbury, Mass), 2003, 9, 232-237.	1.0	3
703	Interfacing dendritic and natural killer cells: a tool for targeted tolerance induction?. Transplantation, 2003, 76, 1657-1661.	0.5	0
704	IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood, 2003, 101, 4887-4893.	0.6	310
705	Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood, 2003, 102, 1797-1805.	0.6	106
706	NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade. Blood, 2003, 102, 4067-4075.	0.6	32
707	MHC class I receptors on natural killer cells: on with the old and in with the new. Clinical Science, 2003, 105, 127-140.	1.8	4
708	Killer cell immunoglobulin-like receptor(KIR)é³ä¼åé¯åŸŸã®æ§‹é€,ãƒãƒ—ãƒã,¿ã,惗,åŠã³åඎč<ã«é−¢ã™ã,‹è§£æž;	• Majør His	to o ompatibi
709	Models for Natural Killer Cell Repertoire Formation. Clinical and Developmental Immunology, 2003, 10, 183-192.	3.3	8
710	HLA Antigen Changes in Malignant Tumors of Mammary Epithelial Origin: Molecular Mechanisms and Clinical Implications. Breast Disease, 2004, 20, 105-125.	0.4	27
712	Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors. Current Molecular Medicine, 2004, 4, 59-65.	0.6	43
713	Cytokine Modulation of the Innate Immune System in the Treatment of Leukemia and Lymphoma. Advances in Pharmacology, 2004, 51, 295-318.	1.2	27
714	Broadly impaired NK cell function in non-obese diabetic mice is partially restored by NK cell activation in vivo and by IL-12/IL-18 in vitro. International Immunology, 2004, 16, 1-11.	1.8	47
715	Decreased expression of killer cell inhibitory receptors on natural killer cells in eutopic endometrium in women with adenomyosis. Human Reproduction, 2004, 19, 1974-1978.	0.4	36

#	Article	IF	CITATIONS
716	A species-specific determinant on $\hat{A}2$ -microglobulin required for Ly49A recognition of its MHC class I ligand. International Immunology, 2004, 16, 197-204.	1.8	13
717	Exclusion of Lipid Rafts and Decreased Mobility of CD94/NKG2A Receptors at the Inhibitory NK Cell Synapse. Molecular Biology of the Cell, 2004, 15, 3210-3223.	0.9	33
719	Non-major histocompatibility complex alloantigen genes affecting immunity. Poultry Science, 2004, 83, 606-610.	1.5	2
720	CD1d1 Displayed on Cell Size Beads Identifies and Enriches an NK Cell Population Negatively Regulated by CD1d1. Journal of Immunology, 2004, 172, 5304-5312.	0.4	12
721	Ligand Binding to Inhibitory Killer Cell Ig-Like Receptors Induce Colocalization with Src Homology Domain 2-Containing Protein Tyrosine Phosphatase 1 and Interruption of Ongoing Activation Signals. Journal of Immunology, 2004, 173, 1571-1578.	0.4	36
722	Immunology of HIV â€" filling in the details. International Journal of STD and AIDS, 2004, 15, 574-583.	0.5	3
723	Distinctive polymorphism of chicken B-FI (major histocompatibility complex class I) molecules. Poultry Science, 2004, 83, 600-605.	1.5	30
724	Expression of KIR and C-type lectin receptors in Behcet's disease. British Journal of Rheumatology, 2004, 43, 423-427.	2.5	29
725	Cutting Edge: Heterozygote Advantage in Autoimmune Disease: Hierarchy of Protection/Susceptibility Conferred by HLA and Killer Ig-Like Receptor Combinations in Psoriatic Arthritis. Journal of Immunology, 2004, 173, 4273-4276.	0.4	247
727	MHC class I down-regulation: tumour escape from immune surveillance? (Review). International Journal of Oncology, 2004, 25, 487.	1.4	56
728	Two Human ULBP/RAET1 Molecules with Transmembrane Regions Are Ligands for NKG2D. Journal of Immunology, 2004, 173, 1078-1084.	0.4	154
729	The Cell Surface-Localized Heat Shock Protein 70 Epitope TKD Induces Migration and Cytolytic Activity Selectively in Human NK Cells. Journal of Immunology, 2004, 172, 972-980.	0.4	131
730	Human and murine inhibitory natural killer cell receptors transfer from natural killer cells to target cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 16873-16878.	3.3	82
731	Membrane-Associated Heparan Sulfate Proteoglycans Are Involved in the Recognition of Cellular Targets by NKp30 and NKp46. Journal of Immunology, 2004, 173, 2392-2401.	0.4	146
732	From The Cover: A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17843-17848.	3.3	233
733	The Rat RT1-A1c MHC Molecule Is a Xenogeneic Ligand Recognized by the Mouse Activating Ly-49W and Inhibitory Ly-49G Receptors. Journal of Immunology, 2004, 172, 3518-3526.	0.4	7
734	Treatment of Colon and Lung Cancer Patients with ex Vivo Heat Shock Protein 70-Peptide-Activated, Autologous Natural Killer Cells. Clinical Cancer Research, 2004, 10, 3699-3707.	3.2	224
735	Investigation of killer cell immunoglobulin-like receptor gene diversity III. KIR2DL3. Tissue Antigens, 2004, 64, 188-194.	1.0	18

#	Article	IF	CITATIONS
736	Natural killer cells and cross-talk with dendritic cells. Clinical and Experimental Allergy Reviews, 2004, 4, 135-139.	0.3	1
737	Immune Interactions at the Maternal-Fetal Interface: a Focus on Antigen Presentation. American Journal of Reproductive Immunology, 2004, 51, 283-289.	1.2	29
738	Interaction Between Natural Killer and Dendritic Cells: the Role of CD40, CD80 and Major Histocompatibility Complex Class I Molecules in Cytotoxicity Induction and Interferon-gamma Production. Scandinavian Journal of Immunology, 2004, 59, 356-362.	1.3	22
739	Low Number of H-2Dd-Negative Haematopoietic Cells in Mixed Bone Marrow Chimeras Convey In Vivo Tolerance to H-2Dd-Negative Cells But Fail to Prevent Resistance to H-2Dd-Negative Leukaemia. Scandinavian Journal of Immunology, 2004, 59, 71-78.	1.3	12
740	Proliferative and Cytotoxic Response of Human Natural Killer Cells Exposed to Transporter Associated with Antigen-Processing-Deficient Cells. Scandinavian Journal of Immunology, 2004, 59, 159-167.	1.3	0
741	Activation of Natural Killer Cells: Underlying Molecular Mechanisms Revealed. Scandinavian Journal of Immunology, 2004, 60, 14-22.	1.3	37
742	Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nature Immunology, 2004, 5, 328-336.	7.0	179
743	Interplay of natural killer cells and their receptors with the adaptive immune response. Nature Immunology, 2004, 5, 996-1002.	7.0	373
744	An innately interesting decade of research in immunology. Nature Medicine, 2004, 10, 1307-1320.	15,2	127
745	Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nature Reviews Immunology, 2004, 4, 190-198.	10.6	210
746	Inhibition of the activating signals in NK92 cells by recombinant GST-sHLA-G1α chain. Cell Research, 2004, 14, 155-160.	5.7	29
747	Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO Journal, 2004, 23, 255-259.	3.5	541
748	Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia, 2004, 18, 2002-2007.	3.3	112
749	Effects of Chlamydia trachomatis infection on the expression of natural killer (NK) cell ligands and susceptibility to NK cell lysis. Clinical and Experimental Immunology, 2004, 138, 54-60.	1.1	34
750	Immunonutrition and cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 551, 29-42.	0.4	82
751	Investigation of KIR diversity in immunosenecence and longevity within the Irish population. Experimental Gerontology, 2004, 39, 1223-1232.	1.2	20
752	Systematic identification of immunoreceptor tyrosine-based inhibitory motifs in the human proteome. Cellular Signalling, 2004, 16, 435-456.	1.7	54
753	Qa-1, a Nonclassical Class I Histocompatibility Molecule With Roles in Innate and Adaptive Immunity. Immunologic Research, 2004, 29, 081-092.	1.3	45

#	Article	IF	CITATIONS
754	Resistance to Cytotoxic Chemotherapy Is Induced by NK Cells in Non-Hodgkin's Lymphoma Cells. Journal of Clinical Immunology, 2004, 24, 553-560.	2.0	3
756	Pit cells as liver-associated natural killer cells: morphology and function. Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan, 2004, 37, 29-36.	1.8	63
757	NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunology, Immunotherapy, 2004, 53, 41-52.	2.0	42
758	Effective immunotherapy against cancer. Cancer Immunology, Immunotherapy, 2004, 53, 879-92.	2.0	126
759	Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Annals of Hematology, 2004, 83, 551-65.	0.8	55
760	Application of xenogeneic stem cells for induction of transplantation tolerance: present state and future directions. Seminars in Immunopathology, 2004, 26, 187-200.	4.0	17
761	A single major chromosomal region controls natural killer cell-like activity in rainbow trout. Immunogenetics, 2004, 55, 825-835.	1.2	61
762	Differential usage of VLA-4 and CXCR4 by CD3+CD56+ NKT cells and CD56+CD16+ NK cells regulates their interaction with endothelial cells. European Journal of Immunology, 2004, 34, 1333-1341.	1.6	23
763	Loss or mismatch of MHC class I is sufficient to trigger NK cell-mediated rejection of resting lymphocytesin vivo– role of KARAP/DAP12-dependent and -independent pathways. European Journal of Immunology, 2004, 34, 1646-1653.	1.6	75
764	Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients. European Journal of Immunology, 2004, 34, 2138-2148.	1.6	32
765	Heat shock proteins: to present or not, that is the question. Immunology Letters, 2004, 94, 1-10.	1.1	63
766	Role of interaction between Ly49 inhibitory receptors and cognate MHC I molecules in IL2-induced development of NK cells in murine bone marrow cell cultures. Immunology Letters, 2004, 94, 209-214.	1.1	7
767	Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Current Opinion in Immunology, 2004, 16, 634-643.	2.4	54
768	HLA expression in choroidal melanomas: Correlation with clinicopathological features. Current Eye Research, 2004, 28, 409-416.	0.7	11
769	HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection. Science, 2004, 305, 872-874.	6.0	1,086
770	Immunomodulating Activities ofGanoderma, a Mushroom with Medicinal Properties. Food Reviews International, 2004, 20, 123-161.	4.3	58
771	Thalamus in flame: targeting of infectious agents to thalamic nuclei. Thalamus & Related Systems, 2004, 2, 297-314.	0.5	0
772	Natural Killer Cell Neoplasms. Clinical Lymphoma and Myeloma, 2004, 5, 197-201.	2.1	6

#	Article	IF	Citations
773	Natural killer cells and autoimmunity. Arthritis Research, 2004, 6, 8.	2.0	100
774	Downregulation and/or Release of NKG2D Ligands as Immune Evasion Strategy of Human Neuroblastoma. Neoplasia, 2004, 6, 558-568.	2.3	216
775	Comparative genomic analysis, diversity and evolution of two KIR haplotypes A and B. Gene, 2004, 335, 121-131.	1.0	117
776	Escape of Mutant Double-Stranded DNA Virus from Innate Immune Control. Immunity, 2004, 20, 747-756.	6.6	109
777	Identification of Probabilistic Transcriptional Switches in the Ly49 Gene Cluster. Immunity, 2004, 21, 55-66.	6.6	94
778	Different checkpoints in human NK-cell activation. Trends in Immunology, 2004, 25, 670-676.	2.9	140
779	Learning how to discriminate between friends and enemies, a lesson from Natural Killer cells. Molecular Immunology, 2004, 41, 569-575.	1.0	68
780	Regulation of FasL expression in natural killer cells. Human Immunology, 2004, 65, 317-327.	1.2	26
781	Investigation of killer cell immunoglobulin-like receptor gene diversity: II. KIR2DS4. Human Immunology, 2004, 65, 613-621.	1.2	47
782	Increased Infection-Related Mortality in KIR-Ligand–Mismatched Unrelated Allogeneic Hematopoietic Stem-Cell Transplantation. Transplantation, 2004, 78, 1081-1085.	0.5	81
783	Role of natural killer cells in the rejection process of corneal allografts in rats. Transplantation, 2004, 77, 676-682.	0.5	27
784	Thalamus in flame: targeting of infectious agents to thalamic nuclei. Thalamus & Related Systems, 2004, 2, 297.	0.5	3
785	Mother-to-Child Transmission of HIV-1: Strong Association With Certain Maternal HLA-B Alleles Independent of Viral Load Implicates Innate Immune Mechanisms. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 659-670.	0.9	59
786	Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood, 2004, 103, 3431-3439.	0.6	92
787	The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood, 2004, 103, 664-672.	0.6	225
788	The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood, 2004, 103, 1770-1778.	0.6	62
789	Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers î±-defensin production. Blood, 2004, 104, 1778-1783.	0.6	306
790	Combined deficiency in lîºBî± and lîºBïµ reveals a critical window of NF-κB activity in natural killer cell differentiation. Blood, 2004, 103, 4573-4580.	0.6	30

#	Article	IF	CITATIONS
791	Cytolytic activity and regulatory functions of inhibitory NK cell receptor–expressing T cells expanded from granulocyte colony-stimulating factor–mobilized peripheral blood mononuclear cells. Blood, 2004, 104, 768-774.	0.6	20
792	The Vertebrate Immune System. , 2004, , 1-56.		0
794	The Immunosuppressive Agent FK506 Enhances the Cytolytic Activity of Inhibitory Natural Killer Cell Receptor (CD94/NKG2A)-Expressing CD8 T Cells. Transplantation, 2005, 80, 1813-1815.	0.5	2
795	Analysis of KIR Ligand Incompatibility in Human Renal Transplantation. Transplantation, 2005, 80, 1121-1123.	0.5	37
796	Natural Killer Cell Alloreactivity for Leukemia Therapy. Journal of Immunotherapy, 2005, 28, 175-182.	1.2	58
797	Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood, 2005, 105, 266-273.	0.6	110
798	Analysis of the receptor-ligand interactions in the natural killer–mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood, 2005, 105, 2066-2073.	0.6	344
799	NK cell adoptive immunotherapy. Blood, 2005, 105, 3006-3006.	0.6	1
800	2B4 (CD244)-CD48 interactions provide a novel MHC class I-independent system for NK-cell self-tolerance in mice. Blood, 2005, 106, 1337-1340.	0.6	50
801	ICOS: a new important player in BMT. Blood, 2005, 105, 3006-3007.	0.6	0
802	KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood, 2005, 106, 4370-4376.	0.6	208
803	The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood, 2005, 106, 779-786.	0.6	171
804	Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. Immunology Letters, 2005, 100, 7-13.	1.1	113
805	Tumour immunology. Current Opinion in Immunology, 2005, 17, 159-162.	2.4	5
806	Immunogenetics of viral infections. Current Opinion in Immunology, 2005, 17, 510-516.	2.4	114
807	Natural Killer Cell Immune Responses. Immunologic Research, 2005, 32, 317-326.	1.3	56
808	Dendritic Cells and Natural Killer Cells in the Pathogenesis of HIV Infection. Immunologic Research, 2005, 33, 001-022.	1.3	23
809	Potential Role of Natural Killer Cell Receptor-Expressing Cells in Immunotherapy for Leukemia. International Journal of Hematology, 2005, 81, 6-12.	0.7	8

#	Article	IF	CITATIONS
810	Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens, 2005, 65, 519-528.	1.0	74
811	Role of NK cells in mismatched unrelated haematopoietic stem-cell transplantation: fact or fiction?. Tissue Antigens, 2005, 65, 515-518.	1.0	2
812	Genetic diversity of KIR natural killer cell markers in populations from France, Guadeloupe, Finland, Senegal and Reunion. Tissue Antigens, 2005, 66, 267-276.	1.0	94
813	Immunotherapy in multiple myeloma - possibility or probability?. British Journal of Haematology, 2005, 130, 344-362.	1.2	36
814	NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nature Medicine, 2005, 11, 1059-1065.	15.2	179
815	A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia, 2005, 19, 1446-1451.	3.3	125
816	Structural and functional aspects of the Ly49 natural killer cell receptors. Immunology and Cell Biology, 2005, 83, 1-8.	1.0	19
817	Altered Immunophenotypic Parameters in Infertile Women. Possible Role of Herpes Viremia. American Journal of Reproductive Immunology, 2005, 54, 101-111.	1.2	5
818	Immunology of the Human Nail Apparatus: The Nail Matrix Is a Site of Relative Immune Privilege. Journal of Investigative Dermatology, 2005, 125, 1139-1148.	0.3	124
819	Imaging fluorescence lifetime heterogeneity applied to GFP-tagged MHC protein at an immunological synapse*. Journal of Microscopy, 2005, 217, 36-43.	0.8	68
820	An Ets element regulates the transcription of the human 2B4 gene in natural killer cells. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2005, 1728, 181-185.	2.4	3
821	KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Experimental Hematology, 2005, 33, 1160-1171.	0.2	91
822	Efficient gene transfer into primary human natural killer cells by retroviral transduction. Experimental Hematology, 2005, 33, 1320-1328.	0.2	49
823	HLA-E Expression on Porcine Cells: Protection from Human NK Cytotoxicity Depends on Peptide Loading. American Journal of Transplantation, 2005, 5, 2085-2093.	2.6	63
824	\hat{l}^2 -endorphin modulation of interferon- \hat{l}^3 , perforin and granzyme B levels in splenic NK cells: Effects of ethanol. Journal of Neuroimmunology, 2005, 166, 29-38.	1.1	18
825	Differential expression of LFA-3, Fas and MHC Class I on Ad5- and Ad12-transformed human cells and their susceptibility to lymphokine-activated killer (LAK) cells. Virology, 2005, 338, 297-308.	1.1	6
826	Selective expansion and engraftment of human CD16+ NK cells in NOD/SCID mice. European Journal of Immunology, 2005, 35, 3599-3609.	1.6	15
827	Hepatitis C virus and the threshold of natural killer cell inhibition. Hepatology, 2005, 41, 675-677.	3.6	5

#	Article	IF	CITATIONS
828	MHC-I recognition by receptors on myelomonocytic cells: New tricks for old dogs?. BioEssays, 2005, 27, 542-550.	1.2	8
829	Distinguishing features of developing natural killer cells. Current Opinion in Immunology, 2005, 17, 151-158.	2.4	75
830	Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Current Opinion in Immunology, 2005, 17, 211-217.	2.4	106
831	Regulation of natural killer cell function: a role for the NK cell's own MHC class I molecules. Medical Microbiology and Immunology, 2005, 194, 169-174.	2.6	3
832	Mesenchymal stem cells avoid allogeneic rejection. Journal of Inflammation, 2005, 2, 8.	1.5	732
833	Xenotransplanation in Pharmaceutical Biotechnology. , 2005, , 265-279.		0
834	Natural Cytotoxicity Receptors: Pattern Recognition and Involvement of Carbohydrates. Scientific World Journal, The, 2005, 5, 151-154.	0.8	10
835	Adenovirus E1A gene-induced tumor rejection through cellular sensitization to immune and nonimmune apoptotic injuries. Frontiers in Bioscience - Landmark, 2005, 10, 1396.	3.0	10
836	Immunosynapse formation coincides with rapid activation of NK cells by syngeneic T cells and correlates with clustering of MHC class I. International Immunology, 2005, 17, 671-676.	1.8	1
837	Structural and functional aspects of the Ly49 natural killer cell receptors. Immunology and Cell Biology, 2005, 83, 1-8.	1.0	38
838	Characterization of inhibitory signaling motifs of the natural killer cell receptor Siglec-7: attenuated recruitment of phosphatases by the receptor is attributed to two amino acids in the motifs. Glycobiology, 2005, 15, 667-676.	1.3	44
839	Two Structurally Related Rat Ly49 Receptors with Opposing Functions (Ly49 Stimulatory Receptor 5) Tj ETQq1 1 of Immunology, 2005, 174, 2702-2711.	0.784314 0.4	rgBT /Overl
840	Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. Journal of Experimental Medicine, 2005, 202, 1001-1012.	4.2	409
842	Insights into Seven and Single Transmembrane-Spanning Domain Receptors and Their Signaling Pathways in Human Natural Killer Cells. Pharmacological Reviews, 2005, 57, 339-357.	7.1	40
843	Specific and Non-Specific Natural Killer Cell Responses to Viral Infection. , 2005, 560, 57-61.		16
844	Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. Journal of Experimental Medicine, 2005, 201, 1319-1332.	4.2	199
845	Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I. Blood, 2005, 105, 2028-2035.	0.6	52
846	IFN- \hat{l}^3 : A Cytokine Essential for Rejection of CTL-Resistant, Virus-Infected Cells. Journal of Interferon and Cytokine Research, 2005, 25, 328-337.	0.5	9

#	Article	IF	CITATIONS
847	NK Cells Can Trigger Allograft Vasculopathy: The Role of Hybrid Resistance in Solid Organ Allografts. Journal of Immunology, 2005, 175, 3424-3430.	0.4	158
848	Immune Selection of Hot-Spot $\hat{I}^22 < i >$ -Microglobulin $< i >$ Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy. Journal of Immunology, 2005, 174, 1462-1471.	0.4	96
849	NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. Journal of Experimental Medicine, 2005, 201, 211-220.	4.2	140
850	Altered IFNγ Signaling and Preserved Susceptibility to Activated Natural Killer Cell–Mediated Lysis of BCR/ABL Targets. Cancer Research, 2005, 65, 2914-2920.	0.4	8
851	Immunosuppressive Factors Secreted by Human Amniotic Epithelial Cells., 2005, 46, 900.		267
852	NK Cells Play a Critical Role in the Regulation of Class I-Deficient Hemopoietic Stem Cell Engraftment: Evidence for NK Tolerance Correlates with Receptor Editing. Journal of Immunology, 2005, 175, 3753-3761.	0.4	12
853	Human decidual NK cells form immature activating synapses and are not cytotoxic. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15563-15568.	3.3	284
854	Immunotherapy of hematological malignancies: what is new?. Annals of Oncology, 2005, 16, ii53-ii62.	0.6	5
855	Natural killer cells play a role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. International Journal of Oncology, 2005, 26, 679.	1.4	5
856	Genetic Variability of the Major Histocompatibility Complex Class I Homologue Encoded by Human Cytomegalovirus Leads to Differential Binding to the Inhibitory Receptor ILT2. Journal of Virology, 2005, 79, 2251-2260.	1.5	34
857	Natural killer cell receptors: Regulating innate immune responses to hematologic malignancy. Seminars in Hematology, 2005, 42, 91-103.	1.8	32
858	Human natural killer cell receptor functions and their implication in diseases. Expert Review of Clinical Immunology, 2005, 1, 405-417.	1.3	6
859	Specific amplification of cDNA ends (SPACE): A new tool for the analysis of rare transcripts and its application for the promoter analysis of killer cell receptor genes. DNA Sequence, 2005, 16, 44-52.	0.7	7
860	HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood, 2005, 105, 251-258.	0.6	291
861	Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opinion on Biological Therapy, 2005, 5, 463-476.	1.4	63
862	Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Molecular Immunology, 2005, 42, 161-182.	1.0	106
863	Mutual interference of HIV and natural killer cell-mediated immune response. Molecular Immunology, 2005, 42, 239-249.	1.0	16
864	Natural killer cells: from "disturbing―background to central players of immune responses. Molecular Immunology, 2005, 42, 381-383.	1.0	12

#	Article	IF	CITATIONS
865	Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Molecular Immunology, 2005, 42, 495-499.	1.0	138
866	KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation. Molecular Immunology, 2005, 42, 531-534.	1.0	45
867	Differential roles of constitutively activated ERK1/2 and NF-ΰB in cytotoxicity and proliferation by human NK cell lines. International Immunopharmacology, 2005, 5, 839-848.	1.7	13
868	Imbalance of NKG2D and its inhibitory counterparts: How does tumor escape from innate immunity?. International Immunopharmacology, 2005, 5, 1099-1111.	1.7	25
869	NK cells: elusive players in autoimmunity. Trends in Immunology, 2005, 26, 613-618.	2.9	102
870	Difference in target cell recognition of naive and activated human natural killer cells: Role of Haymaker (p38.5) in tumoricidal activity. Human Immunology, 2005, 66, 241-251.	1.2	2
871	HLA-C and KIR Genes in Hepatitis C Virus Infection. Human Immunology, 2005, 66, 1106-1109.	1.2	41
872	Cytolytic Pathways Used by Effector Cells Derived from Recipient Naive and Memory T Cells and Natural Killer Cells in Resistance to Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 957-971.	2.0	14
873	Down-regulation of MHC class I expression in human neuronal stem cells using viral stealth mechanism. Biochemical and Biophysical Research Communications, 2005, 326, 825-835.	1.0	20
874	Do NK cells regulate human autoimmunity?. Cytokine, 2005, 32, 76-80.	1.4	22
875	MHC RFLP analyses in channel catfish full-sibling families: identification of the role of MHC molecules in spontaneous allogeneic cytotoxic responses. Developmental and Comparative Immunology, 2005, 29, 457-467.	1.0	18
876	MHC expression in a human adult stem cell line and its down-regulation by hCMV US gene transfection. International Journal of Biochemistry and Cell Biology, 2005, 37, 69-78.	1.2	14
877	Mechanisms of immune evasion of human neuroblastoma. Cancer Letters, 2005, 228, 155-161.	3.2	76
878	KIR genes. Transplant Immunology, 2005, 14, 135-142.	0.6	70
879	The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transplant Immunology, 2005, 14, 203-206.	0.6	42
880	NK CELL RECOGNITION. Annual Review of Immunology, 2005, 23, 225-274.	9.5	2,490
881	Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 2005, 105, 3051-3057.	0.6	1,574
883	Non-Classical HLA-G Antigen and Its Role in the Cancer Progression. Cancer Investigation, 2006, 24, 178-186.	0.6	52

#	Article	IF	Citations
884	Immunology of Pregnancy., 2006,,.		11
885	Innate Immune Recognition and Suppression of Tumors. Advances in Cancer Research, 2006, 95, 293-322.	1.9	55
886	Immunotherapy of multiple myeloma: the start of a long and tortuous journey. Expert Review of Anticancer Therapy, 2006, 6, 1769-1785.	1,1	22
888	Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 2006, 107, 1484-1490.	0.6	955
889	NK Cell Receptors as Tools in Cancer Immunotherapy. Advances in Cancer Research, 2006, 95, 249-292.	1.9	46
890	Immunologic Approaches to Acute Leukemia in the Elderly. Seminars in Hematology, 2006, 43, 118-125.	1.8	11
891	MHC Molecules of the Preimplantation Embryo and Trophoblast. , 2006, , 130-147.		1
892	The Killer Immunoglobulin-Like Receptor Gene Cluster: Tuning the Genome for Defense. Annual Review of Genomics and Human Genetics, 2006, 7, 277-300.	2.5	229
893	Signal Transduction in Natural Killer Cells. Current Topics in Microbiology and Immunology, 2006, 298, 23-57.	0.7	81
894	The Impact of Variation at the KIR Gene Cluster on Human Disease. Current Topics in Microbiology and Immunology, 2006, 298, 225-257.	0.7	113
895	Natural killer cells in human health and disease. Clinical Immunology, 2006, 118, 1-10.	1.4	280
896	Analyses andÂperspectives inÂcancer immunotherapy. Biomedicine and Pharmacotherapy, 2006, 60, 621-628.	2.5	4
897	NATURAL KILLER CELL DEVELOPMENTAL PATHWAYS: A Question of Balance. Annual Review of Immunology, 2006, 24, 257-286.	9.5	386
898	The role of HLA-G in cytokine homeostasis during early pregnancy complicated with maternal infections: A novel etiopathological approach to the neurodevelopmental understanding of schizophrenia. Medical Hypotheses, 2006, 66, 286-293.	0.8	22
899	Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. Journal of Hepatology, 2006, 45, 60-71.	1.8	242
900	Human cytomegalovirus-encoded US2 and US11 target unassembled MHC class I heavy chains for degradation. Molecular Immunology, 2006, 43, 1258-1266.	1.0	23
901	How Do Natural Killer Cells Find Self to Achieve Tolerance?. Immunity, 2006, 24, 249-257.	6.6	172
902	Human NK Cell Education by Inhibitory Receptors for MHC Class I. Immunity, 2006, 25, 331-342.	6.6	1,026

#	Article	IF	CITATIONS
904	Surface NK receptors and their ligands on tumor cells. Seminars in Immunology, 2006, 18, 151-158.	2.7	247
905	Missing self recognition and self tolerance of natural killer (NK) cells. Seminars in Immunology, 2006, 18, 145-150.	2.7	148
906	Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors. Seminars in Immunology, 2006, 18, 159-166.	2.7	58
907	NKG2D and cytotoxic effector function in tumor immune surveillance. Seminars in Immunology, 2006, 18, 176-185.	2.7	78
909	Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood, 2006, 107, 159-166.	0.6	697
910	Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin–like receptors. Blood, 2006, 107, 4449-4457.	0.6	54
911	Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood, 2006, 107, 2030-2036.	0.6	234
912	Self/Non-self Recognition., 2006,, 37-61.		1
913	Critical Roles of Memory T Cells and Antidonor Immunoglobulin in Rejection of Allogeneic Bone Marrow Cells in Sensitized Recipient Mice. Transplantation, 2006, 82, 689-698.	0.5	15
914	Acute Graft-Versus-Host Disease-Challenge for a Broader Application of Allogeneic Hematopoietic Cell Transplantation. Current Stem Cell Research and Therapy, 2006, 1, 203-212.	0.6	13
915	Natural killer cells and HIV-1 disease. Current Opinion in HIV and AIDS, 2006, 1, 226-231.	1.5	7
916	The Changing Role of Natural Killer Cells in Solid Organ Rejection and Tolerance. Transplantation, 2006, 81, 811-817.	0.5	128
918	Effect of sera on the adhesion of natural killer cells to the endothelium in severe pre-eclampsia. Journal of Obstetrics and Gynaecology Research, 2006, 32, 443-448.	0.6	6
919	Effector and regulatory events during natural killer?dendritic cell interactions. Immunological Reviews, 2006, 214, 219-228.	2.8	261
920	Regulation of class I major histocompatibility complex receptor expression in natural killer cells: one promoter is not enough!. Immunological Reviews, 2006, 214, 9-21.	2.8	37
921	Functional subsets of mouse natural killer cells. Immunological Reviews, 2006, 214, 47-55.	2.8	222
922	Activation, coactivation, and costimulation of resting human natural killer cells. Immunological Reviews, 2006, 214, 73-91.	2.8	531
923	Licensing of natural killer cells by self-major histocompatibility complex class I. Immunological Reviews, 2006, 214, 143-154.	2.8	219

#	ARTICLE	IF	CITATIONS
924	Activation and self-tolerance of natural killer cells. Immunological Reviews, 2006, 214, 130-142.	2.8	185
925	Dissecting natural killer cell activation pathways through analysis of genetic mutations in human and mouse. Immunological Reviews, 2006, 214, 92-105.	2.8	62
926	Current status of haploidentical stem cell transplantation. British Journal of Haematology, 2006, 135, 423-437.	1.2	60
927	Resistance Against Natural Killer Cell Cytotoxicity: Analysis of Mechanisms. Scandinavian Journal of Immunology, 2006, 64, 444-449.	1.3	23
928	Rapid production of human KIR2DL4 extracellular domain and verification of its interaction with HLA-G. Biochemistry (Moscow), 2006, 71, S60-S64.	0.7	13
929	Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes and Immunity, 2006, 7, 576-582.	2.2	58
930	NK cells do not mediate renal injury in murine adriamycin nephropathy. Kidney International, 2006, 69, 1159-1165.	2.6	21
931	Evaluation of ex vivo expanded human NK cells on antileukemia activity in SCID-beige mice. Leukemia, 2006, 20, 833-839.	3.3	25
932	Cord blood donor cell leukemia in recipients. Leukemia, 2006, 20, 1633-1634.	3.3	40
933	Non-classical antileukemia activity of early recovering NK cells after induction chemotherapy and HLA-identical stem cell transplantation in myeloid leukemias. Leukemia, 2006, 20, 1632-1633.	3.3	11
934	Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunological Reviews, 2006, 214, 202-218.	2.8	149
935	Human natural killer cell development and biology. Blood Reviews, 2006, 20, 123-137.	2.8	425
936	NK cell-based immunotherapies against tumors. Open Medicine (Poland), 2006, 1, 179-204.	0.6	0
937	CD161B:ClrB Interactions Mediate Activation of Enhanced Lysis of Tumor Target Cells Following NK Cell:DC Co-Culture. Immunologic Research, 2006, 36, 43-50.	1.3	6
938	The chicken immunoregulatory receptor families SIRP, TREM, and CMRF35/CD300L. Immunogenetics, 2006, 58, 180-190.	1.2	36
939	Effects of thermal stress on tumor antigenicity and recognition by immune effector cells. Cancer Immunology, Immunotherapy, 2006, 55, 312-319.	2.0	49
940	Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?. Cancer Immunology, Immunotherapy, 2006, 55, 891-899.	2.0	82
941	Tumor immune escape mechanisms: impact of the neuroendocrine system. Cancer Immunology, Immunotherapy, 2006, 55, 749-760.	2.0	42

#	Article	IF	Citations
942	Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands. Cancer Immunology, Immunotherapy, 2006, 56, 101-109.	2.0	36
943	Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Archivum Immunologiae Et Therapiae Experimentalis, 2006, 54, 323-333.	1.0	49
944	Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery. Journal of Molecular Medicine, 2006, 84, 425-437.	1.7	44
945	What is natural in natural killer cells?. Immunology Letters, 2006, 107, 1-7.	1.1	49
946	The potential involvement of Notch signaling in NK cell development. Immunology Letters, 2006, 107, 50-57.	1.1	30
947	MiHA Reactive CD4 and CD8 T-Cells Effect Resistance to Hematopoietic Engraftment Following Reduced Intensity Conditioning. American Journal of Transplantation, 2006, 6, 2089-2098.	2.6	15
948	Human cytomegalovirus infection of cells of hematopoietic origin: HCMV-induced immunosuppression, immune evasion, and latency. Experimental Hematology, 2006, 34, 555-570.	0.2	50
949	Innervation of lymphoid organs: Clinical implications. Clinical Neuroscience Research, 2006, 6, 3-33.	0.8	6
950	Escape from immune- and nonimmune-mediated tumor surveillance. Seminars in Cancer Biology, 2006, 16, 16-31.	4.3	58
951	Novel approaches using natural killer cells in cancer therapy. Seminars in Cancer Biology, 2006, 16, 412-418.	4.3	48
952	Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. Seminars in Cancer Biology, 2006, 16, 404-411.	4.3	39
953	The dynamics of natural killer cell tolerance. Seminars in Cancer Biology, 2006, 16, 393-403.	4.3	9
954	Natural killer cells in cancer. Seminars in Cancer Biology, 2006, 16, 331-332.	4.3	9
955	Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR-1/ILT2/CD85j. European Journal of Immunology, 2006, 36, 732-741.	1.6	42
956	Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. European Journal of Immunology, 2006, 36, 2159-2169.	1.6	85
957	Regulation of 2B4 (CD244)-mediated NK cell activation by ligand-induced receptor modulation. European Journal of Immunology, 2006, 36, 3268-3276.	1.6	40
958	Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. International Journal of Cancer, 2006, 118, 6-10.	2.3	199
959	Natural killer cells: Primary target for hepatitis C virus immune evasion strategies?. Liver Transplantation, 2006, 12, 363-372.	1.3	100

#	Article	IF	CITATIONS
960	Nonvillous Parts and Trophoblast Invasion. , 2006, , 191-312.		9
961	Detecting the Unusual: Natural Killer Cells. Progress in Molecular Biology and Translational Science, 2006, 81, 473-541.	1.9	1
962	Antigen Presenting Cells and Stromal Cells Trigger Human Natural Killer Lymphocytes to Autoreactivity: Evidence for the Involvement of Natural Cytotoxicity Receptors (NCR) and NKG2D. Clinical and Developmental Immunology, 2006, 13, 325-336.	3.3	19
963	Bridging Innate and Adaptive Immunity: NK, γδT, and NKT Cells. , 2006, , 517-552.		O
964	Recognition of Vaccinia Virus-Infected Cells by Human Natural Killer Cells Depends on Natural Cytotoxicity Receptors. Journal of Virology, 2006, 80, 2225-2233.	1.5	80
965	Epidemiological and Genetic Correlates of Severe Acute Respiratory Syndrome Coronavirus Infection in the Hospital with the Highest Nosocomial Infection Rate in Taiwan in 2003. Journal of Clinical Microbiology, 2006, 44, 359-365.	1.8	98
966	Autoreactive T Cells Mediate NK Cell Degeneration in Autoimmune Disease. Journal of Immunology, 2006, 176, 5247-5254.	0.4	57
967	Segregation of HLA-C from ICAM-1 at NK Cell Immune Synapses Is Controlled by Its Cell Surface Density. Journal of Immunology, 2006, 177, 6904-6910.	0.4	65
968	The First Molecular Basis of the "Missing Self―Hypothesis. Journal of Immunology, 2006, 177, 5759-5760.	0.4	13
969	A Short Isoform of Human Cytomegalovirus US3 Functions as a Dominant Negative Inhibitor of the Full-Length Form. Journal of Virology, 2006, 80, 5397-5404.	1.5	14
970	Cross-Species Dependence of Ly49 Recognition on the Supertype Defining B-Pocket of a Class I MHC Molecule. Journal of Immunology, 2006, 177, 8578-8586.	0.4	7
971	A Novel NF-κB Binding Site Controls Human Granzyme B Gene Transcription. Journal of Immunology, 2006, 176, 4173-4181.	0.4	73
972	Microclusters of inhibitory killer immunoglobulin–like receptor signaling at natural killer cell immunological synapses. Journal of Cell Biology, 2006, 174, 153-161.	2.3	103
973	Interactions Between Natural Killer Cells, Cortisol and Prolactin in Malaria During Pregnancy. Clinical Medicine and Research, 2006, 4, 33-41.	0.4	12
974	Chronic myeloid leukemia and allogeneic natural killer cells: a surprising dialogue. Expert Review of Clinical Immunology, 2006, 2, 627-637.	1.3	0
975	Immature NK Cells Suppress Dendritic Cell Functions during the Development of Leukemia in a Mouse Model. Journal of Immunology, 2006, 176, 4113-4124.	0.4	40
976	The Inhibitory Receptor NKG2A Determines Lysis of Vaccinia Virus-Infected Autologous Targets by NK Cells. Journal of Immunology, 2006, 176, 1141-1147.	0.4	30
977	Cytolytic responses: cadherins put out the fire. Journal of Experimental Medicine, 2006, 203, 261-264.	4.2	20

#	Article	IF	CITATIONS
978	Distinctive Interactions at Multiple Site 2 Subsites by Allele-Specific Rat and Mouse Ly49 Determine Functional Binding and Class I MHC Specificity. Journal of Immunology, 2007, 179, 6856-6866.	0.4	4
979	Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands. Journal of Immunology, 2007, 179, 5977-5989.	0.4	188
980	Immune Mechanisms of Corneal Allograft Rejection. Current Eye Research, 2007, 32, 1005-1016.	0.7	112
981	Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells. Current Gene Therapy, 2007, 7, 458-468.	0.9	11
982	Regulatory T Cells and the Eye. , 2007, 92, 131-139.		23
983	Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Nature Clinical Practice Oncology, 2007, 4, 404-414.	4.3	35
984	DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer Cells. Cancer Research, 2007, 67, 1317-1325.	0.4	198
985	Inhibition of Heavy Chain and \hat{l}^2 2 -Microglobulin Synthesis as a Mechanism of Major Histocompatibility Complex Class I Downregulation during Epstein-Barr Virus Replication. Journal of Virology, 2007, 81, 1390-1400.	1.5	16
986	Human Leukocyte Antigen Class I Antigen Expression Is an Independent Prognostic Factor in Ovarian Cancer. Clinical Cancer Research, 2007, 13, 3591-3596.	3.2	54
987	Detection of KIR3DS1 on the Cell Surface of Peripheral Blood NK Cells Facilitates Identification of a Novel Null Allele and Assessment of KIR3DS1 Expression during HIV-1 Infection. Journal of Immunology, 2007, 179, 1625-1633.	0.4	50
988	KIR2DS1-Positive NK Cells Mediate Alloresponse against the C2 HLA-KIR Ligand Group In Vitro. Journal of Immunology, 2007, 179, 854-868.	0.4	178
990	Activation of naturally occurring lung CD4 ⁺ CD25 ⁺ regulatory T cells requires CD8 and MHC I interaction. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15057-15062.	3.3	20
991	Activation of human natural killer cells by recombinant membrane-expressed fractalkine on the surface of tumor cells. Oncology Reports, 2007, 17, 1371.	1.2	2
992	A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood, 2007, 110, 578-586.	0.6	202
993	Control LPS or get killed. Blood, 2007, 109, 3614-3615.	0.6	0
994	FcÎ ³ Rs join in the cascade. Blood, 2007, 109, 3615-3616.	0.6	5
996	KIR/HLA Ligand Incompatibility in Kidney Transplantation. Transplantation, 2007, 84, 1527-1533.	0.5	54
997	Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Current Opinion in Oncology, 2007, 19, 142-147.	1.1	78

#	Article	IF	CITATIONS
998	Embryonic stem cell transplantation for the treatment of myocardial infarction: Immune privilege or rejection. Transplant Immunology, 2007, 18, 88-93.	0.6	14
999	Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value Blood, 2007, 110, 433-440.	0.6	550
1000	Survival of priceless cells: Active and passive protection of embryonic stem cells against immune destruction. Archives of Biochemistry and Biophysics, 2007, 462, 273-277.	1.4	9
1001	Allogeneic Hematopoietic Stem Cell Transplant Using Mismatched/Haploidentical Donors. Biology of Blood and Marrow Transplantation, 2007, 13, 1249-1267.	2.0	53
1002	Good News, Bad News for Missing-Self Recognition by NK Cells: Autoimmune Control but Viral Evasion. Immunity, 2007, 26, 549-551.	6.6	12
1003	The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis. , 2007, , 111-121.		9
1005	Immunotherapy by Allogeneic Stem Cell Transplantation. Advances in Cancer Research, 2007, 97, 25-60.	1.9	28
1006	Characterization of the Recognition of Tumor Cells by the Natural Cytotoxicity Receptor, NKp44. Biochemistry, 2007, 46, 7426-7436.	1.2	59
1007	Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. Journal of Leukocyte Biology, 2007, 81, 15-27.	1.5	482
1008	Cytokine Gene Therapy Using Adenovirally Transduced, Tumor-Seeking Activated Natural Killer Cells. Human Gene Therapy, 2007, 18, 701-711.	1.4	18
1009	MHC Class I Antigens and Immune Surveillance in Transformed Cells. International Review of Cytology, 2007, 256, 139-189.	6.2	128
1010	Mechanisms of Disease: HCV-induced liver injury. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 622-634.	1.7	91
1011	Mouse Natural Killer CellsFunction and Activation. , 2007, , 169-177.		0
1012	Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?. Frontiers in Bioscience - Landmark, 2007, 12, 4568.	3.0	10
1013	Quantifying the reduction in accessibility of the inhibitory NK cell receptor Ly49A caused by binding MHC class I proteins in cis. European Journal of Immunology, 2007, 37, 516-527.	1.6	39
1014	Donor doubleâ€negative Treg promote allogeneic mixed chimerism and tolerance. European Journal of Immunology, 2007, 37, 3455-3466.	1.6	29
1015	Evolutionary vignettes of natural killer cell receptors. Current Opinion in Immunology, 2007, 19, 553-560.	2.4	19
1016	Self-tolerance, dendritic cell (DC)-mediated activation and tissue distribution of natural killer (NK) cells. Immunology Letters, 2007, 110, 6-17.	1.1	23

#	Article	IF	CITATIONS
1017	Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens. Nature Reviews Immunology, 2007, 7, 279-291.	10.6	226
1018	Prospects for the use of NK cells in immunotherapy of human cancer. Nature Reviews Immunology, 2007, 7, 329-339.	10.6	481
1019	Promiscuity and the single receptor: NKG2D. Nature Reviews Immunology, 2007, 7, 737-744.	10.6	352
1020	Diversity of the killer cell immunoglobulin-like receptor gene KIR2DS4 in the Chinese population. Tissue Antigens, 2007, 69, 133-138.	1.0	10
1022	Up-regulation of Fas (CD95) expression in tumour cells in vivo. Immunology, 2007, 120, 502-511.	2.0	15
1023	Regulation of ligands for the activating receptor NKG2D. Immunology, 2007, 121, 439-447.	2.0	134
1024	Effect of in vivo activation of natural killer (NK) cells by a tilorone analogue on the survival of mice injected intravenously with different experimental murine tumours. Clinical and Experimental Immunology, 2007, 103, 499-505.	1,1	6
1025	Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clinical and Experimental Immunology, 2007, 149, 1-8.	1.1	142
1026	Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion, 2007, 47, 520-528.	0.8	104
1027	Thymic stromal lymphopoietin augments the cytolytic activity of the human natural killer cell line NKâ€92. Apmis, 2007, 115, 948-955.	0.9	2
1028	Human natural killer lymphocytes through the engagement of natural cytotoxicity receptors and NKG2D can trigger self-aggression. Autoimmunity Reviews, 2007, 6, 295-299.	2.5	18
1029	Expansion of natural killer cell receptor (CD94/NKG2A)–expressing cytolytic CD8 T cells and CD4+CD25+ regulatory T cells from the same cord blood unit. Experimental Hematology, 2007, 35, 1562-1566.	0.2	9
1030	HLA-G in the skinâ€"Friend or foe?. Seminars in Cancer Biology, 2007, 17, 480-484.	4.3	10
1031	NKG2D and Natural Cytotoxicity Receptors Are Involved in Natural Killer Cell Interaction with Selfâ€Antigen Presenting Cells and Stromal Cells. Annals of the New York Academy of Sciences, 2007, 1109, 47-57.	1.8	25
1032	Hsp70 Peptide Acting as a Danger Signal for Natural Killer (NK) Cells., 2007,, 21-30.		1
1033	Heat shock protein 70 (Hsp70): Membrane location, export and immunological relevance. Methods, 2007, 43, 229-237.	1.9	165
1034	Chain-terminating natural mutations affect the function of activating KIR receptors 3DS1 and 2DS3. Immunogenetics, 2007, 59, 779-792.	1.2	13
1035	Clustered carbohydrates as a target for natural killer cells: a model system. Histochemistry and Cell Biology, 2007, 127, 313-326.	0.8	6

#	Article	IF	CITATIONS
1036	NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunology, Immunotherapy, 2008, 57, 1541-1552.	2.0	74
1037	Influence of Hsp70 and HLA-E on the killing of leukemic blasts by cytokine/Hsp70 peptide-activated human natural killer (NK) cells. Cell Stress and Chaperones, 2008, 13, 221-230.	1.2	43
1038	Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. International Journal of Cancer, 2008, 123, 2343-2353.	2.3	56
1039	Autologous and allogeneic HLA KIR ligand environments and activating KIR control KIR NK ell functions. European Journal of Immunology, 2008, 38, 3474-3486.	1.6	42
1040	Tolerance and reactivity of NK cells: Two sides of the same coin?. European Journal of Immunology, 2008, 38, 2930-2933.	1.6	11
1041	Different KIRs Confer Susceptibility and Protection to Adults with Latent Autoimmune Diabetes in Latvian and Asian Indian Populations. Annals of the New York Academy of Sciences, 2008, 1150, 133-138.	1.8	14
1042	Regulation of NK cell responsiveness to achieve selfâ€tolerance and maximal responses to diseased target cells. Immunological Reviews, 2008, 224, 85-97.	2.8	115
1043	Negative signaling by inhibitory receptors: the NK cell paradigm. Immunological Reviews, 2008, 224, 70-84.	2.8	310
1044	REVIEW ARTICLE: NK Cell Tolerance and the Maternal–Fetal Interface. American Journal of Reproductive Immunology, 2008, 59, 371-387.	1.2	69
1045	REVIEW ARTICLE: Fetomaternal Immunotolerance. American Journal of Reproductive Immunology, 2008, 60, 482-496.	1.2	46
1046	NK cells and cancer immunosurveillance. Oncogene, 2008, 27, 5932-5943.	2.6	572
1047	Natural killer cells: diversity in search of a niche. Nature Immunology, 2008, 9, 473-475.	7.0	108
1048	Natural killer cell recognition of missing self. Nature Immunology, 2008, 9, 477-480.	7.0	226
1049	Cis interactions of immunoreceptors with MHC and non-MHC ligands. Nature Reviews Immunology, 2008, 8, 269-278.	10.6	92
1050	NK cells at the interface between innate and adaptive immunity. Cell Death and Differentiation, 2008, 15, 226-233.	5.0	291
1051	A study of the killer cell immunoglobulinâ€like receptor gene KIR2DS1 in a Caucasoid Brazilian population with psoriasis vulgaris. Tissue Antigens, 2008, 72, 392-396.	1.0	25
1052	NK cells in autoimmunity: A two-edg'd weapon of the immune system. Autoimmunity Reviews, 2008, 7, 384-390.	2.5	83
1053	Sympathetic modulation of immunity: Relevance to disease. Cellular Immunology, 2008, 252, 27-56.	1.4	213

#	Article	IF	CITATIONS
1054	Donor HLA-C Genotype Has a Profound Impact on the Clinical Outcome Following Liver Transplantation. American Journal of Transplantation, 2008, 8, 1931-1941.	2.6	66
1055	AVIAN INNATE IMMUNE RESPONSES. , 2008, , 129-158.		45
1056	Dissecting the role of hyperthermia in natural killer cell mediated anti-tumor responses. International Journal of Hyperthermia, 2008, 24, 41-56.	1.1	68
1057	Regulation of NK cell cytotoxicity during pregnancy. Reproductive BioMedicine Online, 2008, 16, 211-217.	1.1	26
1059	Trophoblast Immune Receptors in Maternal-Fetal Tolerance. Immunological Investigations, 2008, 37, 395-426.	1.0	36
1060	Patients benefit from the addition of KIR repertoire data to the donor selection procedure for unrelated haematopoietic stem cell transplantation. Molecular Immunology, 2008, 45, 981-989.	1.0	15
1061	The elucidation of KIR2DL4 gene polymorphism. Molecular Immunology, 2008, 45, 1900-1906.	1.0	10
1062	Activating KIRs exert a crucial role on relapse and overall survival after HLA-identical sibling transplantation. Molecular Immunology, 2008, 45, 2255-2261.	1.0	28
1063	Immune regulation and the eye. Trends in Immunology, 2008, 29, 548-554.	2.9	86
1064	The Yin and Yang of HLA and KIR in human disease. Seminars in Immunology, 2008, 20, 343-352.	2.7	334
1065	NK cell receptors in rodents and cattle. Seminars in Immunology, 2008, 20, 369-375.	2.7	10
1066	KIR-HLA intercourse in HIV disease. Trends in Microbiology, 2008, 16, 620-627.	3.5	129
1067	KIR Genotyping and Analysis. , 2008, 415, 49-64.		74
1068	Expression of Cytotoxicity-Associated Genes in Marek's Disease Virusâ€"Infected Chickens. Viral Immunology, 2008, 21, 267-272.	0.6	38
1069	Natural killer cells: Detectors of stress. International Journal of Biochemistry and Cell Biology, 2008, 40, 2335-2340.	1.2	18
1070	Donor Killer Immunoglobulin-Like Receptor (KIR) Genotype-Patient Cognate KIR Ligand Combination and Antithymocyte Globulin Preadministration Are Critical Factors in Outcome of HLA-C-KIR Ligand-Mismatched TÂCell–Replete Unrelated Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation. 2008, 14, 75-87.	2.0	60
1071	NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells, Molecules, and Diseases, 2008, 40, 84-90.	0.6	134
1072	Human natural killer cells. Blood, 2008, 112, 461-469.	0.6	1,572

#	ARTICLE	IF	CITATIONS
1073	NK cells and surveillance in humans. Reproductive BioMedicine Online, 2008, 16, 192-201.	1.1	14
1074	Cancer Immunotherapy: Will Expanding Knowledge Lead to Success in Pediatric Oncology?. Pediatric Clinics of North America, 2008, 55, 147-167.	0.9	5
1075	Regulatory role of NKp44, NKp46, DNAM-1 and NKG2D receptors in the interaction between NK cells and trophoblast cells. Evidence for divergent functional profiles of decidual versus peripheral NK cells. International Immunology, 2008, 20, 1395-1405.	1.8	95
1076	The Sponge as a Model of Cellular Recognition. , 2008, , 75-83.		5
1077	Molecular Basis of the Dual Functions of 2B4 (CD244). Journal of Immunology, 2008, 180, 8159-8167.	0.4	122
1078	Ly49 C/I-dependent NKT cell-derived IL-10 is required for corneal graft survival and peripheral tolerance. Journal of Leukocyte Biology, 2008, 83, 928-935.	1.5	18
1079	Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy. Journal of Immunology, 2008, 180, 6392-6401.	0.4	153
1080	Regulation of the NK Cell Alloreactivity to Bone Marrow Cells by the Combination of the Host NK Gene Complex and MHC Haplotypes. Journal of Immunology, 2008, 180, 3260-3267.	0.4	3
1081	Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A <i>KIR</i> Haplotype. Journal of Immunology, 2008, 181, 6010-6019.	0.4	99
1082	Cutting Edge: Viral Infection Breaks NK Cell Tolerance to "Missing Self― Journal of Immunology, 2008, 181, 7453-7457.	0.4	63
1083	Human Cytomegalovirus UL18 Utilizes US6 for Evading the NK and T-Cell Responses. PLoS Pathogens, 2008, 4, e1000123.	2.1	28
1084	Natural Killer Cell Receptors. Advances in Experimental Medicine and Biology, 2008, 640, 35-52.	0.8	48
1085	Continuous engagement of a self-specific activation receptor induces NK cell tolerance. Journal of Experimental Medicine, 2008, 205, 1829-1841.	4.2	147
1086	Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation. Gene Therapy, 2008, 15, 1302-1310.	2.3	9
1087	Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10095-10100.	3.3	80
1088	Immunology, Phenotype First: How Mutations Have Established New Principles and Pathways in Immunology. Current Topics in Microbiology and Immunology, 2008, , .	0.7	2
1089	Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood, 2008, 111, 5637-5645.	0.6	152
1090	Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood, 2008, 111, 3571-3578.	0.6	154

#	Article	IF	CITATIONS
1091	Enhanced NK-cell development and function in BCAP-deficient mice. Blood, 2008, 112, 131-140.	0.6	29
1092	Natural killer cells recruited into lymph nodes inhibit alloreactive T-cell activation through perforin-mediated killing of donor allogeneic dendritic cells. Blood, 2008, 112, 661-671.	0.6	104
1093	The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for patient and donor suitability for haploidentical stem cell transplantations. Blood, 2008, 112, 435-443.	0.6	95
1094	MHC class lâ€"specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood, 2008, 112, 2369-2380.	0.6	268
1095	HLA Class I Expression, Tumor Escape and Cancer Progression. Current Cancer Therapy Reviews, 2008, 4, 105-110.	0.2	3
1096	Induction of NKG2D Ligands and Subsequent Enhancement of NK Cell-mediated Lysis of Cancer Cells by Arsenic Trioxide. Journal of Immunotherapy, 2008, 31, 475-486.	1.2	30
1097	Rapamycin, But Not Cyclosporine or FK506, Alters Natural Killer Cell Function. Transplantation, 2008, 85, 145-149.	0.5	81
1098	Variable interactions of recipient killer cell immunoglobulin-like receptors with self and allogenic human leukocyte antigen class I ligands may influence the outcome of solid organ transplants. Current Opinion in Organ Transplantation, 2008, 13, 430-437.	0.8	10
1099	A Second Prophylactic MHC-Mismatched Bone Marrow Transplantation Protects Against Rat Acute Myeloid Leukemia (BNML) Without Lethal Graft-Versus-Host Disease. Transplantation, 2008, 85, 102-111.	0.5	15
1100	Natural Killer Cells in Innate Immunity and Cancer. Journal of Immunotherapy, 2008, 31, 685-692.	1.2	45
1101	NK cells interactions with dendritic cells shape innate and adaptive immunity. Frontiers in Bioscience - Landmark, 2008, Volume, 6443.	3.0	33
1102	Células natural killer e vigilância imunológica. Jornal De Pediatria, 2008, 84, S58-S67.	0.9	4
1103	Soluble NKG2D ligands: prevalence, release, and functional impact. Frontiers in Bioscience - Landmark, 2008, Volume, 3448.	3.0	119
1104	Regulation of Tumor Immune Surveillance and Tumor Immune Subversion by TGF-β. Immune Network, 2009, 9, 122.	1.6	17
1105	Development of Functional Human NK Cells in an Immunodeficient Mouse Model with the Ability to Provide Protection against Tumor Challenge. PLoS ONE, 2009, 4, e8379.	1.1	22
1106	Expansion and Activation of Natural Killer Cells for Cancer Immunotherapy. Annals of Laboratory Medicine, 2009, 29, 89-96.	1.2	83
1107	Phenotypic and Functional Analyses of KIR3DL1+and KIR3DS1+NK Cell Subsets Demonstrate Differential Regulation by Bw4 Molecules and Induced KIR3DS1 Expression on Stimulated NK Cells. Journal of Immunology, 2009, 182, 6727-6735.	0.4	30
1108	Natural killer cells: versatile roles in autoimmune and infectious diseases. Expert Review of Clinical Immunology, 2009, 5, 405-420.	1.3	12

#	Article	IF	CITATIONS
1109	NKG2D Ligand MICA Is Retained in the <i>cis</i> -Golgi Apparatus by Human Cytomegalovirus Protein UL142. Journal of Virology, 2009, 83, 12345-12354.	1.5	105
1110	Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy. British Journal of Cancer, 2009, 101, 1321-1328.	2.9	22
1111	Lysophosphatidic acid inhibits the cytotoxic activity of NK cells: involvement of Gs protein-mediated signaling. International Immunology, 2009, 21, 667-677.	1.8	25
1112	Differential Susceptibility of RAE-1 Isoforms to Mouse Cytomegalovirus. Journal of Virology, 2009, 83, 8198-8207.	1.5	40
1113	The Natural Selection of Herpesviruses and Virus-Specific NK Cell Receptors. Viruses, 2009, 1, 362-382.	1.5	48
1114	<i>KIR</i> and <i>HLA</i> Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma. Clinical Cancer Research, 2009, 15, 7330-7334.	3.2	117
1115	Human NK Cell Up-regulation of CD69, HLA-DR, Interferon Î ³ Secretion and Cytotoxic Activity by Plasmacytoid Dendritic Cells is Regulated through Overlapping but Different Pathways. Sensors, 2009, 9, 386-403.	2.1	21
1116	Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. International Immunology, 2009, 21, 257-268.	1.8	25
1117	Enhanced In Vivo Growth of Lymphoma Tumors in the Absence of the NK-Activating Receptor NKp46/NCR1. Journal of Immunology, 2009, 182, 2221-2230.	0.4	134
1118	The Lytic Potential of Human Liver NK Cells Is Restricted by Their Limited Expression of Inhibitory Killer Ig-Like Receptors. Journal of Immunology, 2009, 183, 1789-1796.	0.4	55
1119	Immunologic hurdles of therapeutic stem cell transplantation. Biological Chemistry, 2009, 390, 977-983.	1,2	8
1120	Antigen Specificity Is not Required for Modulation of Lung Allergic Responses by Naturally Occurring Regulatory T Cells. Journal of Immunology, 2009, 183, 1821-1827.	0.4	19
1121	Immune escape mechanisms of intraocular tumors. Progress in Retinal and Eye Research, 2009, 28, 329-347.	7.3	91
1122	Expression of NK cell receptors on decidual T cells in human pregnancy. Journal of Reproductive Immunology, 2009, 80, 22-32.	0.8	67
1123	Fetal–maternal HLA-C mismatch is associated with decidual T cell activation and induction of functional T regulatory cells. Journal of Reproductive Immunology, 2009, 82, 148-157.	0.8	226
1124	Comprehensive analysis of NK cell function in whole blood samples. Journal of Immunological Methods, 2009, 341, 154-164.	0.6	47
1125	Regulatory Allospecific NK Cell Function Is Differentially Associated with HLA C Allotypes. American Journal of Transplantation, 2009, 9, 2624-2630.	2.6	7
1126	The developmental role of natural killer cells at the fetal-maternal interface. American Journal of Obstetrics and Gynecology, 2009, 201, 344-350.	0.7	61

#	Article	IF	Citations
1127	Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference. Clinical Immunology, 2009, 133, 171-178.	1.4	76
1128	Natural killer cellâ€mediated lysis of freshly isolated human tumor cells. International Journal of Cancer, 2009, 124, 757-762.	2.3	35
1129	Overâ€expression of câ€ <i>myc</i> increases the sensitivity of epsteinâ€barr virus immortalized lymphoblastoid cells to nonâ€MHCâ€restricted cytotoxicity. International Journal of Cancer, 1993, 53, 1008-1012.	2.3	4
1130	Natural killer cells remember: An evolutionary bridge between innate and adaptive immunity?. European Journal of Immunology, 2009, 39, 2059-2064.	1.6	130
1131	Natural killer cells play divergent roles in shaping the outcome of hepatitis C virus recurrence following liver transplantation. Liver Transplantation, 2009, 15, 357-359.	1.3	4
1132	Lineage-specific diversification of killer cell Ig-like receptors in the owl monkey, a New World primate. Immunogenetics, 2009, 61, 27-41.	1.2	26
1133	Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunology, Immunotherapy, 2009, 58, 855-865.	2.0	46
1134	Transplantation and innate immunity: the lesson of natural killer cells. Italian Journal of Pediatrics, 2009, 35, 44.	1.0	7
1135	The Role of Natural Killer Cells in Resistance to the Intracellular Bacterium <i>Listeria monocytogenes</i> in Rats. Scandinavian Journal of Immunology, 2009, 70, 238-244.	1.3	27
1136	The allogeneic graftâ€ <i>versus</i> â€cancer effect. British Journal of Haematology, 2009, 147, 614-633.	1.2	132
1137	Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias. Clinical and Experimental Immunology, 2009, 157, 325-331.	1,1	66
1138	Natural killer cellâ€based immunotherapy in cancer: current insights and future prospects. Journal of Internal Medicine, 2009, 266, 154-181.	2.7	180
1139	Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones. Bone Marrow Transplantation, 2009, 43, 875-881.	1.3	25
1140	Mechanisms and functions for the duration of intercellular contacts made by lymphocytes. Nature Reviews Immunology, 2009, 9, 543-555.	10.6	87
1141	Natural killer cells – new understanding of basic biology may lead to more effective allogeneic haematopoietic stem cell transplantation. Internal Medicine Journal, 2009, 39, 639-647.	0.5	6
1142	Role of NK and NKT cells in solid organ transplantation. Transplant International, 2009, 22, 859-868.	0.8	44
1143	A case of myelodysplastic syndrome associated with CD14+CD56+ monocytosis, expansion of NK lymphocytes and defect of HLA-E expression. Leukemia Research, 2009, 33, 181-185.	0.4	10
1144	Natural killer cells in human autoimmunity. Current Opinion in Immunology, 2009, 21, 634-640.	2.4	94

#	Article	IF	CITATIONS
1145	A Role for cis Interaction between the Inhibitory Ly49A Receptor and MHC Class I for Natural Killer Cell Education. Immunity, 2009, 30, 337-347.	6.6	111
1146	Activation of natural killer cells by heat shock protein 70. International Journal of Hyperthermia, 2009, 25, 169-175.	1.1	86
1147	Molecular pathogenesis and early detection of hepatocellular carcinoma – Perspectives from West Africa. Cancer Letters, 2009, 286, 44-51.	3.2	8
1148	The Effect of Single and Combined Activating Killer Immunoglobulin-like Receptor Genotypes on Cytomegalovirus Infection and Immunity after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 315-325.	2.0	82
1149	Natural Killer Cells in Allogeneic Transplantation: Effect on Engraftment, Graft-versus-Tumor, and Graft-versus-Host Responses. Biology of Blood and Marrow Transplantation, 2009, 15, 765-776.	2.0	90
1150	Bovine natural killer cells. Veterinary Immunology and Immunopathology, 2009, 130, 163-177.	0.5	50
1151	NK cell education: not an on-off switch but a tunable rheostat. Trends in Immunology, 2009, 30, 143-149.	2.9	218
1152	Progesterone-mediated immunomodulation in pregnancy: its relevance to leukocyte immunotherapy of recurrent miscarriage. Immunotherapy, 2009, $1,873-882$.	1.0	40
1153	MHC Class I Function at the Neuronal Synapse. , 2009, , 301-319.		1
1154	Immunotherapy in Non–Small-Cell Lung Carcinoma: From Inflammation to Vaccination. Clinical Lung Cancer, 2009, 10, 99-105.	1.1	15
1155	Molecular Mechanisms of Spondyloarthropathies. Advances in Experimental Medicine and Biology, 2009, , .	0.8	3
1156	Immunology of Normal Pregnancy and Preeclampsia. , 2009, , 129-142.		10
1157	Chapter 2 Natural Killer Cell Tolerance. Advances in Immunology, 2009, 101, 27-79.	1.1	120
1158	Immunobiology of Human Cytomegalovirus: from Bench to Bedside. Clinical Microbiology Reviews, 2009, 22, 76-98.	5.7	535
1159	Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood, 2009, 113, 3119-3129.	0.6	343
1160	Role of NKT cells in anterior chamber-associated immune deviation. Expert Review of Clinical Immunology, 2009, 5, 137-144.	1.3	16
1161	Natural killer cells: integrating diversity with function. Immunology, 2009, 126, 449-457.	2.0	107
1162	Human Natural Killer Receptors, Coâ€Receptors, and Their Ligands. Current Protocols in Immunology, 2009, 84, Unit 14.10.	3.6	49

#	Article	IF	CITATIONS
1163	HLA-C Matching and Liver Transplants: Donor-Recipient Genotypes Influence Early Outcome and CD8+KIR2D+ T-Cells Recuperation. Transplantation, 2009, 88, S54-S61.	0.5	21
1164	Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell–depleted allogeneic hematopoietic cell transplantation. Blood, 2009, 113, 3875-3884.	0.6	115
1165	The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood, 2009, 113, 2434-2441.	0.6	218
1166	Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood, 2009, 113, 726-732.	0.6	408
1167	NK cell–mediated killing of target cells triggers robust antigen-specific T cell–mediated and humoral responses. Blood, 2009, 113, 6593-6602.	0.6	123
1168	"Self―reflection by KIR. Blood, 2009, 114, 2-3.	0.6	9
1169	NK antibody therapy: KIR-ative intent. Blood, 2009, 114, 2567-2568.	0.6	4
1170	NK Cell Receptors and Their Interactions with MHC. Current Pharmaceutical Design, 2009, 15, 3301-3310.	0.9	20
1171	Targeting the Immune System in Cancer. Current Pharmaceutical Biotechnology, 2009, 10, 166-184.	0.9	62
1172	Natural killer cells and tumor control. Current Opinion in Hematology, 2010, 17, 514-521.	1.2	10
1173	Imaging Adoptive Cell Transfer Based Cancer Immunotherapy. Current Pharmaceutical Biotechnology, 2010, 11, 672-684.	0.9	5
1174	Structure and function of major histocompatibility complex class I antigens. Current Opinion in Organ Transplantation, 2010, 15, 499-504.	0.8	27
1175	Combined Treatment With Dendritic Cells and 5-fluorouracil Elicits Augmented NK Cell-mediated Antitumor Activity Through the Tumor Necrosis Factor-α Pathway. Journal of Immunotherapy, 2010, 33, 467-474.	1.2	16
1176	Differential Effect of Pretransplant Blood Transfusions on Immune Effector and Regulatory Compartments in HLA-Sensitized and Nonsensitized Recipients. Transplantation, 2010, 90, 1192-1199.	0.5	18
1177	NK cells expressing inhibitory KIR for non–self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood, 2010, 115, 2686-2694.	0.6	79
1178	Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood, 2010, 115, 1166-1174.	0.6	256
1179	Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood, 2010, 116, 2411-2419.	0.6	541
1180	The requirement for NKG2D in NK cell–mediated rejection of parental bone marrow grafts is determined by MHC class I expressed by the graft recipient. Blood, 2010, 116, 5208-5216.	0.6	23

#	Article	IF	CITATIONS
1181	Differential effects of interleukin-12 and interleukin-15 on expansion of NK cell receptor-expressing CD8+ T cells. Annals of Hematology, 2010, 89, 115-120.	0.8	7
1183	Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells. Medical Microbiology and Immunology, 2010, 199, 93-101.	2.6	22
1184	NK Cells, Autoantibodies, and Immunologic Infertility: A Complex Interplay. Clinical Reviews in Allergy and Immunology, 2010, 39, 166-175.	2.9	31
1185	Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B. Clinical Immunology, 2010, 137, 139-146.	1.4	35
1186	B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Experimental Hematology, 2010, 38, 213-221.	0.2	35
1187	Tolerant and diverse natural killer cell repertoires in the absence of selection. Experimental Cell Research, 2010, 316, 1309-1315.	1.2	12
1188	Killer cell immunoglobulinâ€like receptor gene diversity in a Caucasian population of Southern Brazil. International Journal of Immunogenetics, 2010, 37, 83-89.	0.8	15
1189	Compound <i>KIR</i> à€ <i>HLA</i> genotype analyses in the Iranian population by a novel PCR–SSP assay. International Journal of Immunogenetics, 2010, 37, 159-168.	0.8	46
1190	"Hard―and "soft―lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. International Journal of Cancer, 2010, 127, 249-256.	2.3	232
1191	<i>In vivo</i> tumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of ILâ€2. European Journal of Immunology, 2010, 40, 813-823.	1.6	33
1192	Discrepant effects of Chlamydia trachomatis infection on MICA expression of HeLa and U373 cells. Infection, Genetics and Evolution, 2010, 10, 740-745.	1.0	4
1193	The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes and Infection, 2010, 12, 910-918.	1.0	59
1194	Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders. Liver International, 2010, 30, 567-573.	1.9	24
1195	LLT1â€mediated Activation of IFNâ€Î³ Production in Human Natural Killer Cells Involves ERK Signalling Pathway. Scandinavian Journal of Immunology, 2010, 71, 210-219.	1.3	32
1196	The extensive polymorphism of KIR genes. Immunology, 2010, 129, 8-19.	2.0	244
1197	Allergic women show reduced T helper type 1 alloresponses to fetal human leucocyte antigen mismatch during pregnancy. Clinical and Experimental Immunology, 2009, 159, 65-72.	1.1	20
1198	Killer cell immunoglobulin-like receptor (KIR) genes in systemic sclerosis. Clinical and Experimental Immunology, 2010, 160, 325-330.	1.1	19
1199	Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. Leukemia, 2010, 24, 1059-1062.	3.3	6

#	Article	IF	CITATIONS
1200	Granzymes and perforin in solid organ transplant rejection. Cell Death and Differentiation, 2010, 17, 567-576.	5.0	78
1201	In vitro and in vivo delivery of novel anticancer fusion protein MULT1E/FasTI via adenoviral vectors. Cancer Gene Therapy, 2010, 17, 164-170.	2.2	6
1202	Effect of NKG2D ligand expression on host immune responses. Immunological Reviews, 2010, 235, 267-285.	2.8	431
1203	Listeria monocytogenes Infection Affects a Subset of Ly49-Expressing NK Cells in the Rat. PLoS ONE, 2010, 5, e15579.	1.1	4
1204	The role of natural killer cells in cancer therapy. Frontiers in Bioscience - Elite, 2010, E2, 380-391.	0.9	11
1205	The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. Journal of Experimental Medicine, 2010, 207, 207-221.	4.2	89
1206	The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects. Journal of Experimental Medicine, 2010, 207, 671-671.	4.2	25
1207	Natural Killer Cell Protocols. Methods in Molecular Biology, 2010, , .	0.4	4
1208	Natural killer cells in cancer. , 2010, , 55-64.		0
1209	Combined Genotypic and Phenotypic Killer Cell Ig-Like Receptor Analyses Reveal KIR2DL3 Alleles Displaying Unexpected Monoclonal Antibody Reactivity: Identification of the Amino Acid Residues Critical for Staining. Journal of Immunology, 2010, 185, 433-441.	0.4	32
1210	Inhibition of Human Natural Killer Cell Activity by Influenza Virions and Hemagglutinin. Journal of Virology, 2010, 84, 4148-4157.	1.5	83
1211	Partial NK cell tolerance induced by radioresistant host cells in rats transplanted with MHC-mismatched bone marrow. International Immunology, 2010, 22, 973-980.	1.8	4
1212	Intracellular Sequestration of the NKG2D Ligand ULBP3 by Human Cytomegalovirus. Journal of Immunology, 2010, 185, 1093-1102.	0.4	61
1213	Two complementary rat NK cell subsets, Ly49s3+ and NKR-P1B+, differ in phenotypic characteristics and responsiveness to cytokines. Journal of Leukocyte Biology, 2010, 88, 87-93.	1.5	30
1214	NK Cell Patrolling and Elimination of Donor-Derived Dendritic Cells Favor Indirect Alloreactivity. Journal of Immunology, 2010, 184, 2329-2336.	0.4	68
1215	Effect of Ly49 Haplotype Variance on NK Cell Function and Education. Journal of Immunology, 2010, 185, 4783-4792.	0.4	31
1217	NK cells and NKT cells in cutaneous disorders. , 2010, , 311-320.		1
1218	Nature killer cells in the central nervous system. , 2010, , 373-383.		8

#	Article	IF	CITATIONS
1219	NK cells in the eye. , 2010, , 385-401.		6
1220	Clinical trials of NK cells for cancer. , 2010, , 555-570.		2
1221	Natural killer cell induction of tolerance. , 2010, , 617-631.		2
1222	Xenografted Human Amniotic Membrane–Derived Mesenchymal Stem Cells Are Immunologically Tolerated and Transdifferentiated Into Cardiomyocytes. Circulation Research, 2010, 106, 1613-1623.	2.0	190
1224	Tumour infiltrating host cells and their significance for hyperthermia. International Journal of Hyperthermia, 2010, 26, 247-255.	1.1	25
1225	Effects of MHC Class I Alleles on Licensing of Ly49A+ NK Cells. Journal of Immunology, 2010, 184, 3424-3432.	0.4	57
1226	Surgery as a Double-Edged Sword: A Clinically Feasible Approach to Overcome the Metastasis-Promoting Effects of Surgery by Blunting Stress and Prostaglandin Responses. Cancers, 2010, 2, 1929-1951.	1.7	29
1227	Structure of the HCMV UL16-MICB Complex Elucidates Select Binding of a Viral Immunoevasin to Diverse NKG2D Ligands. PLoS Pathogens, 2010, 6, e1000723.	2.1	52
1228	The impact of KIR2DS4 alleles and the expression of KIR in the development of acute GVHD after unrelated allogeneic hematopoietic SCT. Bone Marrow Transplantation, 2010, 45, 1435-1441.	1.3	29
1229	Reconstitution of repertoire of natural killer cell receptors after transplantation: just a question of time?. Bone Marrow Transplantation, 2010, 45, 968-969.	1.3	1
1230	Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. Immunotherapy, 2010, 2, 399-418.	1.0	36
1231	Comparative analysis of NK-cell receptor expression and function across primate species: Perspective on antiviral defenses. Self/nonself, 2010, 1, 103-113.	2.0	7
1232	Cancer Immunotherapy: WillÂExpanding Knowledge Lead to Success in Pediatric Oncology?. Hematology/Oncology Clinics of North America, 2010, 24, 109-127.	0.9	2
1233	Immunotherapy in the Context of Hematopoietic Stem Cell Transplantation: The Emerging Role of Natural Killer Cells and Mesenchymal Stromal Cells. Pediatric Clinics of North America, 2010, 57, 97-121.	0.9	7
1234	Natural Killer Cells: Deciphering Their Role, Diversity and Functions., 2010, , 1-38.		0
1235	Diversity of KIR Genes, Alleles and Haplotypes. , 2010, , 63-91.		2
1236	Natural Killer Cells and Their Role in Hematopoietic Stem Cell Transplantation. , 2010, , 199-219.		0
1237	NK Cells, NKT Cells, and KIR in Solid Organ Transplantation. , 2010, , 221-239.		0

#	ARTICLE	IF	CITATIONS
1238	NK Cells in Autoimmune and Inflammatory Diseases. , 2010, , 241-254.		0
1239	The Role of KIR in Disease. , 2010, , 275-298.		1
1240	Clinical Applications of Adoptive Natural Killer Cell Immunotherapy for Cancer: Current Status and Future Prospects. Onkologie, 2010, 33, 7-7.	1.1	8
1241	Immune Privilege of Corneal Allografts. Ocular Immunology and Inflammation, 2010, 18, 162-171.	1.0	94
1242	Re-educating natural killer cells. Journal of Experimental Medicine, 2010, 207, 2049-2052.	4.2	30
1243	Cellular Immunotherapy of Cancer. Methods in Molecular Biology, 2010, 651, 319-345.	0.4	9
1244	Extending killer Ig-like receptor function: from HLA class I recognition to sensors of microbial products. Trends in Immunology, 2010, 31, 289-294.	2.9	24
1245	CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends in Immunology, 2010, 31, 401-406.	2.9	220
1246	Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?. Best Practice and Research in Clinical Haematology, 2010, 23, 283-290.	0.7	22
1247	Donor KIR Genes 2DL5A, 2DS1 and 3DS1 Are Associated with a Reduced Rate of Leukemia Relapse After HLA-Identical Sibling Stem Cell Transplantation for Acute Myeloid Leukemia but Not Other Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2010, 16, 1257-1264.	2.0	85
1248	Canine CD8 T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules. Veterinary Immunology and Immunopathology, 2010, 133, 144-153.	0.5	28
1249	Interferon-α–Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. Gastroenterology, 2010, 138, 1885-1897.e10.	0.6	177
1250	Role of Chemokines in the Biology of Natural Killer Cells. Current Topics in Microbiology and Immunology, 2010, 341, 37-58.	0.7	179
1252	RNA Therapeutics. Methods in Molecular Biology, 2010, 629, v-vii.	0.4	5
1253	Immunotherapy of Cancer. Methods in Molecular Biology, 2010, , .	0.4	1
1255	Induction of NKG2D Ligands and Increased Sensitivity of Tumor Cells to NK Cell-mediated Cytotoxicity by Hematoporphyrin-based Photodynamic Therapy. Immunological Investigations, 2011, 40, 367-382.	1.0	22
1256	NK Cell Recognition and Killing of Melanoma Cells Is Controlled by Multiple Activating Receptor-Ligand Interactions. Journal of Innate Immunity, 2011, 3, 365-373.	1.8	50
1257	Stimulating natural killer cells to protect against cancer: recent developments. Expert Review of Clinical Immunology, 2011, 7, 367-382.	1.3	23

#	Article	IF	CITATIONS
1259	Self MHC class I–licensed NK cells enhance adaptive CD8 T-cell viral immunity. Blood, 2011, 117, 5133-5141.	0.6	33
1260	KIR/HLA: Genetic Clues for a Role of NK Cells in the Control of HIV. Advances in Experimental Medicine and Biology, 2011, 780, 27-36.	0.8	10
1261	Strategies to optimize the outcome of children given T-cell depleted HLA-haploidentical hematopoietic stem cell transplantation. Best Practice and Research in Clinical Haematology, 2011, 24, 339-349.	0.7	17
1262	ER stress impairs MHC Class I surface expression and increases susceptibility of thyroid cells to NK-mediated cytotoxicity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 431-438.	1.8	35
1263	Unifying concepts of MHC-dependent natural killer cell education. Trends in Immunology, 2011, 32, 364-372.	2.9	241
1264	Assessment of physiologic natural killer cell cytotoxicity in vitro. Human Immunology, 2011, 72, 1007-1012.	1.2	12
1265	Donor liver natural killer cells alleviate liver allograft acute rejection in rats. Hepatobiliary and Pancreatic Diseases International, 2011, 10, 386-392.	0.6	10
1266	Immune recognition and rejection of allogeneic skin grafts. Immunotherapy, 2011, 3, 757-770.	1.0	125
1267	Exploitation of Herpesvirus Immune Evasion Strategies to Modify the Immunogenicity of Human Mesenchymal Stem Cell Transplants. PLoS ONE, 2011, 6, e14493.	1.1	28
1269	Human diversity of killer cell immunoglobulin-like receptors and disease. The Korean Journal of Hematology, 2011, 46, 216.	0.7	72
1270	Current Perspectives on Immunomodulation of NK Cells in Melanoma. , 0, , .		1
1272	StrataGraft Skin Substitute Is Well-tolerated and Is Not Acutely Immunogenic in Patients With Traumatic Wounds. Annals of Surgery, 2011, 253, 672-683.	2.1	80
1273	EGFR Inhibitors Enhanced the Susceptibility to NK Cell-mediated Lysis of Lung Cancer Cells. Journal of Immunotherapy, 2011, 34, 372-381.	1.2	50
1274	Novel transplant strategies for generating graft-versus-leukemia effect in acute myeloid leukemia. Current Opinion in Hematology, 2011, 18, 98-104.	1,2	14
1275	Natural killer cells in rejection and tolerance of solid organ allografts. Current Opinion in Organ Transplantation, 2011, 16, 47-53.	0.8	81
1276	Analyses of HLA-C–specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood, 2011, 117, 98-107.	0.6	101
1277	Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood, 2011, 118, 3254-3262.	0.6	141
1278	Natural killer cell subsets in man and rodents. Tissue Antigens, 2011, 78, 81-88.	1.0	56

#	Article	IF	CITATIONS
1279	<i>Ex vivo</i> Expansion of CD56 ⁺ NK and NKTâ€like Lymphocytes from Peripheral Blood Mononuclear Cells of Patients with Ovarian Neoplasia. Scandinavian Journal of Immunology, 2011, 74, 244-252.	1.3	11
1280	Activated NK cells have a potential therapeutic role in sustaining donor engraftment following paediatric haematopoietic stem cell transplantation for nonâ€malignant disease. British Journal of Haematology, 2011, 154, 527-529.	1.2	O
1281	Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology, 2011, 132, 315-325.	2.0	234
1282	Immunogenetics as a tool in anthropological studies. Immunology, 2011, 133, 143-164.	2.0	87
1283	NK cell development, homeostasis and function: parallels with CD8+ T cells. Nature Reviews Immunology, 2011, 11, 645-657.	10.6	557
1284	Activating and inhibitory receptors of natural killer cells. Immunology and Cell Biology, 2011, 89, 216-224.	1.0	426
1285	KIR-HLA Mismatching in Human Renal Allograft Transplantation: Emergence of a New Concept. American Journal of Transplantation, 2011, 11, 1771-1772.	2.6	8
1286	Immunogenetics of ageing. International Journal of Immunogenetics, 2011, 38, 373-381.	0.8	24
1287	Recent advances in understanding immunology of reproductive failure. Journal of Reproductive Immunology, 2011, 90, 96-104.	0.8	60
1288	Increased sensitivity of cholera toxin B treated K562 cells to natural killer cells. Cellular Immunology, 2011, 269, 1-4.	1.4	2
1289	Mechanisms of Tumor and Viral Immune Escape from Natural Killer Cell-Mediated Surveillance. Journal of Innate Immunity, 2011, 3, 344-354.	1.8	64
1290	Expansion of CD56-Negative, CD16-Positive, KIR-Expressing Natural Killer Cells after T Cell-Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Acta Haematologica, 2011, 126, 13-20.	0.7	20
1291	NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions. Blood, 2011, 118, 2784-2792.	0.6	117
1292	Uterine natural killer (uNK) cells and their missions during pregnancy: A review. Acta Histochemica, 2011, 113, 82-91.	0.9	40
1293	Structural analysis of natural killer cell receptor protein 1 (NKR-P1) extracellular domains suggests a conserved long loop region involved in ligand specificity. Journal of Molecular Modeling, 2011, 17, 1353-1370.	0.8	22
1294	The role of the Major Histocompatibility Complex in the spread of contagious cancers. Mammalian Genome, 2011, 22, 83-90.	1.0	47
1295	An increased frequency of NK cell receptor and HLA-C group 1 combinations in early-onset type 1 diabetes. Diabetologia, 2011, 54, 3062-3070.	2.9	26
1296	Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunology, Immunotherapy, 2011, 60, 1195-1205.	2.0	118

#	Article	IF	CITATIONS
1297	How to cross immunogenetic hurdles to human embryonic stem cell transplantation. Seminars in Immunopathology, 2011, 33, 525-534.	2.8	10
1298	NK Cells Prevalence, Subsets and Function in Viral Hepatitis C. Archivum Immunologiae Et Therapiae Experimentalis, 2011, 59, 449-455.	1.0	21
1299	Mechanisms of NK cell activation: CD4+ T cells enter the scene. Cellular and Molecular Life Sciences, 2011, 68, 3457-3467.	2.4	33
1300	Cis–trans interactions of cell surface receptors: biological roles and structural basis. Cellular and Molecular Life Sciences, 2011, 68, 3469-3478.	2.4	40
1301	The role of Natural Killer cells in the pathogenesis of rheumatoid arthritis: Major contributors or essential homeostatic modulators?. Immunology Letters, 2011, 136, 115-121.	1.1	48
1302	Novel Role for STAT3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells. Cancer Research, 2011, 71, 1615-1626.	0.4	93
1303	CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Review of Vaccines, 2011, 10, 733-742.	2.0	36
1304	Unexpected Role for Granzyme K in CD56bright NK Cell-Mediated Immunoregulation of Multiple Sclerosis. Journal of Immunology, 2011, 187, 781-790.	0.4	138
1305	How the Virus Outsmarts the Host: Function and Structure of Cytomegalovirus MHC-l-Like Molecules in the Evasion of Natural Killer Cell Surveillance. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-12.	3.0	33
1306	The rat NK cell receptors Ly49s4 and Ly49i4 recognize nonclassical MHC-I molecules on <i>Listeria monocytogenes </i> -infected macrophages. Journal of Leukocyte Biology, 2011, 89, 617-623.	1.5	5
1307	Variable NK Cell Receptors Exemplified by Human KIR3DL1/S1. Journal of Immunology, 2011, 187, 11-19.	0.4	61
1308	A Human NK Cell Activation/Inhibition Threshold Allows Small Changes in the Target Cell Surface Phenotype To Dramatically Alter Susceptibility to NK Cells. Journal of Immunology, 2011, 186, 1538-1545.	0.4	49
1309	Ly49-Dependent NK Cell Licensing and Effector Inhibition Involve the Same Interaction Site on MHC Ligands. Journal of Immunology, 2011, 186, 3911-3917.	0.4	16
1310	Natural Killer Cells: Biology, Physiology and Medicine – Part 1. Journal of Innate Immunity, 2011, 3, 213-215.	1.8	7
1311	Natural Killer Cells: Biology, Physiology and Medicine – Part 2. Journal of Innate Immunity, 2011, 3, 327-328.	1.8	5
1312	Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells. Journal of Immunology, 2011, 187, 3546-3554.	0.4	40
1313	Simulations of the NK Cell Immune Synapse Reveal that Activation Thresholds Can Be Established by Inhibitory Receptors Acting Locally. Journal of Immunology, 2011, 187, 760-773.	0.4	16
1314	KIR/HLA Interactions and Pathogen Immunity. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-9.	3.0	82

#	Article	IF	CITATIONS
1315	Natural Killer Cells in Healthy and Diseased Subjects. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-4.	3.0	0
1316	Novel Microchip-Based Tools Facilitating Live Cell Imaging and Assessment of Functional Heterogeneity within NK Cell Populations. Frontiers in Immunology, 2012, 3, 300.	2.2	30
1317	Mechanisms of NK Cell-Macrophage Bacillus anthracis Crosstalk: A Balance between Stimulation by Spores and Differential Disruption by Toxins. PLoS Pathogens, 2012, 8, e1002481.	2.1	36
1318	Illuminating the dynamics of signal integration in Natural Killer cells. Frontiers in Immunology, 2012, 3, 308.	2.2	5
1319	Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Frontiers in Immunology, 2012, 3, 336.	2.2	94
1320	Viral MHC class I inhibition evades CD8 ⁺ T-cell effector responses in vivo but not CD8 ⁺ T-cell priming. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3260-7.	3.3	35
1321	Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 800-811.	1.8	171
1322	Innate Immune Control of HIV. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007070-a007070.	2.9	62
1323	The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells. Current Medicinal Chemistry, 2012, 19, 1780-1791.	1.2	28
1324	The Interaction of NK Cells and Dendritic Cells in the Tumor Environment: How to Enforce NK Cell & Lorent Medicinal Chemistry, 2012, 19, 1771-1779.	1.2	36
1325	An ENU mutagenesis approach to dissect "self―induced immune responses. Oncolmmunology, 2012, 1, 856-862.	2.1	7
1326	CEACAM1 in Malignant Melanoma: A Diagnostic and Therapeutic Target. Current Topics in Medicinal Chemistry, 2012, 12, 3-10.	1.0	20
1327	Control of Acute Myeloid Leukemia Relapse â€" Dance between KIRs and HLA. New England Journal of Medicine, 2012, 367, 866-868.	13.9	8
1328	CD99 ligation upregulates HSP70 on acute lymphoblastic leukemia cells and concomitantly increases NK cytotoxicity. Cell Death and Disease, 2012, 3, e425-e425.	2.7	17
1329	Poxvirus Infection-Associated Downregulation of C-Type Lectin-Related-b Prevents NK Cell Inhibition by NK Receptor Protein-1B. Journal of Immunology, 2012, 188, 4980-4991.	0.4	30
1330	Skewing of the NK Cell Repertoire by MHC Class I via Quantitatively Controlled Enrichment and Contraction of Specific Ly49 Subsets. Journal of Immunology, 2012, 188, 2218-2226.	0.4	48
1331	Ocular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism?. Frontiers in Immunology, 2012, 3, 148.	2.2	55
1332	Biological role of NK cells and immunotherapeutic approaches in breast cancer. Frontiers in Immunology, 2012, 3, 375.	2.2	38

#	Article	IF	Citations
1333	Innate Immunity and Resistance to Tolerogenesis in Allotransplantation. Frontiers in Immunology, 2012, 3, 73.	2.2	28
1334	Dual Role of Heat Shock Proteins (HSPs) in Anti-Tumor Immunity. Current Molecular Medicine, 2012, 12, 1174-1182.	0.6	36
1335	Cancer Immunoediting in Malignant Glioma. Neurosurgery, 2012, 71, 201-223.	0.6	79
1336	Molecular Recognition of Paired Receptors in the Immune System. Frontiers in Microbiology, 2012, 3, 429.	1.5	49
1338	Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood, 2012, 119, 2665-2674.	0.6	581
1339	Human Cytomegalovirus (CMV)-Induced Memory-like NKG2C+ NK Cells Are Transplantable and Expand In Vivo in Response to Recipient CMV Antigen. Journal of Immunology, 2012, 189, 5082-5088.	0.4	331
1340	The impact of HLA-C matching depends on the C1/C2 KIR ligand status in unrelated hematopoietic stem cell transplantation. Immunogenetics, 2012 , 64 , $879-885$.	1.2	17
1341	Structural and functional conservation of CLEC-2 with the species-specific regulation of transcript expression in evolution. Glycoconjugate Journal, 2012, 29, 335-345.	1.4	6
1342	NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy, 2012, 4, 305-313.	1.0	23
1343	Why must T cells be cross-reactive?. Nature Reviews Immunology, 2012, 12, 669-677.	10.6	397
1344	Structural insights into activation of antiviral <scp>NK</scp> cell responses. Immunological Reviews, 2012, 250, 239-257.	2.8	30
1345	Immune regulation in idiopathic bronchiectasis. Annals of the New York Academy of Sciences, 2012, 1272, 68-72.	1.8	8
1346	Clinical Production and Therapeutic Applications of Alloreactive Natural Killer Cells. Methods in Molecular Biology, 2012, 882, 491-507.	0.4	11
1347	Overview of the Killer Cell Immunoglobulin-Like Receptor System. Methods in Molecular Biology, 2012, 882, 391-414.	0.4	53
1348	The immunosuppressive molecule HLA-G and its clinical implications. Critical Reviews in Clinical Laboratory Sciences, 2012, 49, 63-84.	2.7	157
1349	Old and new facts about hyperthermia-induced modulations of the immune system. International Journal of Hyperthermia, 2012, 28, 528-542.	1.1	206
1350	Immunogenetics. Methods in Molecular Biology, 2012, , .	0.4	7
1351	Radiation-Induced Stress Proteins - the Role of Heat Shock Proteins (HSP) in Anti-Tumor Responses. Current Medicinal Chemistry, 2012, 19, 1765-1770.	1.2	50

#	Article	IF	CITATIONS
1352	Genetic regulation on <i>ex vivo</i> blood CD34 ⁺ cells. Journal of Receptor and Signal Transduction Research, 2012, 32, 238-249.	1.3	6
1353	Cytotoxicity of CD56bright NK Cells towards Autologous Activated CD4+ T Cells Is Mediated through NKG2D, LFA-1 and TRAIL and Dampened via CD94/NKG2A. PLoS ONE, 2012, 7, e31959.	1.1	151
1354	NK cell receptors: evolution and diversity. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2012, , .	0.1	1
1355	Genetics of Microscopic Polyangiitis in the Japanese Population. Annals of Vascular Diseases, 2012, 5, 289-295.	0.2	3
1356	Host-Pathogen Co-Evolution: Chlamydia trachomatis Modulates Surface Ligand Expression in Genital Epithelial Cells to Evade Immune Recognition. , 2012, , .		0
1357	Killer Immunoglobulin-Like Receptors and Their Ligands. , 2012, , .		1
1358	Licensed to Kill: Towards Natural Killer Cell Immunotherapy. , 0, , .		0
1359	Stress-Induced Molecules in Regulation of NK Cell Activity. , 0, , .		1
1360	Microfluidic Devices Modulate Tumor Cell Line Susceptibility to NK Cell Recognition. Small, 2012, 8, 2886-2894.	5.2	29
1361	Virus-mediated inhibition of natural cytotoxicity receptor recognition. Cellular and Molecular Life Sciences, 2012, 69, 3911-3920.	2.4	45
1362	The role of natural killer cells in hematopoietic stem cell transplantation. Annals of Medicine, 2012, 44, 130-145.	1.5	13
1363	Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. Journal of Gene Medicine, 2012, 14, 428-439.	1.4	89
1365	Targeting natural killer cells and natural killer T cells in cancer. Nature Reviews Immunology, 2012, 12, 239-252.	10.6	707
1367	HLA class I expressions on peripheral blood mononuclear cells in colorectal cancer patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2012, 24, 77-82.	0.7	4
1368	Killer cell immunoglobulin-like receptor genes in patients with breast cancer. Medical Oncology, 2012, 29, 511-515.	1.2	25
1369	Identification of a chicken CLEC-2 homologue, an activating C-type lectin expressed by thrombocytes. Immunogenetics, 2012, 64, 389-397.	1.2	27
1370	Killerâ€cell immunoglobulinâ€like receptors and malaria caused by <i>Plasmodium falciparum</i> in The Gambia. Tissue Antigens, 2012, 79, 104-113.	1.0	23
1371	Susceptibility to natural killer cellâ€mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16â€binding proteinâ€l induction. Cancer Science, 2012, 103, 7-16.	1.7	25

#	Article	IF	CITATIONS
1372	Review: Immunogenetics of human placentation. Placenta, 2012, 33, S71-S80.	0.7	41
1373	Influence of NK cell magnetic bead isolation methods on phenotype and function of murine NK cells. Journal of Immunological Methods, 2012, 378, 1-10.	0.6	21
1374	Human leukocyte antigen class I on peripheral blood mononuclear cells as a non-invasive biomarker for esophageal cancer. Ecological Management and Restoration, 2012, 25, 273-278.	0.2	3
1375	Autologous stem cell transplant recipients tolerate haploidentical relatedâ€donor natural killer cell–enriched infusions. Transfusion, 2013, 53, 412-418.	0.8	42
1376	The transfer of host MHC class I protein protects donor cells from NK cell and macrophage-mediated rejection during hematopoietic stem cell transplantation and engraftment in mice. Stem Cells, 2013, 31, 2242-2252.	1.4	17
1377	Evaluation of the association of NKG2C copy number variations with susceptibility to human papillomavirus-induced cervical lesions. Human Immunology, 2013, 74, 1352-1356.	1.2	5
1378	Immunologic Disorders. , 2013, , 1-16.		0
1379	Natural killer cell biology: An update and future directions. Journal of Allergy and Clinical Immunology, 2013, 132, 536-544.	1.5	321
1380	Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5103-5108.	3.3	191
1381	Natural killer cells in patients with allergic diseases. Journal of Allergy and Clinical Immunology, 2013, 132, 527-535.	1.5	72
1382	Immunity to viruses. Immunological Reviews, 2013, 255, 5-12.	2.8	86
1383	Natural killer cells: multifaceted players with key roles in hepatitis C immunity. Immunological Reviews, 2013, 255, 68-81.	2.8	65
1384	Therapeutic Efficacy of Human Embryonic Stem Cell–Derived Endothelial Cells in Humanized Mouse Models Harboring a Human Immune System. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2839-2849.	1.1	11
1385	Downregulation of the H-2Kd gene by siRNA affects the cytotoxicity of murine LAK cells. Cancer Cell International, 2013, 13, 112.	1.8	1
1386	Generation of porcine induced pluripotent stem cells and evaluation of their major histocompatibility complex protein expression in vitro. Veterinary Research Communications, 2013, 37, 293-301.	0.6	13
1387	Down-regulation of human leukocyte antigen class I (HLA-I) is associated with poor prognosis in patients with clear cell renal cell carcinoma. Acta Histochemica, 2013, 115, 470-474.	0.9	15
1388	Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA. International Journal of Hyperthermia, 2013, 29, 480-490.	1.1	24
1389	Natural killer cells in human autoimmune disorders. Arthritis Research and Therapy, 2013, 15, 216.	1.6	126

#	Article	IF	CITATIONS
1390	NK cells controlling virus-specific T cells: Rheostats for acute vs. persistent infections. Virology, 2013, 435, 37-45.	1.1	67
1391	How do pathogens drive the evolution of paired receptors?. European Journal of Immunology, 2013, 43, 303-313.	1.6	50
1393	DNA Aptamerâ€Mediated Cell Targeting. Angewandte Chemie - International Edition, 2013, 52, 1472-1476.	7.2	137
1394	Dynamics of Natural Killer Cell Receptor Revealed by Quantitative Analysis of Photoswitchable Protein. Biophysical Journal, 2013, 105, 1987-1996.	0.2	6
1395	Chicken NK cell receptors. Developmental and Comparative Immunology, 2013, 41, 324-333.	1.0	39
1396	Differential Expression of the Ly49GB6, but Not the Ly49GBALB, Receptor Isoform during Natural Killer Cell Reconstitution after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1446-1452.	2.0	3
1397	CMV induces rapid NK cell maturation in HSCT recipients. Immunology Letters, 2013, 155, 11-13.	1.1	22
1398	ATM-dependent spontaneous regression of early Eμ-myc–induced murine B-cell leukemia depends on natural killer and T cells. Blood, 2013, 121, 2512-2521.	0.6	56
1399	Corneal Transplantation and Immune Privilege. International Reviews of Immunology, 2013, 32, 57-67.	1.5	105
1400	<scp>CD</scp> 8+ÂEffector T Cells at the Fetal–Maternal Interface, Balancing Fetal Tolerance and Antiviral Immunity. American Journal of Reproductive Immunology, 2013, 69, 395-407.	1.2	125
1401	Regulation of Ligands for the NKG2D Activating Receptor. Annual Review of Immunology, 2013, 31, 413-441.	9.5	705
1402	Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cellular and Molecular Immunology, 2013, 10, 222-229.	4.8	139
1403	Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition. Annual Review of Immunology, 2013, 31, 227-258.	9.5	1,012
1404	NK cell-based immunotherapy for malignant diseases. Cellular and Molecular Immunology, 2013, 10, 230-252.	4.8	518
1405	Interaction of ES Cell Derived Neural Progenitor Cells with Natural Killer Cells and Cytotoxic T Cells. Methods in Molecular Biology, 2013, 1029, 65-75.	0.4	0
1406	Abundant stage-dependent Ly49E expression by liver NK cells is not essential for their differentiation and function. Journal of Leukocyte Biology, 2013, 93, 699-711.	1.5	18
1407	Tissueâ€specific effector functions of innate lymphoid cells. Immunology, 2013, 139, 416-427.	2.0	37
1408	The Tumor Immunoenvironment. , 2013, , .		4

#	Article	IF	CITATIONS
1409	MHC Class I Antigens In Malignant Cells., 2013,,.		3
1410	DAP12 impacts trafficking and surface stability of killer immunoglobulin-like receptors on natural killer cells. Journal of Leukocyte Biology, 2013, 94, 301-313.	1.5	13
1411	HLA Engineering of Human Pluripotent Stem Cells. Molecular Therapy, 2013, 21, 1232-1241.	3.7	208
1412	Targeting Natural Killer Cells to Acute Myeloid Leukemia $\langle i \rangle$ In Vitro $\langle j i \rangle$ with a CD16 \tilde{A} — 33 Bispecific Killer Cell Engager and ADAM17 Inhibition. Clinical Cancer Research, 2013, 19, 3844-3855.	3.2	208
1413	Natural killer cells and their receptors in multiple sclerosis. Brain, 2013, 136, 2657-2676.	3.7	68
1414	Memory NK cells: why do they reside in the liver?. Cellular and Molecular Immunology, 2013, 10, 196-201.	4.8	26
1415	<i>Ex Vivo</i> Generation of Highly Purified and Activated Natural Killer Cells from Human Peripheral Blood. Human Gene Therapy Methods, 2013, 24, 241-252.	2.1	8
1416	Superresolution Microscopy Reveals Nanometer-Scale Reorganization of Inhibitory Natural Killer Cell Receptors upon Activation of NKG2D. Science Signaling, 2013, 6, ra62.	1.6	69
1417	The role of KIR genes and ligands in leukemia surveillance. Frontiers in Immunology, 2013, 4, 27.	2.2	25
1418	The genetic predisposition of natural killer cell to BK virus–associated nephropathy in renal transplant patients. Kidney International, 2013, 84, 359-365.	2.6	39
1419	Virus Encoded MHC-Like Decoys Diversify the Inhibitory KIR Repertoire. PLoS Computational Biology, 2013, 9, e1003264.	1.5	20
1420	No monkey business: why studying NK cells in non-human primates pays off. Frontiers in Immunology, 2013, 4, 32.	2.2	47
1421	Natural Killer Cells Modulation in Hematological Malignancies. Frontiers in Immunology, 2013, 4, 459.	2.2	29
1422	Killer Cell Immunoglobulin-Like Receptor Gene Associations with Autoimmune and Allergic Diseases, Recurrent Spontaneous Abortion, and Neoplasms. Frontiers in Immunology, 2013, 4, 8.	2.2	51
1423	Tumor-Primed NK Cells: Waiting for the Green Light. Frontiers in Immunology, 2013, 4, 408.	2.2	46
1424	Quantified Colocalization Reveals Heterotypic Histocompatibility Class I Antigen Associations on Trophoblast Cell Membranes: Relevance for Human Pregnancy1. Biology of Reproduction, 2013, 89, 94.	1.2	13
1425	Education of Murine NK Cells Requires Both <i>cis</i> and <i>trans</i> Recognition of MHC Class I Molecules. Journal of Immunology, 2013, 191, 5044-5051.	0.4	39
1426	Feto-maternal interactions and immunological tolerance of the mother to her semiallogeneic fetus. Egyptian Journal of Histology, 2013, 36, 1-12.	0.0	0

#	Article	IF	CITATIONS
1427	At the Bench: Preclinical rationale for exploiting NK cells and $\hat{I}^{3}\hat{I}$ T lymphocytes for the treatment of high-risk leukemias. Journal of Leukocyte Biology, 2013, 94, 1123-1139.	1.5	43
1428	Natural killer cell licensing in mice with inducible expression of MHC class I. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4232-7.	3.3	36
1429	NK Cell Tolerance of Self-Specific Activating Receptor KIR2DS1 in Individuals with Cognate HLA-C2 Ligand. Journal of Immunology, 2013, 190, 4650-4660.	0.4	55
1430	Modulation of NK Cell Function by Genetically Coupled C-Type Lectin-Like Receptor/Ligand Pairs Encoded in the Human Natural Killer Gene Complex. Frontiers in Immunology, 2013, 4, 362.	2.2	79
1431	Influence of tumors on protective anti-tumor immunity and the effects of irradiation. Frontiers in Oncology, 2013, 3, 14.	1.3	7
1432	Genome-Wide siRNA Screen Reveals a New Cellular Partner of NK Cell Receptor KIR2DL4: Heparan Sulfate Directly Modulates KIR2DL4-Mediated Responses. Journal of Immunology, 2013, 191, 5256-5267.	0.4	46
1433	A database for curating the associations between killer cell immunoglobulin-like receptors and diseases in worldwide populations. Database: the Journal of Biological Databases and Curation, 2013, 2013, bat021.	1.4	27
1434	<scp>ITIM</scp> â€dependent negative signaling pathways for the control of cellâ€mediated xenogeneic immune responses. Xenotransplantation, 2013, 20, 397-406.	1.6	14
1435	Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. International Journal of Cancer, 2013, 133, 908-919.	2.3	20
1436	Delayed onset of graft- <i>versus</i> -host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells. Clinical and Experimental Immunology, 2013, 173, 355-364.	1.1	11
1437	Genetic and Environmental Determinants of Human NK Cell Diversity Revealed by Mass Cytometry. Science Translational Medicine, 2013, 5, 208ra145.	5.8	491
1438	KIR Gene Mismatching and KIR/C Ligands in Liver Transplantation. Transplantation, 2013, 95, 1037-1044.	0.5	34
1439	The Natural Killer Cell Response to HCV Infection. Immune Network, 2013, 13, 168.	1.6	18
1440	Natural Killer Cell Inhibitory Receptor Expression in Humans and Mice: A Closer Look. Frontiers in Immunology, 2013, 4, 65.	2.2	34
1441	Natural Cytotoxicity Receptors: Broader Expression Patterns and Functions in Innate and Adaptive Immune Cells. Frontiers in Immunology, 2013, 4, 69.	2.2	141
1442	Increased Numbers of NK Cells, NKT-Like Cells, and NK Inhibitory Receptors in Peripheral Blood of Patients with Chronic Obstructive Pulmonary Disease. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	33
1443	Immunogenetics of Hematopoietic Stem Cell Transplantation. , 0, , .		0
1444	Serendipity. Coincidence. Luck Critical Reviews in Oncogenesis, 2014, 19, 15-19.	0.2	0

#	Article	IF	CITATIONS
1445	Allograft Tolerance. , 2014, , 650-664.		0
1446	Contribution of the Ly49E Natural Killer Receptor in the Immune Response to Plasmodium berghei Infection and Control of Hepatic Parasite Development. PLoS ONE, 2014, 9, e87463.	1.1	4
1447	NK Cell Phenotypic Modulation in Lung Cancer Environment. PLoS ONE, 2014, 9, e109976.	1.1	69
1448	Mechanical Stress Downregulates MHC Class I Expression on Human Cancer Cell Membrane. PLoS ONE, 2014, 9, e111758.	1.1	6
1449	Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors. Frontiers in Immunology, 2014, 5, 87.	2.2	77
1450	Ultrasound-Induced Cell–Cell Interaction Studies in a Multi-Well Microplate. Micromachines, 2014, 5, 27-49.	1.4	28
1451	Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients. American Journal of Hematology, 2014, 89, E176-83.	2.0	25
1452	Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy, 2014, 6, 597-610.	1.0	63
1453	A Genetic Defect in Mice That Impairs Missing Self Recognition Despite Evidence for Normal Maturation and MHC Class l–Dependent Education of NK Cells. Journal of Immunology, 2014, 192, 1577-1586.	0.4	15
1454	NK Receptors: Tools for a Polyvalent Cell Family. Frontiers in Immunology, 2014, 5, 617.	2.2	5
1455	Quantifying the Protection of Activating and Inhibiting NK Cell Receptors during Infection with a CMV-Like Virus. Frontiers in Immunology, 2014, 5, 20.	2,2	11
1456	Beyond NK Cells: The Expanding Universe of Innate Lymphoid Cells. Frontiers in Immunology, 2014, 5, 282.	2.2	51
1457	A Negative Feedback Modulator of Antigen Processing Evolved from a Frameshift in the Cowpox Virus Genome. PLoS Pathogens, 2014, 10, e1004554.	2.1	18
1458	Effects of Peptide on NK Cell-Mediated MHC I Recognition. Frontiers in Immunology, 2014, 5, 133.	2.2	55
1459	Cell Transfer Therapy for Cancer: Past, Present, and Future. Journal of Immunology Research, 2014, 2014, 1-9.	0.9	30
1460	Know Thyself: NK-Cell Inhibitory Receptors Prompt Self-Tolerance, Education, and Viral Control. Frontiers in Immunology, 2014, 5, 175.	2.2	32
1461	The Critical Role of IL-15ââ,¬â€œPl3Kââ,¬â€œmTOR Pathway in Natural Killer Cell Effector Functions. Frontiers in Immunology, 2014, 5, 187.	2.2	176
1462	Recipients with <i>In Utero </i> Induction of Tolerance Upregulated MHC Class I in the Engrafted Donor Skin. Disease Markers, 2014, 2014, 1-9.	0.6	O

#	ARTICLE	IF	CITATIONS
1463	The Early Days of NK Cells: An Example of How a Phenomenon Led to Detection of a Novel Immune Receptor System ââ,¬â€œ Lessons from a Rat Model. Frontiers in Immunology, 2014, 5, 283.	2.2	18
1464	Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica, 2014, 99, 836-847.	1.7	160
1465	Immunology of Graft Rejection. , 2014, , 10-38.		0
1466	TLR Ligands Stimulation Protects MSC from NK Killing. Stem Cells, 2014, 32, 290-300.	1.4	76
1468	Angiostatic Effects of <scp>NK</scp> Cellâ€Derived <scp>IFN</scp> â€∢i>γ Counteracted by Tumour Cell <scp>B</scp> clâ€x <scp>_L</scp> Expression. Scandinavian Journal of Immunology, 2014, 79, 90-97.	1.3	5
1469	Perforin-dependent direct cytotoxicity in natural killer cells induces considerable knockdown of spontaneous lung metastases and computer modelling-proven tumor cell dormancy in a HT29 human colon cancer xenograft mouse model. Molecular Cancer, 2014, 13, 244.	7.9	54
1470	Radiation therapy combined with <i>Listeria monocytogenes </i> -based cancer vaccine synergize to enhance tumor control in the B16 melanoma model. Oncolmmunology, 2014, 3, e29028.	2.1	11
1471	Natural Killer Cells Play a Critical Role in Cardiac Allograft Vasculopathy in an Interleukin-6–Dependent Manner. Transplantation, 2014, 98, 1029-1039.	0.5	26
1472	Mammalian non-classical major histocompatibility complex I and its receptors: Important contexts of gene, evolution, and immunity. Indian Journal of Human Genetics, 2014, 20, 129.	0.7	26
1473	Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy. Journal of Immunology Research, 2014, 2014, 1-6.	0.9	67
1474	Cysteine Cathepsins as Regulators of the Cytotoxicity of NK and T Cells. Frontiers in Immunology, 2014, 5, 616.	2.2	73
1475	Innate Immune Responses. , 2014, , 121-147.		24
1476	Killer immunoglobulin-like receptor and their HLA ligands in Guillain–Barré Syndrome. Journal of Neuroimmunology, 2014, 267, 92-96.	1.1	24
1477	Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. Molecular Immunology, 2014, 58, 160-168.	1.0	41
1478	NK cell development and function – Plasticity and redundancy unleashed. Seminars in Immunology, 2014, 26, 114-126.	2.7	46
1479	Biology and pathogenesis of cytomegalovirus in periodontal disease. Periodontology 2000, 2014, 64, 40-56.	6.3	49
1480	Natural Killer Cells., 2014,, 187-199.		0
1481	Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy, 2014, 16, 1453-1466.	0.3	47

#	Article	IF	CITATIONS
1482	Immunological Challenges and Therapies in Xenotransplantation. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015578-a015578.	2.9	19
1483	Heat Shock Proteins of Malaria. , 2014, , .		6
1485	Paired immunoglobulin-like receptor A is an intrinsic, self-limiting suppressor of IL-5–induced eosinophil development. Nature Immunology, 2014, 15, 36-44.	7.0	56
1486	Mutagenesis of Ly49B Reveals Key Structural Elements Required for Promiscuous Binding to MHC Class I Molecules and New Insights into the Molecular Evolution of Ly49s. Journal of Immunology, 2014, 192, 1558-1569.	0.4	1
1487	Recognition of Tumors by the Innate Immune System and Natural Killer Cells. Advances in Immunology, 2014, 122, 91-128.	1.1	296
1488	Combination of radiofrequency ablation and sequential cellular immunotherapy improves progressionâ€free survival for patients with hepatocellular carcinoma. International Journal of Cancer, 2014, 134, 342-351.	2.3	97
1489	The Combination of Type I IFN, TNF-α, and Cell Surface Receptor Engagement with Dendritic Cells Enables NK Cells To Overcome Immune Evasion by Dengue Virus. Journal of Immunology, 2014, 193, 5065-5075.	0.4	28
1490	Stromal-dependent tumor promotion by MIF family members. Cellular Signalling, 2014, 26, 2969-2978.	1.7	18
1491	Endoplasmic reticulum aminopeptidase 1 function and its pathogenic role in regulating innate and adaptive immunity in cancer and major histocompatibility complex class lâ€associated autoimmune diseases. Tissue Antigens, 2014, 84, 177-186.	1.0	32
1492	The activating Ly49W and inhibitory Ly49G NK cell receptors display similar affinities for identical MHC class I ligands. Immunogenetics, 2014, 66, 467-477.	1.2	4
1493	Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy. Cancer Immunology, Immunotherapy, 2014, 63, 821-833.	2.0	26
1494	Infusions of Allogeneic Natural Killer Cells as Cancer Therapy. Clinical Cancer Research, 2014, 20, 3390-3400.	3.2	86
1495	The Emerging Role of Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/cfs). Molecular Neurobiology, 2014, 49, 741-756.	1.9	87
1496	Tumor MHC Class I Expression Improves the Prognostic Value of T-cell Density in Resected Colorectal Liver Metastases. Cancer Immunology Research, 2014, 2, 530-537.	1.6	43
1497	Immunological memory within the innate immune system. EMBO Journal, 2014, 33, 1295-303.	3.5	98
1498	Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology, 2014, , .	0.8	14
1499	NK Cell Killer Ig-like Receptor Repertoire Acquisition and Maturation Are Strongly Modulated by HLA Class I Molecules. Journal of Immunology, 2014, 192, 2602-2610.	0.4	19
1500	Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica, 2014, 99, 1248-1254.	1.7	57

#	Article	IF	CITATIONS
1501	KIR B or not to be?that is the question for ALL. Blood, 2014, 124, 2623-2624.	0.6	4
1502	Description of a novel <i><scp>KIR3DL1</scp>*0150211</i> allele isolated using molecular techniques. Tissue Antigens, 2014, 84, 596-597.	1.0	0
1503	Immune response to bovine viral diarrhea virus—looking at newly defined targets. Animal Health Research Reviews, 2015, 16, 4-14.	1.4	33
1504	Haploidentical hematopoietic transplantation from KIR ligand–mismatched donors with activating KIRs reduces nonrelapse mortality. Blood, 2015, 125, 3173-3182.	0.6	108
1505	Functional glycosylation in the human and mammalian uterus. Fertility Research and Practice, 2015, 1, 17.	4.1	30
1506	Human <scp>KIR</scp> repertoires: shaped by genetic diversity and evolution. Immunological Reviews, 2015, 267, 178-196.	2.8	102
1507	Loss of <scp>CD</scp> 155 expression predicts poor prognosis in hepatocellular carcinoma. Histopathology, 2015, 66, 706-714.	1.6	23
1508	Coâ€evolution of <scp>MHC</scp> class I and variable <scp>NK</scp> cell receptors in placental mammals. Immunological Reviews, 2015, 267, 259-282.	2.8	80
1509	Umbilical cord blood plasma contains soluble NKG2D ligands that mediate loss of natural killer cell function and cytotoxicity. European Journal of Immunology, 2015, 45, 2324-2334.	1.6	21
1510	Slpâ€ 7 6 is a critical determinant of NKâ€cell mediated recognition of missingâ€self targets. European Journal of Immunology, 2015, 45, 2072-2083.	1.6	13
1511	<scp>NK</scp> cells: tuned by peptide?. Immunological Reviews, 2015, 267, 214-227.	2.8	45
1512	The role of KIR2DL3/HLA-C*0802 in Brazilian patients with rheumatoid vasculitis. Clinics, 2015, 70, 408-412.	0.6	10
1513	Free ISG15 triggers an antitumor immune response against breast cancer: a new perspective. Oncotarget, 2015, 6, 7221-7231.	0.8	61
1514	Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors. Frontiers in Immunology, 2015, 6, 202.	2.2	130
1515	Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. Frontiers in Immunology, 2015, 6, 230.	2,2	65
1516	Can Selective MHC Downregulation Explain the Specificity and Genetic Diversity of NK Cell Receptors?. Frontiers in Immunology, 2015, 6, 311.	2.2	11
1517	NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Frontiers in Immunology, 2015, 6, 368.	2.2	411
1518	NKp46 Clusters at the Immune Synapse and Regulates NK Cell Polarization. Frontiers in Immunology, 2015, 6, 495.	2.2	43

#	Article	IF	Citations
1519	Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. Frontiers in Immunology, 2015, 6, 567.	2.2	22
1520	Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory?. Frontiers in Immunology, 2015, 6, 573.	2.2	51
1521	Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy. Frontiers in Immunology, 2015, 6, 601.	2.2	140
1522	Human Parthenogenetic Embryonic Stem Cell-Derived Neural Stem Cells Express HLA-G and Show Unique Resistance to NK Cell-Mediated Killing. Molecular Medicine, 2015, 21, 185-196.	1.9	13
1523	Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. Nature Reviews Drug Discovery, 2015, 14, 487-498.	21.5	203
1524	NK Cells and Cancer Immunoediting. Current Topics in Microbiology and Immunology, 2015, 395, 115-145.	0.7	76
1525	Coâ€evolution of the <scp>MHC</scp> class I and <scp>KIR</scp> gene families in rhesus macaques: ancestry and plasticity. Immunological Reviews, 2015, 267, 228-245.	2.8	35
1526	Phenotype of NK Cells Determined on the Basis of Selected Immunological Parameters in Children Treated due to Acute Lymphoblastic Leukemia. Medicine (United States), 2015, 94, e2369.	0.4	4
1527	Altered effector functions of NK cells in chronic hepatitis C are associated with <i>IFNL3</i> polymorphism. Journal of Leukocyte Biology, 2015, 98, 283-294.	1.5	11
1528	Regulation of natural cytotoxicity receptors by heparan sulfate proteoglycans in <i>â€cis</i> : A lesson from NKp44. European Journal of Immunology, 2015, 45, 1180-1191.	1.6	26
1529	Alcohol and HCV: Implications for Liver Cancer. Advances in Experimental Medicine and Biology, 2015, 815, 197-216.	0.8	26
1530	Maternal uterine natural killer cells nurture fetal growth: in medio stat virtus. Trends in Molecular Medicine, 2015, 21, 60-67.	3.5	31
1531	Immunotherapeutic Applications of NK Cells. Pharmaceuticals, 2015, 8, 250-256.	1.7	24
1532	The Distal Upstream Promoter in Ly49 Genes, Pro1, Is Active in Mature NK Cells and T Cells, Does Not Require TATA Boxes, and Displays Enhancer Activity. Journal of Immunology, 2015, 194, 6068-6081.	0.4	7
1533	KIR3DS1-Specific D0 Domain Polymorphisms Disrupt KIR3DL1 Surface Expression and HLA Binding. Journal of Immunology, 2015, 195, 1242-1250.	0.4	11
1534	Killer Cell Immunoglobulin-like Receptors and Their HLA Ligands are Related with the Immunopathology of Chagas Disease. PLoS Neglected Tropical Diseases, 2015, 9, e0003753.	1.3	11
1535	Immunology of a Transmissible Cancer Spreading among Tasmanian Devils. Journal of Immunology, 2015, 195, 23-29.	0.4	26
1536	ABO, Tissue Typing, and Crossmatch Incompatibility. , 2015, , 1245-1256.		O

#	Article	IF	CITATIONS
1537	Zebrafish Nk-lysins: First insights about their cellular and functional diversification. Developmental and Comparative Immunology, 2015, 51, 148-159.	1.0	69
1538	Infections and Nervous System Dysfunction. , 2015, , 422-443.		0
1539	The New Deal: A Potential Role for Secreted Vesicles in Innate Immunity and Tumor Progression. Frontiers in Immunology, 2015, 6, 66.	2.2	92
1540	Toward beta cell replacement for diabetes. EMBO Journal, 2015, 34, 841-855.	3.5	40
1541	Role of Donor Activating KIR–HLA Ligand–Mediated NK Cell Education Status in Control of Malignancy inÂHematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2015, 21, 829-839.	2.0	30
1542	Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients. Journal of Immunotherapy, 2015, 38, 24-36.	1.2	154
1543	Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation. Journal of Immunology, 2015, 195, 4524-4536.	0.4	35
1544	Bone Marrow Cell Rejection, MHC, NK Cells, and Missing Self Recognition: Ain't That Peculiar (with) Tj ETQq1	1.0.78431	l4 _g rgBT/Ove
1545	Human NK cells activated by EBV ⁺ lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells. Oncolmmunology, 2015, 4, e991613.	2.1	36
1546	<i><scp>KIR3DL1</scp>*0250102</i> : a novel threeâ€domain <scp>KIR</scp> subtype identified in West Africa. Tissue Antigens, 2015, 85, 151-152.	1.0	0
1547	Diversity in medical education: data drought and socioeconomic barriers. Cmaj, 2015, 187, 11-11.	0.9	23
1548	Diversification and Functional Specialization of Human NK Cell Subsets. Current Topics in Microbiology and Immunology, 2015, 395, 63-93.	0.7	56
1549	Agonist antibody that induces human malignant cells to kill one another. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6158-E6165.	3.3	16
1550	The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy. Oncolmmunology, 2015, 4, e1042198.	2.1	36
1551	Surveillance of cell and tissue perturbation by receptors in the <scp>LRC</scp> . Immunological Reviews, 2015, 267, 117-136.	2.8	30
1552	Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncolmmunology, 2015, 4, e1038017.	2.1	14
1553	Varicella-Zoster Virus and Herpes Simplex Virus 1 Differentially Modulate NKG2D Ligand Expression during Productive Infection. Journal of Virology, 2015, 89, 7932-7943.	1.5	34
1554	KIR and HLA under pressure: evidences of coevolution across worldwide populations. Human Genetics, 2015, 134, 929-940.	1.8	45

#	Article	IF	CITATIONS
1555	Natural killer cells in the innate immunity network of atherosclerosis. Immunology Letters, 2015, 168, 51-57.	1.1	31
1556	Classical and non-classical MHC I molecule manipulation by human cytomegalovirus: so many targets—but how many arrows in the quiver?. Cellular and Molecular Immunology, 2015, 12, 139-153.	4.8	115
1557	Biological Basis of Alcohol-Induced Cancer. Advances in Experimental Medicine and Biology, 2015, , .	0.8	6
1558	Immunology of Normal Pregnancy and Preeclampsia. , 2015, , 161-179.		7
1559	Killer Cell Immunoglobulin like Receptors (KIR) Gene Variations in Rheumatic Fever and Rheumatic Heart Disease Patients from North India. Journal of Clinical Infectious Diseases & Practice, 2016, 01, .	0.1	0
1560	NK Cells in T Cell Regulation. , 2016, , 253-261.		0
1561	High-risk corneal allografts: A therapeutic challenge. World Journal of Transplantation, 2016, 6, 10.	0.6	32
1562	Research and Science Today $1(11)/2016$. SSRN Electronic Journal, 0 , , .	0.4	0
1563	Growth and Metastasis of Intraocular Tumors in Aged Mice. , 2016, 57, 2366.		9
1564	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. Journal of Immunology Research, 2016, 2016, 1-14.	0.9	36
1565	The Memories of NK Cells: Innate-Adaptive Immune Intrinsic Crosstalk. Journal of Immunology Research, 2016, 2016, 1-14.	0.9	39
1566	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. Frontiers in Immunology, 2016, 7, 94.	2.2	26
1567	Type 1 Innate Lymphoid Cell Biology: Lessons Learnt from Natural Killer Cells. Frontiers in Immunology, 2016, 7, 426.	2.2	75
1568	Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. Frontiers in Immunology, 2016, 7, 454.	2.2	26
1569	The Impact of HLA Class I-Specific Killer Cell Immunoglobulin-Like Receptors on Antibody-Dependent Natural Killer Cell-Mediated Cytotoxicity and Organ Allograft Rejection. Frontiers in Immunology, 2016, 7, 585.	2.2	40
1570	Cord Blood as a Source of Natural Killer Cells. Frontiers in Medicine, 2015, 2, 93.	1.2	56
1571	Activating Receptor Signals Drive Receptor Diversity in Developing Natural Killer Cells. PLoS Biology, 2016, 14, e1002526.	2.6	11
1572	NK Cells in Antiviral Defense. , 2016, , 243-252.		1

#	Article	IF	CITATIONS
1573	KIR genotypic diversity in Portuguese and analysis of KIR gene allocation after allogeneic hematopoietic stem cell transplantation. Hla, 2016, 87, 375-380.	0.4	0
1574	T Cells Going Innate. Trends in Immunology, 2016, 37, 546-556.	2.9	46
1575	NK Cell Responses in Immunotherapy: Novel Targets and Applications. , 2016, , 79-108.		0
1576	Compartment-specific expression of natural killer cell markers in renal transplantation: immune profile in acute rejection. Transplant International, 2016, 29, 443-452.	0.8	17
1577	Re-discovering NK cell allo-reactivity in the therapy of solid tumors. , 2016, 4, 54.		11
1578	Can we make a better match or mismatch with KIR genotyping?. Hematology American Society of Hematology Education Program, 2016, 2016, 106-118.	0.9	18
1579	Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation. Blood, 2016, 128, 2616-2623.	0.6	54
1580	The Influence of HLA and KIR Genes on Malignant Melanoma Development and Progression. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 73-81.	1.0	11
1582	Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition. Journal of Experimental Medicine, 2016, 213, 791-807.	4.2	81
1583	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Annals of Oncology, 2016, 27, 1492-1504.	0.6	460
1584	Contribution of alloantigens to hepatic ischemia/reperfusion injury: Roles of natural killer cells and innate immune recognition of nonself. Liver Transplantation, 2016, 22, 80-90.	1.3	9
1585	Rationale of hyperthermia for radio(chemo)therapy and immune responses in patients with bladder cancer: Biological concepts, clinical data, interdisciplinary treatment decisions and biological tumour imaging. International Journal of Hyperthermia, 2016, 32, 455-463.	1.1	14
1586	Emerging insights into natural killer cells in human peripheral tissues. Nature Reviews Immunology, 2016, 16, 310-320.	10.6	349
1587	Evidence for Differential Glycosylation of Trophoblast Cell Types. Molecular and Cellular Proteomics, 2016, 15, 1857-1866.	2.5	32
1588	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood, 2016, 128, 297-312.	0.6	54
1589	From Adoptive Immunity to CAR Therapy: An Evolutionary Perspective. , 2016, , 560-568.		1
1590	Innate Allorecognition Results in Rapid Accumulation of Monocyte-Derived Dendritic Cells. Journal of Immunology, 2016, 197, 2000-2008.	0.4	22
1591	Multi-functional lectin-like transcript-1: A new player in human immune regulation. Immunology Letters, 2016, 177, 62-69.	1.1	19

#	Article	IF	CITATIONS
1592	hi <scp>PSC</scp> â€derived <scp>iMSC</scp> s: NextGen <scp>MSC</scp> s as an advanced therapeutically active cell resource for regenerative medicine. Journal of Cellular and Molecular Medicine, 2016, 20, 1571-1588.	1.6	86
1593	Innate lymphoid cells and the <scp>MHC</scp> . Hla, 2016, 87, 5-11.	0.4	31
1594	Human Herpesvirus 6B Downregulates Expression of Activating Ligands during Lytic Infection To Escape Elimination by Natural Killer Cells. Journal of Virology, 2016, 90, 9608-9617.	1.5	37
1595	Teach Your NK Cells Well. Immunity, 2016, 45, 229-231.	6.6	4
1596	An overview of the potential strategies for NK cellâ€based immunotherapy for acute myeloid leukemia. Pediatric Blood and Cancer, 2016, 63, 2078-2085.	0.8	9
1597	Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome. Annals of Surgical Oncology, 2016, 23, 508-515.	0.7	49
1598	Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients. Cancer Research, 2016, 76, 5326-5336.	0.4	26
1599	LRBA is Essential for Allogeneic Responses in Bone Marrow Transplantation. Scientific Reports, 2016, 6, 36568.	1.6	9
1600	Immunological profiling of patients with ulcerative colitis leads to identification of two inflammatory conditions and CD1a as a disease marker. Journal of Translational Medicine, 2016, 14, 310.	1.8	15
1601	Investigation of immunomodulatory and anti-inflammatory effects of eriodictyol through its cellular anti-oxidant activity. Cell Stress and Chaperones, 2016, 21, 773-781.	1.2	33
1603	Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma. Clinical Cancer Research, 2016, 22, 5211-5222.	3.2	137
1604	Curculigoside augments cell-mediated immune responses in metastatic tumor-bearing animals. Immunopharmacology and Immunotoxicology, 2016, 38, 264-269.	1.1	10
1605	Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a. Cellular and Molecular Immunology, 2016, 13, 57-64.	4.8	31
1606	Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. International Journal of Cancer, 2016, 138, 271-280.	2.3	35
1607	Strategies and developments of immunotherapies in osteosarcoma. Oncology Letters, 2016, 11, 511-520.	0.8	43
1608	The antileukemic potential of natural killer cells. Immunotherapy, 2016, 8, 425-434.	1.0	2
1609	Negative Impact of Unidirectional Host-versus-Graft Killer Cell Immunoglobulin–like Receptor Ligand Mismatch on Transplantation Outcomes after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 316-323.	2.0	10
1610	Lymphocytes that Kill. , 2016, , 243-251.		0

#	Article	IF	Citations
1611	Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: AÂJapanese National Registry Study. Biology of Blood and Marrow Transplantation, 2016, 22, 423-431.	2.0	9
1612	Natural Killer Cells. Current Topics in Microbiology and Immunology, 2016, , .	0.7	5
1613	Killer-cell immunoglobulin-like receptor genes and ligands and their role in hematologic malignancies. Cancer Immunology, Immunotherapy, 2016, 65, 427-440.	2.0	28
1614	Immunomodulatory and cellular antioxidant activities of pure compounds from Teucrium ramosissimum Desf Tumor Biology, 2016, 37, 7703-7712.	0.8	19
1615	The TGF- \hat{l}^2 /SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia, 2016, 30, 800-811.	3.3	109
1616	The evolution of natural killer cell receptors. Immunogenetics, 2016, 68, 3-18.	1.2	91
1617	Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?. Cancer Immunology, Immunotherapy, 2016, 65, 453-463.	2.0	50
1618	CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells. AIDS Research and Human Retroviruses, 2017, 33, 93-100.	0.5	21
1619	Functions of Cancer-Derived Extracellular Vesicles in Immunosuppression. Archivum Immunologiae Et Therapiae Experimentalis, 2017, 65, 311-323.	1.0	89
1620	Analysis of killer cell immunoglobulin-like receptors (KIRs) and their HLA ligand genes polymorphisms in Iranian patients with systemic sclerosis. Clinical Rheumatology, 2017, 36, 853-862.	1.0	16
1621	<scp>HLA</scp> â€stripped platelets: preclinical developments and clinical outlooks. ISBT Science Series, 2017, 12, 148-153.	1.1	0
1622	Tumour and placenta establishment: The importance of antigen processing and presentation. Placenta, 2017, 56, 34-39.	0.7	26
1623	Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer. Immunology Letters, 2017, 186, 20-27.	1.1	31
1624	Contribution of inhibitory receptor TIGIT to NK cell education. Journal of Autoimmunity, 2017, 81, 1-12.	3.0	40
1625	Innate lymphoid cells and their stromal microenvironments. Immunology Letters, 2017, 189, 3-9.	1.1	3
1626	Bitter Melon Enhances Natural Killer–Mediated Toxicity against Head and Neck Cancer Cells. Cancer Prevention Research, 2017, 10, 337-344.	0.7	74
1627	Herpesviral capture of immunomodulatory host genes. Virus Genes, 2017, 53, 762-773.	0.7	22
1628	Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunologic Research, 2017, 65, 880-887.	1.3	55

#	Article	IF	Citations
1629	Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. Protein and Cell, 2017, 8, 861-877.	4.8	53
1630	Thermal treatment of luteolin-7-O- \hat{l}^2 -glucoside improves its immunomodulatory and antioxidant potencies. Cell Stress and Chaperones, 2017, 22, 775-785.	1.2	19
1631	Immunological characterization of a rigid \hat{l}_{\pm} -Tn mimetic on murine iNKT and human NK cells. Glycoconjugate Journal, 2017, 34, 553-562.	1.4	4
1632	The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Cancer Medicine, 2017, 6, 1614-1626.	1.3	28
1633	The Ablâ€1 Kinase is Dispensable for <scp>NK</scp> Cell Inhibitory Signalling and is not Involved in Murine <scp>NK</scp> Cell Education. Scandinavian Journal of Immunology, 2017, 86, 135-142.	1.3	8
1634	Overview of Basic Immunology for Clinical Investigators. Advances in Experimental Medicine and Biology, 2017, 995, 1-31.	0.8	4
1635	Prospective study of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced renal cell cancer. Immunology Letters, 2017, 184, 98-104.	1.1	29
1637	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. European Journal of Cancer, 2017, 76, 152-166.	1.3	82
1638	Rejection versus escape: the tumor MHC dilemma. Cancer Immunology, Immunotherapy, 2017, 66, 259-271.	2.0	115
1639	Markers and function of human NK cells in normal and pathological conditions. Cytometry Part B - Clinical Cytometry, 2017, 92, 100-114.	0.7	110
1640	Guidelines for the use of flow cytometry and cell sorting in immunological studies [*] . European Journal of Immunology, 2017, 47, 1584-1797.	1.6	505
1641	The association between <i>MICA/MICB</i> polymorphism and respiratory syncytial virus infection in children. International Journal of Immunogenetics, 2017, 44, 328-336.	0.8	3
1642	Dysregulated cellular functions and cell stress pathways provide critical cues for activating and targeting natural killer cells to transformed and infected cells. Immunological Reviews, 2017, 280, 93-101.	2.8	55
1643	NK cell-based immunotherapy for cancer. Seminars in Immunology, 2017, 31, 37-54.	2.7	246
1644	Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Seminars in Immunology, 2017, 31, 64-75.	2.7	110
1645	Natural killer cell-mediated immunosurveillance of human cancer. Seminars in Immunology, 2017, 31, 20-29.	2.7	240
1646	Natural killer cells in HIV-1 infection and therapy. Aids, 2017, 31, 2317-2330.	1.0	90
1647	MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nature Communications, 2017, 8, 385.	5.8	178

#	Article	IF	CITATIONS
1648	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Clinical Cancer Research, 2017, 23, 6054-6061.	3.2	75
1649	Frontline Science: A hyporesponsive subset of rat NK cells negative for Ly49s3 and NKR-P1B are precursors to the functionally mature NKR-P1B+ subset. Journal of Leukocyte Biology, 2017, 102, 1289-1298.	1.5	2
1650	The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity, 2017, 47, 820-833.	6.6	485
1651	Immune selection during tumor checkpoint inhibition therapy paves way for NK-cell "missing self― recognition. Immunogenetics, 2017, 69, 547-556.	1.2	30
1652	Natural killer cells in malignant hematology: A primer for the non-immunologist. Blood Reviews, 2017, 31, 1-10.	2.8	34
1653	Roles of WNT, NOTCH, and Hedgehog signaling in the differentiation and function of innate and innate-like lymphocytes. Journal of Leukocyte Biology, 2017, 101, 827-840.	1.5	32
1654	Role for coronin 1 in mouse NK cell function. Immunobiology, 2017, 222, 291-300.	0.8	3
1655	Decreased percentage of <scp>NKG</scp> 2D+ <scp>NK</scp> cells in patients withÂincident onset of Type 1 Diabetes. Clinical and Experimental Pharmacology and Physiology, 2017, 44, 180-190.	0.9	9
1656	Diversification of both <i><scp>KIR</scp></i> and <i><scp>NKG</scp>2</i> natural killer cell receptor genes in macaques â€" implications for highly complex <scp>MHC</scp> â€dependent regulation of natural killer cells. Immunology, 2017, 150, 139-145.	2.0	18
1657	Recent Progress Using Pluripotent Stem Cells for Cardiac Regenerative Therapy. Circulation Journal, 2017, 81, 929-935.	0.7	13
1658	Donor Natural Killer Cells and Their Therapeutic Potential in Allogeneic Hematopoietic Stem Cell Transplantation. , 0, , .		0
1659	Transforming Growth Factor-Î ² 2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers. Frontiers in Veterinary Science, 2017, 4, 84.	0.9	33
1660	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 2537-2549.	2.0	6
1661	The Four-Way Stop Sign: Viruses, 12-Lipoxygenase, Islets, and Natural Killer Cells in Type 1 Diabetes Progression. Frontiers in Endocrinology, 2017, 8, 246.	1.5	4
1662	Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection. Frontiers in Immunology, 2017, 8, 41.	2.2	32
1663	In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. Frontiers in Immunology, 2017, 8, 87.	2.2	43
1664	Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation. Frontiers in Immunology, 2017, 8, 166.	2.2	39
1665	Host Immune Responses in HIV-1 Infection: The Emerging Pathogenic Role of Siglecs and Their Clinical Correlates. Frontiers in Immunology, 2017, 8, 314.	2.2	40

#	Article	IF	CITATIONS
1666	Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines. Frontiers in Immunology, 2017, 8, 391.	2.2	42
1667	Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. Frontiers in Immunology, 2017, 8, 496.	2.2	144
1668	Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease. Frontiers in Immunology, 2017, 8, 513.	2.2	19
1669	The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Frontiers in Immunology, 2017, 8, 631.	2.2	154
1670	Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections?. Frontiers in Immunology, 2017, 8, 832.	2.2	139
1671	Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity. Frontiers in Immunology, 2017, 8, 1033.	2.2	17
1672	The More, The Better: "Do the Right Thing―For Natural Killer Immunotherapy in Acute Myeloid Leukemia. Frontiers in Immunology, 2017, 8, 1330.	2.2	21
1673	Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. Frontiers in Immunology, 2017, 8, 1444.	2.2	62
1674	Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors. Frontiers in Immunology, 2017, 8, 1466.	2.2	20
1675	Natural Killer Cells from the Subcutaneous Adipose Tissue Underexpress the NKp30 and NKp44 in Obese Persons and Are Less Active against Major Histocompatibility Complex Class I Non-Expressing Neoplastic Cells. Frontiers in Immunology, 2017, 8, 1486.	2.2	20
1676	Broad Impairment of Natural Killer Cells From Operationally Tolerant Kidney Transplanted Patients. Frontiers in Immunology, 2017, 8, 1721.	2.2	11
1677	A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice. ELife, 2017, 6, .	2.8	5
1678	Significantly enhanced lung metastasis and reduced organ NK cell functions in diet-induced obese rats. BMC Obesity, 2017, 4, 24.	3.1	19
1679	Clinical Applications of Natural Killer Cells. , O, , .		O
1680	NK Cells and Cancer., 0,,.		1
1681	Introductory Chapter: A Brief Overview on Natural Killer Cells. , 0, , .		2
1682	NK cells for cancers. , 0, , 602-610.		0
1683	Human Leukocyte Antigen-C Genotype and Killer Immunoglobulin-like Receptor-Ligand Matching in Korean Living Donor Liver Transplantation. Annals of Laboratory Medicine, 2017, 37, 45-52.	1.2	7

#	Article	IF	CITATIONS
1685	Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget, 2017, 8, 24031-24044.	0.8	77
1686	Human Natural Killer Receptors, Coâ€Receptors, and Their Ligands. Current Protocols in Immunology, 2018, 121, e47.	3.6	15
1687	Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution. Transfusion, 2018, 58, 1458-1467.	0.8	19
1688	A nanoscale reorganization of the IL-15 receptor is triggered by NKG2D in a ligand-dependent manner. Science Signaling, 2018, 11, .	1.6	28
1689	Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends in Immunology, 2018, 39, 222-239.	2.9	139
1690	Genetics of Natural Killer Cells in Human Health, Disease, and Survival. Annual Review of Immunology, 2018, 36, 519-548.	9.5	86
1691	NK cell therapy for hematologic malignancies. International Journal of Hematology, 2018, 107, 262-270.	0.7	64
1693	Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation. Blood, 2018, 131, 1053-1062.	0.6	111
1694	Cancer Immunosurveillance by Natural Killer Cells and Other Innate Lymphoid Cells., 2018, , 163-180.		3
1695	Characterization of the interaction between human decidua parietalis mesenchymal stem/stromal cells and natural killer cells. Stem Cell Research and Therapy, 2018, 9, 102.	2.4	14
1696	The early expansion of anergic NKG2A ^{pos} /CD56 ^{dim} /CD16 ^{neg} natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation. Haematologica, 2018, 103, 1390-1402.	1.7	61
1697	HLA-G mediated immune regulation is impaired by a single amino acid exchange in the alpha 2 domain. Human Immunology, 2018, 79, 453-462.	1.2	47
1698	NKG2D–MICA Interaction: A Paradigm Shift in Innate Recognition. Journal of Immunology, 2018, 200, 2229-2230.	0.4	8
1699	Identification of MHC Class Ib Ligands for Stimulatory and Inhibitory Ly49 Receptors and Induction of Potent NK Cell Alloresponses in Rats. Journal of Immunology, 2018, 200, 2847-2859.	0.4	8
1700	Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. Annals of Hematology, 2018, 97, 1027-1039.	0.8	19
1701	The biology of natural killer cells during sepsis. Immunology, 2018, 153, 190-202.	2.0	86
1702	Recall features and allorecognition in innate immunity. Transplant International, 2018, 31, 6-13.	0.8	3
1703	NK Cell Effector Functions Regulation by Modulating nTreg Cell Population During Progressive Growth of Dalton's Lymphoma in Mice. Immunological Investigations, 2018, 47, 40-56.	1.0	12

#	Article	IF	CITATIONS
1704	Cancer-derived extracellular vesicles: friend and foe of tumour immunosurveillance. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20160481.	1.8	68
1705	Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy. Stem Cells, 2018, 36, 134-145.	1.4	48
1706	SMAD4 promotes TGF-β–independent NK cell homeostasis and maturation and antitumor immunity. Journal of Clinical Investigation, 2018, 128, 5123-5136.	3.9	55
1708	Impact of the Donor KIR Genotype on the Clinical Outcome of Hematopoietic Stem Cell Unrelated Transplants: A Single Center Experience. , 2018, , .		1
1709	Immunopathology of Kidney Transplantation. , 0, , .		1
1710	TGF \hat{I}^2 Imprinting During Activation Promotes Natural Killer Cell Cytokine Hypersecretion. Cancers, 2018, 10, 423.	1.7	38
1711	Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth. ACS Nano, 2018, 12, 12096-12108.	7.3	285
1712	Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications. International Journal of Molecular Sciences, 2018, 19, 3648.	1.8	32
1713	Diversity of Killer Cell Immunoglobulin-Like Receptors and Disease. Clinics in Laboratory Medicine, 2018, 38, 637-653.	0.7	26
1714	Natural Killer Cell Education Is Associated With a Distinct Glycolytic Profile. Frontiers in Immunology, 2018, 9, 3020.	2.2	36
1715	Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?. Theranostics, 2018, 8, 5784-5800.	4.6	42
1716	Overview of Basic Immunology and Translational Relevance for Clinical Investigators. Advances in Experimental Medicine and Biology, 2018, 995, 1-41.	0.8	6
1718	Complex mammalian-like haematopoietic system found in a colonial chordate. Nature, 2018, 564, 425-429.	13.7	60
1719	Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A. Frontiers in Immunology, 2018, 9, 2848.	2.2	27
1720	Extracellular Vesicles in Bladder Cancer: Biomarkers and Beyond. International Journal of Molecular Sciences, 2018, 19, 2822.	1.8	35
1721	Spatial and temporal coordination of antiviral responses by group 1 <scp>ILC </scp> s. Immunological Reviews, 2018, 286, 23-36.	2.8	18
1722	Positive & Positive Roles of Innate Effector Cells in Controlling Cancer Progression. Frontiers in Immunology, 2018, 9, 1990.	2.2	29
1723	Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies. Journal of Immunology Research, 2018, 2018, 1-20.	0.9	93

#	Article	IF	CITATIONS
1724	Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review. Cancer Cell International, 2018, 18, 133.	1.8	28
1725	Role of donor HLA class I mismatch, KIRâ€ligand mismatch and HLA:KIR pairings in hematological malignancy relapse after unrelated hematopoietic stem cell transplantation. Hla, 2018, 92, 42-46.	0.4	9
1726	O-GlcNAc Modification During Pregnancy: Focus on Placental Environment. Frontiers in Physiology, 2018, 9, 1263.	1.3	14
1727	Natural Killer Cells: Development, Maturation, and Clinical Utilization. Frontiers in Immunology, 2018, 9, 1869.	2.2	709
1728	Donor KIR Genotype Impacts on Clinical Outcome after T Cell–Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients. Biology of Blood and Marrow Transplantation, 2018, 24, 2493-2500.	2.0	20
1729	Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy. Blood Advances, 2018, 2, 335-346.	2.5	47
1730	NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia. Trends in Immunology, 2018, 39, 577-590.	2.9	119
1731	Alopecia areata: a review of disease pathogenesis. British Journal of Dermatology, 2018, 179, 1033-1048.	1.4	183
1732	Haploidentical Hematopoietic Cell Transplantation. , 2018, , 1617-1632.e6.		0
1733	Urochordata: Botryllus – Natural Chimerism and Tolerance Induction in a Colonial Chordate. , 2018, , 503-519.		0
1734	Therapeutic implications of NK cell regulation of allogeneic CD8 T cell-mediated immune responses stimulated through the direct pathway of antigen presentation in transplantation. MAbs, 2018, 10, 1-15.	2.6	2
1735	Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review. Frontiers in Immunology, 2017, 8, 1825.	2.2	39
1736	Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer. Frontiers in Immunology, 2018, 9, 283.	2.2	213
1737	CD1-Restricted T Cells During Persistent Virus Infections: "Sympathy for the Devil― Frontiers in Immunology, 2018, 9, 545.	2.2	7
1738	Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors–Human Leukocyte Antigen Ligand Mismatch and Activation Receptor–Ligand Interactions. Frontiers in Immunology, 2018, 9, 1345.	2.2	52
1739	Growth and Immune Evasion of Lymph Node Metastasis. Frontiers in Oncology, 2018, 8, 36.	1.3	106
1740	Natural killer cells' immune response requires a minimal nanoscale distribution of activating antigens. Nanoscale, 2018, 10, 14651-14659.	2.8	24
1741	Cellular Mechanisms Controlling Surfacing of AICL Glycoproteins, Cognate Ligands of the Activating NK Receptor NKp80. Journal of Immunology, 2018, 201, 1275-1286.	0.4	6

#	Article	IF	CITATIONS
1742	Cell encapsulation potential of chitosan-alginate electrostatic complex in preventing natural killer and CD8 ⁺ cell-mediated cytotoxicity: an in vitro experimental study. Journal of Microencapsulation, 2018, 35, 522-532.	1.2	4
1743	Immunotoxicity Testing. Methods in Molecular Biology, 2018, , .	0.4	5
1744	Tumor Challenges in Immunotoxicity Testing. Methods in Molecular Biology, 2018, 1803, 169-180.	0.4	1
1745	MicroRNA regulation of natural killer cell development and function in leukemia. Molecular Immunology, 2019, 115, 12-20.	1.0	8
1746	Current Flow Cytometric Assays for the Screening and Diagnosis of Primary HLH. Frontiers in Immunology, 2019, 10, 1740.	2.2	15
1747	Adoptive cell therapy using engineered natural killer cells. Bone Marrow Transplantation, 2019, 54, 785-788.	1.3	75
1748	Regulation of KIR3DL3 Expression via miRNA. Genes, 2019, 10, 603.	1.0	10
1749	Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability. Cancers, 2019, 11, 966.	1.7	12
1750	Expression of carcinoma, apoptosis, and cellâ€death–related genes are determinants for sensitivity of pediatric cancer cell lines to lysis by natural killer cells. Pediatric Blood and Cancer, 2019, 66, e27783.	0.8	11
1751	Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. Cancers, 2019, 11, 996.	1.7	28
1752	<p>Preparation of highly activated natural killer cells for advanced lung cancer therapy</p> . OncoTargets and Therapy, 2019, Volume 12, 5077-5086.	1.0	11
1753	A collagen-based microwell migration assay to study NK-target cell interactions. Scientific Reports, 2019, 9, 10672.	1.6	9
1754	Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation. Frontiers in Immunology, 2019, 10, 1179.	2.2	269
1755	Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors. Cancers, 2019, 11, 1534.	1.7	57
1756	Synergized regulation of NK cell education by NKG2A and specific Ly49 family members. Nature Communications, 2019, 10, 5010.	5.8	43
1757	Key features and homing properties of NK cells in the liver are shaped by activated iNKT cells. Scientific Reports, 2019, 9, 16362.	1.6	0
1758	Advances in NK cell bio. Molecular Immunology, 2019, 115, 1-2.	1.0	0
1759	Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells. Frontiers in Immunology, 2019, 10, 2357.	2.2	99

#	Article	IF	CITATIONS
1760	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	1.6	766
1761	Exploiting NK Cell Surveillance Pathways for Cancer Therapy. Cancers, 2019, 11, 55.	1.7	41
1762	Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Frontiers in Immunology, 2019, 10, 1782.	2.2	45
1763	NK Cell Dysfunction and Checkpoint Immunotherapy. Frontiers in Immunology, 2019, 10, 1999.	2.2	105
1764	Natural killer cells and cancer therapy, what we know and where we are going. Immunotherapy, 2019, 11, 1231-1251.	1.0	8
1765	Immune evasion by TGF \hat{I}^2 -induced miR-183 repression of MICA/B expression in human lung tumor cells. Oncolmmunology, 2019, 8, e1557372.	2.1	30
1766	Inhibitory Receptor Crosslinking Quantitatively Dampens Calcium Flux Induced by Activating Receptor Triggering in NK Cells. Frontiers in Immunology, 2018, 9, 3173.	2.2	9
1767	Hepatic Natural Killer Cells: Organ-Specific Sentinels of Liver Immune Homeostasis and Physiopathology. Frontiers in Immunology, 2019, 10, 946.	2.2	104
1768	An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More. Frontiers in Immunology, 2019, 10, 1415.	2.2	57
1769	CAR-T immunotherapies: Biotechnological strategies to improve safety, efficacy and clinical outcome through CAR engineering. Biotechnology Advances, 2019, 37, 107411.	6.0	12
1770	The Natural Cytotoxicity Receptors in Health and Disease. Frontiers in Immunology, 2019, 10, 909.	2.2	243
1771	Introduction. Advances in Experimental Medicine and Biology, 2019, 1151, 1-14.	0.8	3
1772	Human NK cell receptor KIR2DS4 detects a conserved bacterial epitope presented by HLA-C. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12964-12973.	3.3	59
1773	Back signaling of HLA class I molecules and T/NK cell receptor ligands in epithelial cells reflects the rejection-specific microenvironment in renal allograft biopsies. American Journal of Transplantation, 2019, 19, 2692-2704.	2.6	14
1774	Fifty Years (Well, Almost!) in Immunology. Journal of Immunology, 2019, 202, 3115-3122.	0.4	0
1775	Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. Trends in Cancer, 2019, 5, 208-232.	3.8	54
1776	NK cells to cure cancer. Seminars in Immunology, 2019, 41, 101272.	2.7	70
1777	Tumor mechanisms of resistance to immune attack. Progress in Molecular Biology and Translational Science, 2019, 164, 61-100.	0.9	9

#	Article	IF	CITATIONS
1778	Spatial Clustering of Receptors and Signaling Molecules Regulates NK Cell Response to Peptide Repertoire Changes. Frontiers in Immunology, 2019, 10, 605.	2.2	10
1779	Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer. Frontiers in Immunology, 2019, 10, 1047.	2.2	77
1780	Natural Killer Cells in Autoimmunity. , 2019, , 45-52.		0
1781	Natural killer cells: From surface receptors to the cure of highâ€risk leukemia (Ceppellini Lecture). Hla, 2019, 93, 185-194.	0.4	11
1782	Diversity and association of HLA/KIR receptors with type 2 diabetes in South India. International Journal of Immunogenetics, 2019, 46, 166-178.	0.8	3
1783	CD56dim CD16â^' Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α. Frontiers in Immunology, 2019, 10, 14.	2.2	41
1784	Characterization of human natural killer cells for therapeutic use. Cytotherapy, 2019, 21, 315-326.	0.3	5
1785	NK cell recognition of hematopoietic cells by SLAM-SAP families. Cellular and Molecular Immunology, 2019, 16, 452-459.	4.8	15
1786	Two to Tango: Co-evolution of Hominid Natural Killer Cell Receptors and MHC. Frontiers in Immunology, 2019, 10, 177.	2.2	59
1787	Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions. Biochemical and Biophysical Research Communications, 2019, 515, 1-8.	1.0	21
1788	Preconditioning human natural killer cells with chorionic villous mesenchymal stem cells stimulates their expression of inflammatory and anti-tumor molecules. Stem Cell Research and Therapy, 2019, 10, 50.	2.4	11
1789	Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cellular and Molecular Immunology, 2019, 16, 430-441.	4.8	327
1790	Memory and CARâ€NK cellâ€based novel approaches for HIV vaccination and eradication. Journal of Cellular Physiology, 2019, 234, 14812-14817.	2.0	11
1791	Introductory Chapter: Are We There Yet? The Long and Winding Road to Cancer Immunotherapy. , 2019,		0
1792	Cellular crosstalk mediating immune evasion in pancreatic cancer microenvironment. Annals of Pancreatic Cancer, 0, 2, 13-13.	1.2	0
1793	Natural Killer (NK) Cell Alloreactivities against Leukemic Cells: Functions beyond Defense., 2019,,.		1
1794	Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy. Blood Science, 2019, 1, 4-11.	0.4	10
1795	The Dual Role of HLA-C in Tolerance and Immunity at the Maternal-Fetal Interface. Frontiers in Immunology, 2019, 10, 2730.	2.2	90

#	Article	IF	CITATIONS
1796	A self-marker-like protein governs hemocyte allorecognition in Halocynthia roretzi. Zoological Letters, 2019, 5, 34.	0.7	2
1797	The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation. Frontiers in Immunology, 2019. 10. 2816.	2.2	37
1798	The Immunology of Transplantation. , 2019, , 9-35.		0
1799	Harnessing NK Cells for Cancer Treatment. Frontiers in Immunology, 2019, 10, 2836.	2.2	66
1800	Alessandro Moretta and Transporter Associated With Antigen Processing (TAP) Deficiency: On Giant's Shoulders. Frontiers in Immunology, 2019, 10, 2404.	2.2	0
1801	Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review). Oncology Reports, 2019, 41, 2625-2635.	1.2	9
1802	The rise of human stem cell-derived natural killer cells for cancer immunotherapy. Expert Opinion on Biological Therapy, 2019, 19, 141-148.	1.4	19
1803	Inducible down-regulation of MHC class I results in natural killer cell tolerance. Journal of Experimental Medicine, 2019, 216, 99-116.	4.2	45
1804	Nanoscale Mechanosensing of Natural Killer Cells is Revealed by Antigenâ€Functionalized Nanowires. Advanced Materials, 2019, 31, e1805954.	11.1	44
1805	The Optimal Killer Cell Immunoglobulin-Like Receptor Donorâ€"We Can Recognize, but Can We Search?. Biology of Blood and Marrow Transplantation, 2019, 25, e3-e4.	2.0	0
1806	Myths, reality and future of mesenchymal stem cell therapy. Cell and Tissue Research, 2019, 375, 563-574.	1.5	18
1807	Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immuneâ€therapeutic strategies in cancer therapy. Journal of Leukocyte Biology, 2019, 105, 1243-1251.	1.5	37
1808	Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells. Seminars in Immunopathology, 2019, 41, 59-68.	2.8	115
1809	Evidence of functional Cd94 polymorphism in a free-living house mouse population. Immunogenetics, 2019, 71, 321-333.	1.2	2
1810	Tumour-intrinsic resistance to immune checkpoint blockade. Nature Reviews Immunology, 2020, 20, 25-39.	10.6	856
1811	Distribution of human killer cell immunoglobulinâ€like receptors and ligands among blood donors of Catalonia. Hla, 2020, 95, 179-188.	0.4	7
1812	Natural killer T cell cytotoxic activity in cervical cancer is facilitated by the LINC00240/microRNA-124-3p/STAT3/MICA axis. Cancer Letters, 2020, 474, 63-73.	3.2	40
1813	Eliciting an immune hot tumor niche with biomimetic drug-based multi-functional nanohybrids augments immune checkpoint blockade-based breast cancer therapy. Nanoscale, 2020, 12, 3317-3329.	2.8	30

#	Article	IF	CITATIONS
1814	Role of cancer immunology in chronic myelogenous leukemia. Leukemia Research, 2020, 88, 106273.	0.4	19
1815	Natural Killer Cells. , 2020, , 229-242.		1
1816	HCMV Infection in a Mesenchymal Stem Cell Niche: Differential Impact on the Development of NK Cells versus ILC3. Journal of Clinical Medicine, 2020, 9, 10.	1.0	15
1817	PTPN21â€CDS long isoform inhibits the response of acute lymphoblastic leukemia cells to NKâ€mediated lysis via the KIR/HLAâ€I axis. Journal of Cellular Biochemistry, 2020, 121, 3298-3312.	1.2	3
1818	Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles. Frontiers in Immunology, 2020, 11, 561553.	2.2	37
1819	The Genetic Mechanisms Driving Diversification of the KIR Gene Cluster in Primates. Frontiers in Immunology, 2020, 11, 582804.	2.2	15
1820	The distinct MHCâ€unrestricted immunobiology of innateâ€like and adaptiveâ€like human γδT cell subsets—Nature's CARâ€T cells. Immunological Reviews, 2020, 298, 25-46.	2.8	29
1821	Expression of Inhibitory Receptors on T and NK Cells Defines Immunological Phenotypes of HCV Patients with Advanced Liver Fibrosis. IScience, 2020, 23, 101513.	1.9	11
1822	Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients. International Journal of Molecular Sciences, 2020, 21, 7295.	1.8	49
1823	The Oncometabolite 5′-Deoxy-5′-Methylthioadenosine Blocks Multiple Signaling Pathways of NK Cell Activation. Frontiers in Immunology, 2020, 11, 2128.	2.2	6
1824	Manufacturing of natural killer cells for treating solid malignancies. Journal of Immunology and Regenerative Medicine, 2020, 10, 100031.	0.2	0
1825	Immune reaction and regulation in transplantation based on pluripotent stem cell technology. Inflammation and Regeneration, 2020, 40, 12.	1.5	20
1826	Effects of obesity on NK cells in a mouse model of postmenopausal breast cancer. Scientific Reports, 2020, 10, 20606.	1.6	11
1827	Emerging Role of Extracellular Vesicles in Immune Regulation and Cancer Progression. Cancers, 2020, 12, 3563.	1.7	44
1828	Suppression of Non-Random Fertilization by MHC Class I Antigens. International Journal of Molecular Sciences, 2020, 21, 8731.	1.8	1
1829	Immune phenotype of patients with stage IV metastatic inflammatory breast cancer. Breast Cancer Research, 2020, 22, 134.	2.2	12
1830	Roles for the FCRL6 Immunoreceptor in Tumor Immunology. Frontiers in Immunology, 2020, 11, 575175.	2.2	16
1831	Recent Advances in the Role of Natural Killer Cells in Acute Kidney Injury. Frontiers in Immunology, 2020, 11, 1484.	2.2	3

#	Article	IF	Citations
1832	Natural killer cell–derived extracellular vesicles in cancer therapy. Scandinavian Journal of Immunology, 2020, 92, e12938.	1.3	22
1833	Control of Viral Infection by Natural Killer Cell Inhibitory Receptors. Cell Reports, 2020, 32, 107969.	2.9	17
1834	NK Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1273, 69-90.	0.8	60
1836	Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer. Frontiers in Immunology, 2020, 11, 2156.	2.2	49
1837	Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment. Cancers, 2020, 12, 2528.	1.7	12
1838	Epistatic interactions between killer immunoglobulin-like receptors and human leukocyte antigen ligands are associated with ankylosing spondylitis. PLoS Genetics, 2020, 16, e1008906.	1.5	12
1839	Role of Natural Killer Cells in Uveal Melanoma. Cancers, 2020, 12, 3694.	1.7	16
1840	Role of the Main Non HLA-Specific Activating NK Receptors in Pancreatic, Colorectal and Gastric Tumors Surveillance. Cancers, 2020, 12, 3705.	1.7	10
1841	Natural killer cell-based immunotherapy for acute myeloid leukemia. Journal of Hematology and Oncology, 2020, 13, 167.	6.9	55
1842	Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. Frontiers in Immunology, 2020, 11, 575609.	2.2	34
1843	A Central Role for Ly49 Receptors in NK Cell Memory. Journal of Immunology, 2020, 204, 2867-2875.	0.4	8
1844	Targeting Natural Killer Cells for Improved Immunity and Control of the Adaptive Immune Response. Frontiers in Cellular and Infection Microbiology, 2020, 10, 231.	1.8	37
1845	Current Advances in Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, , .	0.8	4
1846	The cancer–natural killer cell immunity cycle. Nature Reviews Cancer, 2020, 20, 437-454.	12.8	308
1847	A New Humanized Mouse Model Mimics Humans in Lacking α-Gal Epitopes and Secreting Anti-Gal Antibodies. Journal of Immunology, 2020, 204, 1998-2005.	0.4	7
1848	Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies. Blood Reviews, 2020, 44, 100678.	2.8	38
1849	Generation of Retinal Pigment Epithelial Cells Derived from Human Embryonic Stem Cells Lacking Human Leukocyte Antigen Class I and II. Stem Cell Reports, 2020, 14, 648-662.	2.3	35
1850	Comprehensive Phenotyping of Human PB NK Cells by Flow Cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 891-899.	1.1	21

#	ARTICLE	IF	CITATIONS
1851	N-Glycans Mediate the Ebola Virus-GP1 Shielding of Ligands to Immune Receptors and Immune Evasion. Frontiers in Cellular and Infection Microbiology, 2020, 10, 48.	1.8	11
1852	High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. Frontiers in Immunology, 2019, 10, 3123.	2.2	67
1853	Unparalleled Rapid Evolution of KIR Genes in Rhesus and Cynomolgus Macaque Populations. Journal of Immunology, 2020, 204, 1770-1786.	0.4	12
1854	Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. Cells, 2020, 9, 1578.	1.8	8
1855	Harnessing NK Cell Checkpoint-Modulating Immunotherapies. Cancers, 2020, 12, 1807.	1.7	17
1856	Extranodal NK/T-Cell Lymphomas: The Role of Natural Killer Cells and EBV in Lymphomagenesis. International Journal of Molecular Sciences, 2020, 21, 1501.	1.8	15
1857	Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?. Frontiers in Immunology, 2020, 11, 275.	2.2	101
1858	Regulation of MHC class I-independent NK cell education by SLAM family receptors. Advances in Immunology, 2020, 145, 159-185.	1.1	3
1859	A gastric cancer cell derived extracellular compounds suppresses CD161+CD3-lymphocytes and aggravates tumor formation in a syngeneic mouse model. Molecular Immunology, 2020, 120, 136-145.	1.0	2
1860	Human iPSC-Derived Neural Crest Stem Cells Exhibit Low Immunogenicity. Molecular Therapy - Methods and Clinical Development, 2020, 16, 161-171.	1.8	16
1861	Innovation in induced mesenchymal stem cell uses in therapy. , 2020, , 115-126.		0
1862	51Cr-release to monitor NK cell cytotoxicity. Methods in Enzymology, 2020, 631, 497-512.	0.4	5
1863	Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D. Frontiers in Immunology, 2020, 11, 40.	2.2	40
1864	Evolutionary perspective on the hematopoietic system through a colonial chordate: allogeneic immunity and hematopoiesis. Current Opinion in Immunology, 2020, 62, 91-98.	2.4	12
1865	NK Cell-Based Immunotherapy in Renal Cell Carcinoma. Cancers, 2020, 12, 316.	1.7	20
1866	Candida Species-Dependent Release of IL-12 by Dendritic Cells Induces Different Levels of NK Cell Stimulation. Journal of Infectious Diseases, 2020, 221, 2060-2071.	1.9	6
1867	Evaluation of serum-free media formulations in feeder cell–stimulated expansion of natural killer cells. Cytotherapy, 2020, 22, 322-328.	0.3	17
1868	Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML. Bone Marrow Transplantation, 2020, 55, 1975-1984.	1.3	8

#	Article	IF	CITATIONS
1869	Downregulation of HLA-ABC expression through promoter hypermethylation and downmodulation of MIC-A/B surface expression in LMP2A-positive epithelial carcinoma cell lines. Scientific Reports, 2020, 10, 5415.	1.6	12
1870	Production of ULBP1-KO pigs with human CD55 expression using CRISPR technology. Journal of Applied Animal Research, 2020, 48, 93-101.	0.4	4
1871	Natural Killer Cells: Tumor Surveillance and Signaling. Cancers, 2020, 12, 952.	1.7	56
1872	Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. British Journal of Pharmacology, 2020, 177, 2889-2903.	2.7	10
1873	Paths taken towards NK cell–mediated immunotherapy of human cancer—a personal reflection. Scandinavian Journal of Immunology, 2021, 93, e12993.	1.3	5
1874	Inhibitory KIR2DL2 Gene: Risk for Deep Endometriosis in Euro-descendants. Reproductive Sciences, 2021, 28, 291-304.	1.1	9
1875	Human chorionic gonadotropinâ€mediated modulation of pregnancyâ€compatible peripheral blood natural killer cells in frozen embryo transfer cycles. American Journal of Reproductive Immunology, 2021, 85, e13324.	1.2	3
1876	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cellular and Molecular Immunology, 2021, 18, 112-127.	4.8	159
1877	Tumor-Infiltrating Natural Killer Cells. Cancer Discovery, 2021, 11, 34-44.	7.7	223
1878	Chimeric antigen receptor (CAR) natural killer (NK)â€cell therapy: leveraging the power of innate immunity. British Journal of Haematology, 2021, 193, 216-230.	1.2	61
1879	Expression of human leukocyte antigen class I and β2â€microglobulin in colorectal cancer and its prognostic impact. Cancer Science, 2021, 112, 91-100.	1.7	8
1880	Natural killer cells in reproduction: Before, during and after pregnancy., 2021, , 55-72.		0
1881	Killer-cell immunoglobulin-like receptor genotype and haplotype combinations in children treated for acute lymphoblastic leukemia. Central-European Journal of Immunology, 2021, 46, 210-216.	0.4	1
1882	Natural Killer Cell Therapy in Allogeneic Hematopoietic Cell Transplantation. , 2021, , 847-857.		0
1883	The Interplay of Exosomes and NK Cells in Cancer Biology. Cancers, 2021, 13, 473.	1.7	30
1884	An immunogenetic view of COVID-19. Genetics and Molecular Biology, 2021, 44, e20210036.	0.6	10
1885	Natural Kills Cells: Cellular Biology and Role in Infections and Human Disease. , 2021, , .		0
1886	Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor \hat{l}^2 ., 2021, 9, e001740.		18

#	Article	IF	CITATIONS
1887	GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. Frontiers in Immunology, 2021, 12, 626098.	2.2	21
1888	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. Blood Advances, 2021, 5, 1069-1080.	2.5	20
1889	Uterine natural killer cells: from foe to friend in reproduction. Human Reproduction Update, 2021, 27, 720-746.	5.2	52
1890	The Immunology of Syncytialized Trophoblast. International Journal of Molecular Sciences, 2021, 22, 1767.	1.8	10
1891	Human natural killer cells in major histocompatibility complex class I deficiency. Scandinavian Journal of Immunology, 2021, 94, e13029.	1.3	3
1892	Pancreatic Cancer Stem-Like Cells With High Calreticulin Expression Associated With Immune Surveillance. Pancreas, 2021, 50, 405-413.	0.5	3
1893	Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy. Clinical and Experimental Immunology, 2021, 205, 1-11.	1,1	11
1894	Hypergravity-induced changes in actin response of breast cancer cells to natural killer cells. Scientific Reports, 2021, 11, 7267.	1.6	1
1895	Platelet-Mediated Protection of Cancer Cells From Immune Surveillance – Possible Implications for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 640578.	2.2	45
1896	Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment. Cancers, 2021, 13, 1589.	1.7	7
1897	Natural Killer Cells: From Innate to Adaptive Features. Annual Review of Immunology, 2021, 39, 417-447.	9.5	85
1900	Professional killers: The role of extracellular vesicles in the reciprocal interactions between natural killer, CD8+ cytotoxic Tâ€cells and tumour cells. Journal of Extracellular Vesicles, 2021, 10, e12075.	5.5	33
1901	Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. Frontiers in Immunology, 2021, 12, 643310.	2.2	27
1902	Uterine natural killer cells and recurrent spontaneous abortion. American Journal of Reproductive Immunology, 2021, 86, e13433.	1.2	20
1903	Human NK cells, their receptors and function. European Journal of Immunology, 2021, 51, 1566-1579.	1.6	75
1904	Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 633205.	2.2	42
1905	Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 670540.	2.2	10
1906	Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. British Journal of Cancer, 2021, 125, 422-432.	2.9	59

#	Article	IF	CITATIONS
1907	Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options. Progress in Retinal and Eye Research, 2022, 86, 100971.	7.3	35
1908	Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	38
1909	Immunological considerations and challenges for regenerative cellular therapies. Communications Biology, 2021, 4, 798.	2.0	44
1910	Natural Killer Cell Activation by Weissella cibaria JW15 Isolated from Kimchi. Journal of Bacteriology and Virology, 2021, 51, 62-73.	0.0	O
1911	Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors. Cancers, 2021, 13, 2796.	1.7	13
1912	Natural killer cells in antiviral immunity. Nature Reviews Immunology, 2022, 22, 112-123.	10.6	204
1913	Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma. Frontiers in Veterinary Science, 2021, 8, 672361.	0.9	8
1914	Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma. Cells, 2021, 10, 1369.	1.8	6
1915	Natural Killer Cell Activation by Weissella cibaria JW15 Isolated from Kimchi. Journal of Bacteriology and Virology, 2021, 51, 62-73.	0.0	2
1916	NKG2D Natural Killer Cell Receptor—A Short Description and Potential Clinical Applications. Cells, 2021, 10, 1420.	1.8	22
1917	Emerging nanomaterials for cancer immunotherapy. Exploration of Medicine, 2021, 2, 208-231.	1.5	1
1918	Human Keratinocytes Inhibit CD4+ T-Cell Proliferation through TGFB1 Secretion and Surface Expression of HLA-G1 and PD-L1 Immune Checkpoints. Cells, 2021, 10, 1438.	1.8	9
1919	Research advances on the immune research and prospect of immunotherapy in pituitary adenomas. World Journal of Surgical Oncology, 2021, 19, 162.	0.8	13
1920	Evolution of Cellular Immunity Effector Cells; Perspective on Cytotoxic and Phagocytic Cellular Lineages. Cells, 2021, 10, 1853.	1.8	8
1921	Infusion reactions in natural killer cell immunotherapy: a retrospective review. Cytotherapy, 2021, 23, 627-634.	0.3	7
1922	CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Research and Therapy, 2021, 12, 374.	2.4	33
1923	Dynamic mRNA expression of donorâ€derived activating KIR genes and their significant effects on clinical outcome after haematopoietic stem cell transplantation. Clinical and Experimental Immunology, 2021, 205, 417-428.	1.1	2
1924	Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy. Cancer Letters, 2021, 511, 68-76.	3.2	33

#	Article	IF	CITATIONS
1925	Implications of a â€~Third Signal' in NK Cells. Cells, 2021, 10, 1955.	1.8	3
1926	Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer. Frontiers in Oncology, 2021, 11, 682075.	1.3	6
1927	Relevance of Polymorphic KIR and HLA Class I Genes in NK-Cell-Based Immunotherapies for Adult Leukemic Patients. Cancers, 2021, 13, 3767.	1.7	10
1928	Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma., 2021, 9, e002958.		10
1929	The Role of Natural Killer Cells in Soft Tissue Sarcoma: Prospects for Immunotherapy. Cancers, 2021, 13, 3865.	1.7	4
1930	Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2022, 71, 589-599.	2.0	17
1931	NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors. Molecular Aspects of Medicine, 2021, 80, 100968.	2.7	5
1932	Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients. Transplantation and Cellular Therapy, 2021, 27, 686.e1-686.e9.	0.6	3
1933	Effect of Conventional Chemotherapies on Natural Killer Cell Activity. Current Cancer Therapy Reviews, 2021, 17, 251-254.	0.2	0
1934	Role of Toll‑like receptors in natural killer cell function in acute lymphoblastic leukemia (Review). Oncology Letters, 2021, 22, 748.	0.8	3
1935	Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFN \hat{I}^3 /STAT1 Signaling in Hepatocellular Carcinoma Cells. Frontiers in Oncology, 2021, 11, 707473.	1.3	6
1936	MICA and KIR: Immunogenetic Factors Influencing Left Ventricular Systolic Dysfunction and Digestive Clinical Form of Chronic Chagas Disease. Frontiers in Immunology, 2021, 12, 714766.	2.2	1
1937	Generation of Monkey Induced Pluripotent Stem Cell-Derived Cartilage Lacking Major Histocompatibility Complex Class I Molecules on the Cell Surface. Tissue Engineering - Part A, 2022, 28, 94-106.	1.6	6
1938	From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies. Frontiers in Oncology, 2021, 11, 720501.	1.3	47
1939	KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia. ImmunoHorizons, 2021, 5, 687-702.	0.8	2
1940	Analysis of Several Pathways for Efficient Killing of Prostate Cancer Stem Cells: A Central Role of NF-κB RELA. International Journal of Molecular Sciences, 2021, 22, 8901.	1.8	10
1941	Microglia and Perivascular Macrophages Act as Antigen Presenting Cells to Promote CD8 T Cell Infiltration of the Brain. Frontiers in Immunology, 2021, 12, 726421.	2.2	53
1942	Exhausted NK cells and cytokine storms in COVID-19: Whether NK cell therapy could be a therapeutic choice. Human Immunology, 2022, 83, 86-98.	1.2	37

#	ARTICLE	IF	CITATIONS
1943	The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies. Frontiers in Immunology, 2021, 12, 737311.	2.2	28
1944	Natural killer cellâ€'based immunotherapy for lung cancer: Challenges and perspectives (Review). Oncology Reports, 2021, 46, .	1.2	14
1945	Extracellular matrix protein N-glycosylation mediates immune self-tolerance in <i>Drosophila melanogaster</i> . Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	7
1946	Killer immunoglobulin-like receptor 2DS5 is associated with recovery from coronavirus disease 2019. Intensive Care Medicine Experimental, 2021, 9, 45.	0.9	5
1947	Immunomodulatory Effect of Irreversible Electroporation Alone and Its Cooperating With Immunotherapy in Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 712042.	1.3	15
1948	Activation Status Dictates the Function of Unlicensed Natural Killer Cells. Blood Advances, 2021, 5, 4219-4232.	2.5	1
1949	Advances in generating HLA-Universal platelets for transfusion medicine. Journal of Immunology and Regenerative Medicine, 2021, 14, 100053.	0.2	0
1950	Role of Heat Shock Proteins in Immune Modulation in Malaria. Advances in Experimental Medicine and Biology, 2021, 1340, 169-186.	0.8	1
1951	Adoptive NK cell therapies in children with cancer: Clinical challenges and future possibilities. , 2021, , 405-437.		0
1952	Towards a Conceptual Framework for Innate Immunity. Lecture Notes in Computer Science, 2005, , 112-125.	1.0	41
1953	Heat Shock Proteins in Immunity. , 2006, , 279-304.		77
1954	Fever, Pyrogens and Cancer., 2006,, 276-337.		7
1955	Cellular Adoptive Immunotherapy After Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, 2009, 144, 497-537.	0.2	5
1956	Natural Killer Cell Activity and Killer Immunoglobulin-Like Receptors in Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, 2009, 144, 47-69.	0.2	4
1957	THE NK/DC COMPLOT. Advances in Experimental Medicine and Biology, 2009, 633, 7-16.	0.8	8
1958	Immune Effector Cells in the Tumor Microenvironment: Their Role in Regulation of Tumor Progression. , 2008, , 1-33.		3
1959	KIR Genes and Their Role in Spondyloarthropathies. Advances in Experimental Medicine and Biology, 2009, 649, 286-299.	0.8	14
1960	Bridging Innate NK Cell Functions with Adaptive Immunity. Advances in Experimental Medicine and Biology, 2011, 780, 45-55.	0.8	32

#	Article	IF	CITATIONS
1961	Contemplations on the Evolution of PRO- and Eukaryotic Mono(ADP-Ribosyl)Transferases in the Context of the Immune System. Advances in Experimental Medicine and Biology, 1997, 419, 453-458.	0.8	1
1962	Immunobiological Characterization of the Trophoblast-Decidual Interface in Human Pregancy. , 1994, , 3-13.		5
1963	Natural Killer Cells and Killer-Cell Immunoglobulin-Like Receptor Polymorphisms: Their Role in Hematopoietic Stem Cell Transplantation. Methods in Molecular Biology, 2014, 1109, 139-158.	0.4	5
1964	Development of Self-Recognition Systems in Natural Killer Cells. Advances in Experimental Medicine and Biology, 1998, 452, 1-12.	0.8	9
1965	Class I MHC Antigens and the Control of Virus Infections by NK Cells. , 1993, , 400-406.		2
1966	Nonvillous Parts and Trophoblast Invasion. , 2000, , 171-272.		54
1967	Corneal Immunosuppressive Mechanisms, Anterior Chamber-Associated Immune Deviation (ACAID) and Their Role in Allograft Rejection. Methods in Molecular Biology, 2016, 1371, 205-214.	0.4	15
1968	Retroviral Gene Transfer into Primary Human Natural Killer Cells. Methods in Molecular Biology, 2009, 506, 127-137.	0.4	11
1969	Hepatic NK, NKT, and T Cells., 2007, , 71-82.		2
1970	Analysis of Individual Natural Killer Cell Responses. , 2008, 415, 179-196.		12
1971	Mammalian Host Defenses: Innate and Adaptive Immunity. , 2009, , 577-626.		2
1972	KIR Genotyping by Multiplex PCR-SSP. Methods in Molecular Biology, 2010, 612, 365-375.	0.4	52
1973	Assessing Licensing of NK Cells. Methods in Molecular Biology, 2010, 612, 39-49.	0.4	23
1974	Tumor Challenges in Immunotoxicity Testing. Methods in Molecular Biology, 2010, 598, 143-155.	0.4	8
1975	Recent Advances in Hematopoietic Stem Cell Transplantation and Perspectives of RNAi Applications. Methods in Molecular Biology, 2010, 629, 505-521.	0.4	2
1976	MHC Class I Molecules and Cancer Progression: Lessons Learned from Preclinical Mouse Models. , 2020, , 189-204.		1
1977	Overview of Basic Immunology and Clinical Application. Advances in Experimental Medicine and Biology, 2020, 1244, 1-36.	0.8	8
1978	Natural Killer Cell Immunotherapy for Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, 1257, 141-154.	0.8	11

#	Article	IF	CITATIONS
1979	HSP60-peptide interference with CD94/NKG2 receptors. , 2003, , 257-272.		1
1980	Natural Killer Cells for Osteosarcoma. Advances in Experimental Medicine and Biology, 2014, 804, 341-353.	0.8	28
1981	Cmv1 and Natural Killer Cell Responses to Murine Cytomegalovirus Infection. Current Topics in Microbiology and Immunology, 2008, 321, 101-122.	0.7	38
1982	Inhibitory and Regulatory Immune Synapses. Current Topics in Microbiology and Immunology, 2010, 340, 63-79.	0.7	22
1983	Toward a Quantitative Analysis of the Repertoire of Class I MHC-Specific Inhibitory Receptors on Natural Killer Cells. Current Topics in Microbiology and Immunology, 1998, 230, 135-160.	0.7	18
1984	Ontogeny and Differentiation of Murine Natural Killer Cells and Their Receptors. Current Topics in Microbiology and Immunology, 1998, 230, 161-190.	0.7	4
1985	Killer Cell Inhibitory Receptor Expression by T Cells. Current Topics in Microbiology and Immunology, 1998, 230, 25-39.	0.7	20
1986	The CD94/NKG2 C-Type Lectin Receptor Complex. Current Topics in Microbiology and Immunology, 1998, 230, 41-52.	0.7	39
1987	Triggering of Natural Killer Cell Mediated Cytotoxicity by Costimulatory Molecules. Current Topics in Microbiology and Immunology, 1998, 230, 53-61.	0.7	12
1988	Fc Receptors on Natural Killer Cells. Current Topics in Microbiology and Immunology, 1998, 230, 63-88.	0.7	65
1989	Signal Transduction During NK Cell Activation: Balancing Opposing Forces. Current Topics in Microbiology and Immunology, 1998, 230, 103-122.	0.7	25
1990	ILT Receptors at the Interface Between Lymphoid and Myeloid Cells. Current Topics in Microbiology and Immunology, 2000, 251, 161-166.	0.7	31
1991	gp49: An Ig-like Receptor with Inhibitory Properties on Mast Cells and Natural Killer Cells. Current Topics in Microbiology and Immunology, 1999, 244, 107-113.	0.7	3
1992	Immunobiology of the Decidua. Current Topics in Microbiology and Immunology, 1997, 222, 45-66.	0.7	9
1993	Recognition by Immune Cells. Molecular Biology Intelligence Unit, 1997, , 371-447.	0.2	1
1994	Maternal Alloimmune Stimulation: Variable actions. , 1999, , 205-217.		2
1995	Alternatively spliced Ly-49D and H transcripts are found in IL-2-activated NK cells. Immunogenetics, 1996, 44, 478-482.	1.2	3
1996	Polymorphic KIR-HLA System Regulates Natural Killer Cell Response. , 2016, , 369-380.		1

#	Article	IF	CITATIONS
1997	Emerging Concepts for the Pathogenesis of Chronic Disabling Inflammatory Diseases: Neuroendocrine-immune Interactions and Evolutionary Biology., 2007,, 217-231.		7
1998	Immunology of Graft Rejection. , 2008, , 9-32.		1
1999	NK cells in autoimmune diseases: Linking innate and adaptive immune responses. Autoimmunity Reviews, 2018, 17, 142-154.	2.5	94
2000	Using genome editing to engineer universal platelets. Emerging Topics in Life Sciences, 2019, 3, 301-311.	1.1	7
2001	Enhancement of Tumor Cell Lysis by Natural Killer Cells after Blocking of HLA-Monomorphic Determinant Using F(ab')2 Fragment of W6/32. Cancer Detection and Prevention, 1998, 22, 168-175.	2.1	2
2002	XENOGRAFT REJECTION OF PORCINE ISLET-LIKE CELL CLUSTERS IN NORMAL AND NATURAL KILLER CELL-DEPLETED MICE1. Transplantation, 1996, 61, 1313-1320.	0.5	80
2003	MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I-INDEPENDENT KILLING OF XENOGENEIC TARGETS BY RAT ALLOSPECIFIC NATURAL KILLER CELLS1. Transplantation, 1997, 63, 119-123.	0.5	15
2004	CYTOLYTIC ACTIVITY AGAINST ALLOGENEIC HUMAN ENDOTHELIA. Transplantation, 1998, 66, 67-77.	0.5	21
2005	HLA-G EXPRESSION PROTECTS PORCINE ENDOTHELIAL CELLS AGAINST NATURAL KILLER CELL-MEDIATED XENOGENEIC CYTOTOXICITY1,2. Transplantation, 1999, 67, 31-37.	0.5	57
2006	NATURAL KILLER CELL AND ???? AND ???? LYMPHOCYTE TRAFFIC INTO THE LIVER GRAFT IMMEDIATELY AFTER LIVER TRANSPLANTATIONone. Transplantation, 2000, 69, 633-639.	0.5	22
2007	ALLOREACTIVITY OF NATURAL KILLER CELLS IN ALLOGENEIC LIVER TRANSPLANTATION 1,2. Transplantation, 2001, 72, 116-122.	0.5	33
2008	Viral proteins that regulate cellular signalling Journal of General Virology, 1998, 79, 1323-1335.	1.3	30
2011	Innate Natural Killer Cell Responses to Infection. , 0, , 133-155.		1
2012	Mycobacterium leprae renders Schwann cells and mononuclear phagocytes susceptible or resistant to killer cells. Infection and Immunity, 1991, 59, 684-688.	1.0	27
2013	Cytotoxic T cells isolated from the central nervous systems of mice infected with Theiler's virus. Journal of Virology, 1991, 65, 6612-6620.	1.5	115
2014	Major histocompatibility complex class I antigens and the control of viral infections by natural killer cells. Journal of Virology, 1995, 69, 3967-3971.	1.5	93
2015	Inflammatory infiltration of the upper airway epithelium during Sendai virus infection: involvement of epithelial dendritic cells. Journal of Virology, 1997, 71, 226-236.	1.5	81
2016	Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. Journal of Virology, 1997, 71, 267-275.	1.5	282

#	Article	IF	CITATIONS
2017	ITAMs versus ITIMs: striking a balance during cell regulation. Journal of Clinical Investigation, 2002, 109, 161-168.	3.9	157
2018	Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression Journal of Clinical Investigation, 1991, 87, 284-292.	3.9	282
2019	Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene Journal of Clinical Investigation, 1991, 88, 282-289.	3.9	60
2020	Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA Journal of Clinical Investigation, 1993, 91, 684-692.	3.9	79
2021	ITAMs versus ITIMs: striking a balance during cell regulation. Journal of Clinical Investigation, 2002, 109, 161-168.	3.9	86
2022	Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. Journal of Clinical Investigation, 2008, 118, 1017-26.	3.9	141
2023	Natural killer cells in herpesvirus infections. F1000Research, 2017, 6, 1231.	0.8	9
2024	Characterization of Greenbeard Genes Involved in Long-Distance Kind Discrimination in a Microbial Eukaryote. PLoS Biology, 2016, 14, e1002431.	2.6	49
2025	Nucleosome Presence at AML-1 Binding Sites Inversely Correlates with Ly49 Expression: Revelations from an Informatics Analysis of Nucleosomes and Immune Cell Transcription Factors. PLoS Computational Biology, 2016, 12, e1004894.	1.5	3
2026	CD100 on NK Cells Enhance IFNÎ ³ Secretion and Killing of Target Cells Expressing CD72. PLoS ONE, 2007, 2, e818.	1.1	30
2027	Matched Sizes of Activating and Inhibitory Receptor/Ligand Pairs Are Required for Optimal Signal Integration by Human Natural Killer Cells. PLoS ONE, 2010, 5, e15374.	1.1	45
2028	Natural Killer Cell Mediated Missing-Self Recognition Can Protect Mice from Primary Chronic Myeloid Leukemia In Vivo. PLoS ONE, 2011, 6, e27639.	1.1	14
2029	Plasmodium falciparum-Infected Erythrocytes Induce Granzyme B by NK Cells through Expression of Host-Hsp70. PLoS ONE, 2012, 7, e33774.	1.1	84
2030	Decrease of Peripheral and Intestinal NKG2A-Positive T Cells in Patients with Ulcerative Colitis. PLoS ONE, 2012, 7, e44113.	1.1	2
2031	Association of HLA Class-I and Inhibitory KIR Genotypes in Gabonese Patients Infected by Chikungunya or Dengue Type-2 Viruses. PLoS ONE, 2014, 9, e108798.	1.1	23
2032	Killer Cell Immunoglobulin-Like Receptor Alleles Alter HIV Disease in Children. PLoS ONE, 2016, 11, e0151364.	1.1	10
2033	Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors—A Retrospective Study. PLoS ONE, 2017, 12, e0169512.	1.1	28
2034	KIR content genotypes associate with carriage of hepatitis B surface antigen, e antigen and HBV viral load in Gambians. PLoS ONE, 2017, 12, e0188307.	1.1	13

#	Article	IF	CITATIONS
2035	Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress and Chaperones, 2003, 8, 348.	1.2	102
2036	Use of Immune Modulator Interferon-Gamma to Support Combating COVID-19 Pandemic. International Journal of Coronaviruses, 2020, $1, 1-15$.	0.8	3
2037	Natural killer cells in autoimmunity: clues or tools?. Inflammation and Cell Signaling, 0, , .	1.6	3
2039	Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget, 2015, 6, 26982-26994.	0.8	27
2040	Towards a Conceptual Framework for Innate Immunity. SSRN Electronic Journal, 0, , .	0.4	7
2041	Cytomegalovirus and Tumors: Two Players for One Goal-Immune Escape. The Open Virology Journal, 2011, 5, 60-69.	1.8	23
2042	The Antitumor Immunity Mediated by NK Cells: The Role of The NCRs. The Open Cancer Immunology Journal, 2018, 07, 7-15.	0.2	1
2043	"Liï½ï½‰ï½" ーï½ï½†½†ï½°ï½"â€ç°èfžæ´»æ€§åŒ−ã®ãŸã,ã®â€œè"è,ªã®ç― Japanese Journal	l of.C linica	l I mmunolo
2044	Medawar's Paradox and Immune Mechanisms of Fetomaternal Tolerance. , 2020, 4, 1-26.		21
2045	Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3797-3803.	0.5	8
2046	Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies. Frontiers in Immunology, 2020, 11, 607030.	2.2	14
2047	The Role of Immune Checkpoint Blockade in Uveal Melanoma. International Journal of Molecular Sciences, 2020, 21, 879.	1.8	57
2048	The Influence of Culture Medium Type on Cellular Phenotype of Canine Adipose Derived Stem Cells. Open Journal of Regenerative Medicine, 2014, 03, 28-37.	0.5	2
2049	Killer Cell Immunoglobulin-like Receptor (KIR) Analysis in Adult Korean Patients with Acute Myeloid Leukemia. The Korean Journal of Hematology, 2006, 41, 139.	0.7	2
2050	Immunological aspects of liver cell transplantation. World Journal of Transplantation, 2016, 6, 42.	0.6	22
2051	When and How to Evaluate the Natural Killer Cell Function. Annual Research & Review in Biology, 2014, 4, 3586-3614.	0.4	2
2052	LIRâ€1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibodyâ€dependent cellular cytotoxicity. Clinical and Translational Immunology, 2021, 10, e1346.	1.7	8
2053	Epithelial cells remove precancerous cells by cell competition via MHC class l–LILRB3 interaction. Nature Immunology, 2021, 22, 1391-1402.	7.0	22

#	ARTICLE	IF	CITATIONS
2054	The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 11385.	1.8	7
2055	Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. Cancers, 2021, 13, 4986.	1.7	6
2056	Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions. Journal of Experimental and Clinical Cancer Research, 2021, 40, 333.	3.5	8
2057	Searching for the Elusive Regulatory Innate Lymphoid Cell. Journal of Immunology, 2021, 207, 1949-1957.	0.4	10
2058	The Genomic Organization of the LILR Region Remained Largely Conserved Throughout Primate Evolution: Implications for Health And Disease. Frontiers in Immunology, 2021, 12, 716289.	2.2	8
2059	The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review. International Immunopharmacology, 2021, 101, 108220.	1.7	6
2060	Adhesional Chemokine, fractalkine. Japanese Journal of Clinical Immunology, 2000, 23, 90-102.	0.0	0
2061	The Uteroplacental Circulation: Extravillous Trophoblast. , 2000, , 89-129.		3
2062	Synergistic effects of in vivo depletion of Ly-49A and Ly-49G2 natural killer cell subsets in the rejection of H2b bone marrow cell allografts. Blood, 2000, 95, 3840-3844.	0.6	2
2063	CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis. Blood, 2000, 96, 224-233.	0.6	O
2064	NK cells. , 2001, , 245-254.		0
2065	Function of the transporter associated with antigen processing (TAP) in cellular immunity, tumor escape, and virus persistence., 2003,, 319-337.		0
2068	Prinzipien der Tumorimmunologie. , 2006, , 101-169.		0
2069	Die Immunologie im Überblick. , 2007, , 251-277.		O
2070	Immunopathogenesis and Outcomes of Recurrent Hepatitis C., 2007,, 459-470.		0
2073	Haploidentical Stem Cell Transplantation. , 2008, , 289-317.		O
2074	Innate Immunity to Mouse Cytomegalovirus. , 2008, , 445-456.		0
2075	A relevância das células natural killer (NK) e killer immunoglobulin-like receptors (KIR) no transplante de células-tronco hematopoéticas (TCTH). Revista Brasileira De Hematologia E Hemoterapia, 2008, 30, .	0.7	O

#	Article	IF	Citations
2076	Natural killer cells and immune surveillance. Jornal De Pediatria, 2008, 84, 58-67.	0.9	7
2077	State-of-the-Art Lecture: The liver as an immune organ. , 2009, , 77-86.		O
2078	Progesterone, Pregnancy, and Innate Immunity. , 2010, , 205-226.		0
2079	Natural Killer Cells in the Treatment of Human Cancer. , 2010, , 405-421.		O
2080	Hematopoietic Cell Transplantation from Partially HLA-Mismatched (HLA-Haploidentical) Related Donors., 2010,, 299-343.		0
2082	Natural killer (NK) cell neoplasms. , 2010, , 659-680.		0
2083	Hematopoietic Stem Cell Transplantation Across Genetic Barriers Using a Nonmyeloablative Conditioning Regimen., 2010,, 119-162.		0
2084	Physiological and Pathological Aspects of Human NK Cells. , 0, , .		0
2085	MHC Class I Antigens and the Tumor Microenvironment. , 2013, , 253-286.		0
2086	Aspects of Research in Progress and Controversies in Immunology. Journal of Immunological Techniques in Infectious Diseases, 2013, 02, .	0.1	0
2087	The role of NK cell on hematopoietic cell transplantation. Journal of Hematopoietic Cell Transplantation, 2013, 2, 85-93.	0.1	0
2088	Immunogenicity of Stem Cells. Advances in Medical Technologies and Clinical Practice Book Series, 2013, , 96-111.	0.3	0
2089	Overview of MHC Class I Antigens. , 2013, , 1-11.		0
2091	Role of Heat Shock Proteins in Immune Modulation in Malaria. , 2014, , 119-132.		2
2093	The role of Killer Cell Immunoglobulin-like Receptors in cure by Hematopoietic Stem Cell Transplantation. Journal of Hematopoietic Cell Transplantation, 2014, 3, 12-26.	0.1	0
2094	Natural Killer Cell Mediated Defence Directed Selectively Against Target Cells Lacking MHC Class I Gene Products. Hamatologie Und Bluttransfusion, 1992, , 267-278.	0.0	0
2096	Human Trophoblast-Uterine Immunological Interactions. , 1993, , 151-159.		1
2097	Veto Cells and the Induction of Transplant Tolerance in Primates. , 1994, , 291-323.		0

#	Article	IF	CITATIONS
2098	Immunobiology of MHC Class I-Deficient Mice. , 1994, , 267-295.		0
2099	Evolution of Class I HLA Antigen Presenting Molecules. , 1994, , 161-172.		0
2100	Role of Decidual Large Granular Lymphocytes/Natural Killer Cells in Human Implantation. , 1995, , 268-274.		0
2101	Prinzipien der Tumorimmunologie., 1996,, 53-85.		0
2103	The Immunopathology of Recurrent Abortion. Current Topics in Microbiology and Immunology, 1997, 222, 189-203.	0.7	1
2104	Interleukin-12–Activated Natural Killer Cells Recognize B7 Costimulatory Molecules on Tumor Cells and Autologous Dendritic Cells. Blood, 1998, 91, 196-206.	0.6	11
2105	Tumour immunology. , 1998, , 73-87.		1
2106	Molecular Typing Shows a High Level of HLA Class I Incompatibility in Serologically Well Matched Donor/Patient Pairs: Implications for Unrelated Bone Marrow Donor Selection. Blood, 1998, 92, 4864-4871.	0.6	2
2107	Inhibitory Role of Murine Ly49 Lectin-like Receptors on Natural Killer Cells. Current Topics in Microbiology and Immunology, 1999, 244, 97-105.	0.7	2
2108	MHC Class I Molecules and Cancer Progression: Lessons Learned from Preclinical Mouse Models. , 2015, , 161-175.		0
2110	Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas. , 2015, , 319-332.		0
2111	Immunology of Uveitis., 2016,, 39-81.		0
2112	Killer Cell Immunoglobulin-Like Receptors in Clinical Transplantation. , 0, , 1150-1160.		0
2114	Mobile Innate Immune Cells. , 2018, , 115-158.		0
2115	Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies. Clinical Hematology International, 2019, 1, 134-141.	0.7	2
2116	Role of KIR typing in donor selection prior to allogeneic hematopoietic stem cell transplantation: literature review. Oncogematologiya, 2019, 13, 67-74.	0.1	0
2117	Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Coexpression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung. Journal of Pathology and Translational Medicine, 2019, 53, 86-93.	0.4	3
2119	Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas. , 2020, , 363-378.		0

#	Article	IF	Citations
2120	Natural killer cells and immunotherapy based on monoclonal antibodies. Biomedical Reviews, 2021, 31, 61.	0.6	0
2121	Resistance of KIR Ligand–Missing Leukocytes to NK Cells In Vivo in Patients with Acquired Aplastic Anemia. ImmunoHorizons, 2020, 4, 430-441.	0.8	2
2122	Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies. ImmunoTargets and Therapy, 2021, Volume 10, 387-407.	2.7	9
2123	Effective Murine Model Induction for Niche Study in Immune Cells Against Leukemia. Advances in Experimental Medicine and Biology, 2020, 1232, 415-420.	0.8	1
2124	Signaling Pathways Governing Activation of Innate Immune Cells. , 2020, , 93-131.		0
2127	Core Concepts in Immunology: The Definition of Autoimmunity and Its Unique Application to the Seat of Tolerance, the Liver. , 2020, , 1-16.		0
2131	Molekulare Mechanismen der Abwehr konnataler und perinataler Virusinfektionen., 2005,, 507-529.		0
2132	Innate Immunity in Type C Hepatitis. , 2008, , 1-15.		0
2133	Surgical Therapy for Atrial Fibrillation. , 2008, , 225-232.		0
2140	A novel type of class I gene organization in vertebrates: a large family of non-MHC-linked class I genes is expressed at the RNA level in the amphibian Xenopus. EMBO Journal, 1993, 12, 4385-96.	3.5	60
2141	Low-dose human cytomegalovirus infection of human fibroblast cultures induces lymphokine-activated killer cell resistance: interferon-beta-mediated target cell protection does not correlate with up-regulation of HLA class I surface molecules. Immunology, 1994, 82, 171-7.	2.0	4
2142	A novel role for MHC class II antigens: evidence implicating a protective effect on tumour cells against cytotoxicity by NK and LAK cells. Immunology, 1994, 83, 240-4.	2.0	13
2143	Protection against natural killer cells by interferon-gamma treatment of K562 cells cannot be explained by augmented major histocompatibility complex class I expression. Immunology, 1994, 83, 75-80.	2.0	22
2144	Role of major histocompatibility complex class I antigens in modulating the performance of murine tumour cells in cold target competition assays. Immunology, 1995, 84, 86-90.	2.0	11
2146	Crosstalk between macrophages and natural killer cells in the tumor microenvironment. International Immunopharmacology, 2021, 101, 108374.	1.7	23
2147	The New Kid on the Block: HLA-C, a Key Regulator of Natural Killer Cells in Viral Immunity. Cells, 2021, 10, 3108.	1.8	6
2148	A Transcriptional Signature of IL-2 Expanded Natural Killer Cells Predicts More Favorable Prognosis in Bladder Cancer. Frontiers in Immunology, 2021, 12, 724107.	2.2	17
2149	Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 750022.	1.8	18

#	Article	IF	CITATIONS
2150	Donor activating killer cell immunoglobulinâ€like receptors genes correlated with Epstein–Barr virus reactivation after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2022, 196, 1007-1017.	1.2	4
2151	Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance. Molecular Therapy - Oncolytics, 2021, 23, 547-559.	2.0	5
2152	Immune System in Action. Advances in Experimental Medicine and Biology, 2021, 1342, 1-43.	0.8	0
2153	usEPs as a Possible Immunotherapy. Series in Bioengineering, 2021, , 419-451.	0.3	0
2155	Natural Killer Cells in the Malignant Niche of Multiple Myeloma. Frontiers in Immunology, 2021, 12, 816499.	2.2	14
2156	High-resolution human KIR genotyping. Immunogenetics, 2022, 74, 369-379.	1.2	9
2157	Viral immune evasins impact antigen presentation by allele-specific trapping of MHCÂI at the peptide-loading complex. Scientific Reports, 2022, 12, 1516.	1.6	3
2158	The Immunology of Preeclampsia. , 2022, , 131-153.		0
2159	Natural killer cells. , 2022, , 213-216.		1
2160	A Hot Topic: Cancer Immunotherapy and Natural Killer Cells. International Journal of Molecular Sciences, 2022, 23, 797.	1.8	6
2161	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters. Frontiers in Immunology, 2021, 12, 804988.	2.2	5
2163	Pioneer Role of Extracellular Vesicles as Modulators of Cancer Initiation in Progression, Drug Therapy, and Vaccine Prospects. Cells, 2022, 11, 490.	1.8	21
2164	Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia. Cancer Immunology Research, 2022, 10, 291-302.	1.6	17
2165	Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. Cell Reports Medicine, 2022, 3, 100508.	3.3	20
2166	Killer Cell Immunoglobulin-Like Receptor Haplotype B Modulates Susceptibility to EBV-Associated Classic Hodgkin Lymphoma. Frontiers in Immunology, 2022, 13, 829943.	2.2	4
2167	KIR2DS1–HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials. Lancet Haematology,the, 2022, 9, e133-e142.	2.2	5
2168	The War Is on: The Immune System against Glioblastomaâ€"How Can NK Cells Drive This Battle?. Biomedicines, 2022, 10, 400.	1.4	5
2169	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). European Journal of Immunology, 2021, 51, 2708-3145.	1.6	198

#	ARTICLE	IF	CITATIONS
2170	Immunological tolerance in the evolution of male pregnancy. Molecular Ecology, 2023, 32, 819-840.	2.0	13
2171	The Immunogenetics of Alopecia areata. Advances in Experimental Medicine and Biology, 2022, 1367, 19-59.	0.8	6
2172	Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies. International Journal of Biological Sciences, 2022, 18, 1974-1988.	2.6	9
2173	Practical Considerations and Workflow in Utilizing KIR Genotyping in Transplantation Medicine. Methods in Molecular Biology, 2022, 2463, 291-310.	0.4	2
2174	Natural killer cell-based strategies for immunotherapy of cancer. Advances in Protein Chemistry and Structural Biology, 2022, 129, 91-133.	1.0	6
2175	Engineered Cell Membrane-Derived Nanocarriers: The Enhanced Delivery System for Therapeutic Applications. Frontiers in Cell and Developmental Biology, 2022, 10, 844050.	1.8	5
2176	Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. Frontiers in Immunology, 2022, 13, 844866.	2.2	68
2177	SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells. Cell Reports, 2022, 38, 110503.	2.9	31
2178	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. Communications Biology, 2022, 5, 271.	2.0	14
2179	T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion., 2022, 10, e003715.		10
2180	Expression of the Nonclassical MHC Class I, Saha-UD in the Transmissible Cancer Devil Facial Tumour Disease (DFTD). Pathogens, 2022, 11, 351.	1.2	0
2181	Negative Regulation and Protective Function of Natural Killer Cells in HIV Infection: Two Sides of a Coin. Frontiers in Immunology, 2022, 13, 842831.	2.2	6
2182	Influence of Fetomaternal Microchimerism on Maternal NK Cell Reactivity against the Child's Leukemic Blasts. Biomedicines, 2022, 10, 603.	1.4	1
2183	Comparative genetics of KIR haplotype diversity in humans and rhesus macaques: the balancing act. Immunogenetics, 2022, , $1.$	1.2	4
2184	Innate lymphoid cells in colorectal cancer. Scandinavian Journal of Immunology, 2022, 95, e13156.	1.3	10
2185	Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nature Reviews Drug Discovery, 2022, 21, 559-577.	21.5	68
2186	Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. Molecular Immunology, 2022, 144, 58-70.	1.0	23
2187	Unlaid Eggs: Ovarian Damage after Low-Dose Radiation. Cells, 2022, 11, 1219.	1.8	2

#	Article	IF	Citations
2188	Multifunctional nanomedicines for synergistic photodynamic immunotherapy based on tumor immune microenvironment. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 173, 103-120.	2.0	1
2189	Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. International Journal of Molecular Sciences, 2021, 22, 13311.	1.8	54
2190	Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies. Cancers, 2022, 14, 183.	1.7	8
2191	Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life, 2021, 11, 1355.	1.1	8
2192	Donor NK and T Cells in the Periphery of Lung Transplant Recipients Contain High Frequencies of Killer Cell Immunoglobulin-Like Receptor-Positive Subsets. Frontiers in Immunology, 2021, 12, 778885.	2.2	4
2193	Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression. Journal of Immunology, 2022, 208, 492-500.	0.4	5
2194	Lessons from transmissible cancers for immunotherapy and transplant. Immunological Medicine, 2022, 45, 146-161.	1.4	1
2195	Single-cell RNA-sequencing reveals distinct immune cell subsets and signaling pathways in IgA nephropathy. Cell and Bioscience, 2021, 11, 203.	2.1	11
2196	Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia. Frontiers in Immunology, 2021, 12, 796072.	2.2	2
2197	Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors. International Journal of Molecular Sciences, 2022, 23, 164.	1.8	14
2198	Effect of cytokines on NK cell activity and activating receptor expression in high-risk cutaneous melanoma patients. European Cytokine Network, 2019, 30, 160-167.	1.1	5
2199	The tricks for fighting against cancer using CAR NK cells: A review. Molecular and Cellular Probes, 2022, 63, 101817.	0.9	5
2233	Monoclonal antibodies with various reactivity to p58 killer inhibitory receptors. Hybridoma, 1999, 18, 521-7.	0.9	0
2234	KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection. Frontiers in Immunology, 2022, 13, 821533.	2.2	7
2236	A novel magnetically controlled bioreactor for ex vivo expansion of NK-92 cells. Bioresources and Bioprocessing, 2022, 9, .	2.0	0
2237	Adaptive Immune Responses and Immunity to SARS-CoV-2. Frontiers in Immunology, 2022, 13, .	2.2	39
2238	Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nature Communications, 2022, 13, 2576.	5.8	21
2239	Immunogenomics of Killer Cell Immunoglobulin-Like Receptor (KIR) and HLA Class I: Coevolution and Consequences for Human Health. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1763-1775.	2.0	15

#	Article	IF	CITATIONS
2240	Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy. International Immunopharmacology, 2022, 109, 108783.	1.7	8
2241	The metabolic characteristic of decidual immune cells and their unique properties in pregnancy loss*. Immunological Reviews, 2022, 308, 168-186.	2.8	5
2242	Homotypic and heterotypic in cis associations of MHC class I molecules at the cell surface. Current Research in Immunology, 2022, 3, 85-99.	1.2	2
2243	Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nature Reviews Immunology, 2023, 23, 90-105.	10.6	110
2244	The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Frontiers in Pharmacology, 0, 13 , .	1.6	94
2245	Natural killer cells: a promising immunotherapy for cancer. Journal of Translational Medicine, 2022, 20, .	1.8	56
2246	Natural killer cells and acute myeloid leukemia: promises and challenges. Cancer Immunology, Immunotherapy, 2022, 71, 2849-2867.	2.0	5
2247	Natural killer cell exhaustion in SARS-CoV-2 infection. Innate Immunity, 2022, 28, 189-198.	1.1	5
2249	Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance. Frontiers in Immunology, $0,13,.$	2.2	1
2250	Roles of exosomal circRNAs in tumour immunity and cancer progression. Cell Death and Disease, 2022, 13, .	2.7	20
2251	Recruited and Tissue-Resident Natural Killer Cells in the Lung During Infection and Cancer. Frontiers in Immunology, 0, 13, .	2.2	7
2252	Imprint of Initial Education and Loss of Ly49C/I in Activated Natural Killer Cells of TAP1-KO and C57BL/6 Wildtype Mice. Frontiers in Immunology, 0, 13, .	2.2	0
2253	Infections and nervous system dysfunctions. , 2023, , 481-500.		1
2254	Natural killer cells: the next wave in cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	4
2255	Natural Killer Cell Recognition and Control of Epithelial Cancers. Cancer Journal (Sudbury, Mass), 2022, 28, 263-269.	1.0	0
2256	Enhanced development of functional human <scp>NK</scp> cells in <scp>NODâ€</scp> <i> scidâ€IL2rg ^{null} </i> mice expressing human <scp>IL15</scp> . FASEB Journal, 2022, 36, .	0.2	14
2257	The Role of NK Cells and Their Exosomes in Graft Versus Host Disease and Graft Versus Leukemia. Stem Cell Reviews and Reports, 0, , .	1.7	4
2259	Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies. Frontiers in Immunology, $0,13,.$	2.2	12

#	Article	IF	CITATIONS
2260	Differential involvement of CD40, CD80, and major histocompatibility complex class I molecules in cytotoxicity induction and interferonâ $\hat{\epsilon}^3$ production by human natural killer effectors. Journal of Leukocyte Biology, 2002, 72, 305-311.	1.5	13
2261	Role of Membrane Estrogen Receptor (GPER1) on the Function of Immune Cells and Its Consequences on Breast Cancer Pathophysiology. , 2022, , .		0
2262	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers, 2022, 14, 4192.	1.7	6
2263	Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation. Frontiers in Immunology, 0, 13 , .	2.2	2
2264	Frequency of HLA alleles and KIR Ligands in Acute Myeloid Leukemia in Indian Cohort. Indian Journal of Hematology and Blood Transfusion, O, , .	0.3	0
2265	Human natural killer cells: Form, function, and development. Journal of Allergy and Clinical Immunology, 2023, 151, 371-385.	1.5	14
2266	Receptors of immune cells mediates recognition for tumors. Progress in Molecular Biology and Translational Science, 2023, , 219-267.	0.9	2
2268	Delayed Diagnosis of Chronic Necrotizing Granulomatous Skin Lesions due to TAP2 Deficiency. Journal of Clinical Immunology, 2023, 43, 217-228.	2.0	5
2269	A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival. Frontiers in Genetics, 0, 13, .	1.1	2
2270	Tumor MHC class I expression alters cancer-associated myelopoiesis driven by host NK cells. , 2022, 10, e005308.		3
2271	Immunocyteâ€Derived Nanodrugs for Cancer Therapy. Advanced Functional Materials, 2022, 32, .	7.8	5
2272	Adaptive single-KIR ⁺ NKG2C ⁺ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia., 2022, 10, e005577.		12
2273	Relationship between KIR genotypes and HLA-ligands with SARS-CoV-2 infection in the Saudi population. Journal of King Saud University - Science, 2023, 35, 102416.	1.6	3
2274	Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells. Seminars in Immunology, 2022, 61-64, 101660.	2.7	4
2275	Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. Journal of Hematology and Oncology, 2022, 15, .	6.9	37
2276	Leukocyte immunoglobulin-like receptor subfamily B: A novel immune checkpoint molecule at the maternal-fetal interface. Journal of Reproductive Immunology, 2023, 155, 103764.	0.8	4
2277	Cord blood stem cell-generated KIR+NK cells effectively target leukemia cell lines. Human Immunology, 2022, , .	1.2	0
2279	Adaptive NK cell response to human cytomegalovirus: Facts and open issues. Seminars in Immunology, 2023, 65, 101706.	2.7	14

#	ARTICLE	IF	CITATIONS
2280	Designing Cancer Immunotherapies That Engage T Cells and NK Cells. Annual Review of Immunology, 2023, 41, 17-38.	9.5	30
2281	Emerging Antibodies in Cancer Therapy. Advanced NanoBiomed Research, 2023, 3, .	1.7	1
2282	SARS-CoV-2 escapes direct NK cell killing through Nsp1-mediated downregulation of ligands for NKG2D. Cell Reports, 2022, 41, 111892.	2.9	13
2283	Dopamine, Immunity, and Disease. Pharmacological Reviews, 2023, 75, 62-158.	7.1	43
2285	Phenotypic and functional cellular differences between human CD3- decidual and peripheral blood leukocytes Journal of Immunology, 1994, 152, 4255-4261.	0.4	83
2286	Host MHC class I molecules modulate in vivo expression of a NK cell receptor Journal of Immunology, 1994, 153, 2407-2416.	0.4	92
2287	Differential Effects of the Rejection of Bone Marrow Allografts by the Depletion of Activating Versus Inhibiting Ly-49 Natural Killer Cell Subsets. Journal of Immunology, 1998, 160, 87-94.	0.4	59
2288	The Ly-49 Family: Regulation of Cytotoxicity and Cytokine Production in Murine CD3+ Cells. Journal of Immunology, 1998, 160, 1158-1165.	0.4	108
2289	Fetal Mouse NK Cell Clones Are Deficient in Ly49 Expression, Share a Common Broad Lytic Specificity, and Undergo Continuous and Extensive Diversification In Vitro. Journal of Immunology, 1998, 160, 2197-2206.	0.4	16
2290	Cutting Edge: Human Myelomonocytic Cells Express an Inhibitory Receptor for Classical and Nonclassical MHC Class I Molecules. Journal of Immunology, 1998, 160, 3096-3100.	0.4	372
2291	The α2 Domain of H-2Dd Restricts the Allelic Specificity of the Murine NK Cell Inhibitory Receptor Ly-49A. Journal of Immunology, 1998, 160, 5971-5978.	0.4	23
2292	Natural Killer Cell Lysis of Cytomegalovirus (CMV)-Infected Cells Correlates with Virally Induced Changes in Cell Surface Lymphocyte Function-Associated Antigen-3 (LFA-3) Expression and Not with the CMV-Induced Down-Regulation of Cell Surface Class I HLA. Journal of Immunology, 1998, 161, 2365-2374.	0.4	65
2293	Role of Conserved Glycosylation Site Unique to Murine Class I MHC in Recognition by Ly-49 NK Cell Receptor. Journal of Immunology, 1998, 161, 2301-2306.	0.4	25
2294	External and Internal Calibration of the MHC Class I-Specific Receptor Ly49A on Murine Natural Killer Cells. Journal of Immunology, 1998, 161, 6133-6138.	0.4	39
2295	Positive Recognition of MHC Class I Molecules by the Ly49D Receptor of Murine NK Cells. Journal of Immunology, 1999, 162, 2035-2043.	0.4	102
2296	Mouse NKR-P1B, a Novel NK1.1 Antigen with Inhibitory Function. Journal of Immunology, 1999, 162, 5917-5923.	0.4	74
2297	Triggering of Murine NK Cells by CD40 and CD86 (B7-2). Journal of Immunology, 1999, 162, 5910-5916.	0.4	59
2298	The MHC Class I Molecule H-2Dp Inhibits Murine NK Cells via the Inhibitory Receptor Ly49A. Journal of Immunology, 1999, 162, 7010-7014.	0.4	16

#	Article	IF	CITATIONS
2299	Tolerance and Alloreactivity of the Ly49D Subset of Murine NK Cells. Journal of Immunology, 1999, 163, 1859-1867.	0.4	66
2300	Stochastic Acquisition of Qa1 Receptors During the Development of Fetal NK Cells In Vitro Accounts in Part But Not in Whole for the Ability of These Cells to Distinguish Between Class I-Sufficient and Class I-Deficient Targets. Journal of Immunology, 1999, 163, 3176-3184.	0.4	19
2301	NK Cell Triggering by the Human Costimulatory Molecules CD80 and CD86. Journal of Immunology, 1999, 163, 4207-4212.	0.4	80
2302	NK and CTL Recognition of a Single Chain H-2Dd Molecule: Distinct Sites of H-2Dd Interact with NK and TCR. Journal of Immunology, 1999, 163, 3699-3708.	0.4	19
2303	Impaired Anti-Viral T Cell Responses Due to Expression of the LY49A Inhibitory Receptor. Journal of Immunology, 1999, 163, 5526-5534.	0.4	61
2304	Natural Killing of Xenogeneic Cells Mediated by the Mouse Ly-49D Receptor. Journal of Immunology, 1999, 163, 4694-4700.	0.4	40
2305	HLA-E and HLA-G Expression on Porcine Endothelial Cells Inhibit Xenoreactive Human NK Cells Through CD94/NKG2-Dependent and -Independent Pathways. Journal of Immunology, 1999, 163, 6301-6305.	0.4	49
2306	Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. Immunotherapy Advances, 0, , .	1.2	O
2307	Targeted Nanophotoimmunotherapy Potentiates Cancer Treatment by Enhancing Tumor Immunogenicity and Improving the Immunosuppressive Tumor Microenvironment. Bioconjugate Chemistry, 2023, 34, 283-301.	1.8	3
2308	Mapping the interplay between NK cells and HIV: therapeutic implications. Journal of Leukocyte Biology, 2023, 113, 109-138.	1.5	1
2309	The lung, the niche, and the microbe: Exploring the lung microbiome in cancer and immunity. Frontiers in Immunology, $0,13,.$	2.2	4
2310	Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Communications, 2023, 43, 177-213.	3.7	8
2311	Natural Killer Cell-Based Cancer Immunotherapy: From Bench to Bedside. , 0, , .		0
2312	Genome rearrangements, male pregnancy and immunological tolerance $\hat{a} \in \text{``the curious case of the syngnathid immune system. Frontiers in Marine Science, 0, 10, .}$	1.2	4
2313	Innate receptors modulating adaptive T cell responses: KIR-HLA interactions and T cell-mediated control of chronic viral infections. Immunogenetics, 2023, 75, 269-282.	1.2	4
2314	Natural killer cells in the treatment of glioblastoma: Diverse antitumor functions and potential clinical applications., 2023,, 335-367.		1
2315	Antitumor Immunity Exerted by Natural Killer and Natural Killer T Cells in the Liver. Journal of Clinical Medicine, 2023, 12, 866.	1.0	2
2316	iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors. Stem Cell Research and Therapy, 2023, 14, .	2.4	5

#	Article	IF	Citations
2317	Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles. Molecular Therapy - Methods and Clinical Development, 2023, 29, 173-184.	1.8	5
2319	Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy. International Journal of Pharmaceutics, 2023, 634, 122655.	2.6	8
2320	Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire. Frontiers in Immunology, 0, 14, .	2.2	1
2321	Engineering cytokine therapeutics., 2023, 1, 286-303.		29
2322	COVID-19: Attacks Immune Cells and Interferences With Antigen Presentation Through MHC-Like Decoy System. Journal of Immunotherapy, 2023, 46, 75-88.	1.2	2
2323	Comparison of NK alloreactivity prediction models based on KIR-MHC interactions in haematopoietic stem cell transplantation. Frontiers in Immunology, 0, 14, .	2.2	0
2324	NK cells in COVID-19—from disease to vaccination. Journal of Leukocyte Biology, 2023, 114, 507-512.	1.5	2
2325	Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics. Cancers, 2023, 15, 1743.	1.7	4
2326	The Role of NK Cells in EBV Infection and Related Diseases: Current Understanding and Hints for Novel Therapies. Cancers, 2023, 15, 1914.	1.7	2
2327	Effectiveness of Exosomes in the Immune Cascade. Physiology, 0, , .	4.0	0
2328	IL17RB and IL17REL Expression Are Associated with Improved Prognosis in HPV-Infected Head and Neck Squamous Cell Carcinomas. Pathogens, 2023, 12, 572.	1.2	0
2329	The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy. Cancers, 2023, 15, 2323.	1.7	14
2341	The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer. British Journal of Cancer, 2023, 129, 1041-1049.	2.9	4
2343	Major Histocompatibility Complex. , 2023, , 903-913.		0
2345	An Updated in the Management of Alopecia Areata., 0,,.		0
2354	The show and tell of cross-presentation. Advances in Immunology, 2023, , .	1.1	0
2372	Immune Evasive Stem Cell Islets. , 2023, , 299-316.		0
2373	Xenogeneic and Allogenic Cellular Rejection (CR). , 2024, , 227-286.		0

Article IF Citations